
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml"
      xmlns:dc="http://purl.org/dc/terms/"
      xmlns:doi="http://dx.doi.org/"
      lang="en" xml:lang="en"
      itemscope itemtype="http://schema.org/Article"
      class="no-js">



<head prefix="og: http://ogp.me/ns#">




<link rel="stylesheet" href="/resource/css/screen.css?b9b9e8003b4f9b22eec280728a346cf1"/>
  <!-- allows for  extra head tags -->


<!-- hello -->
<link rel="stylesheet" type="text/css"
      href="https://fonts.googleapis.com/css?family=Open+Sans:400,400i,600">

<link media="print" rel="stylesheet" type="text/css"  href="/resource/css/print.css"/>
    <script type="text/javascript">
        var siteUrlPrefix = "/plosmedicine/";
    </script>
  <script src="/resource/js/vendor/modernizr-v2.7.1.js" type="text/javascript"></script>
  <script src="/resource/js/vendor/detectizr.min.js" type="text/javascript"></script>

  <link rel="shortcut icon" href="/resource/img/favicon.ico" type="image/x-icon"/>
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>






  <link rel="canonical" href="https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004591" />
  <meta name="description" content="Using electronic health records from the TriNetX network, Teng-Li Lin and colleagues compare the risk of cardiovascular disease in patients with psoriasis who were prescribed biologic versus oral therapies." />

  <meta name="citation_abstract" content="Background Psoriasis is associated with various cardiovascular diseases (CVDs). The aim of this study was to compare the risk of CVD in patients with psoriasis who were prescribed biologics or oral therapies, and to assess the association between different classes of biologics and CVD risk.   Methods and Findings This retrospective cohort study utilized the TriNetX Global Collaborative Network (2014&ndash;2025). Patients with psoriasis newly prescribed biologics (BIO-cohort) and those newly initiating oral anti-psoriatic drugs without biologic exposure (Non-BIO-cohort) were enrolled. A propensity score-matched analysis was conducted, accounting for age, sex, race, comorbidities, body mass index, serum lipid profile, and inflammatory marker levels. Cardiovascular risk was compared between the BIO- and Non-BIO-cohorts using Cox regression to calculate hazard ratios (HRs) with 95% confidence intervals (CIs). After matching, each cohort comprised 12,732 patients, with approximately 50% being female, a mean age of 57 years, and 55% identifying as White. The 5-year cumulative incidence of any CVDs was significantly lower in the BIO-cohort (10.68%; 95% CI [10.03%, 11.36%]) than in the Non-BIO-cohort (16.17%; 95% CI: [15.34%, 17.05%]) (p &lt; 0.001). The BIO-cohort had attenuated risks of any CVDs (HR 0.621; 95% CI [0.571, 0.676]), cerebrovascular diseases (HR 0.616; 95% CI [0.519, 0.731]), arrhythmias (HR 0.632; 95% CI [0.565, 0.706]), inflammatory heart diseases (HR 0.566; 95% CI [0.360, 0.891]), ischemic heart diseases (HR 0.579; 95% CI [0.465, 0.721]), heart failure (HR 0.637; 95% CI [0.521, 0.780]), non-ischemic cardiomyopathy (HR 0.654; 95% CI [0.466, 0.918]), thrombotic disorders (HR 0.570; 95% CI [0.444, 0.733]), peripheral arterial occlusive diseases (HR 0.501; 95% CI [0.383, 0.656]), and major adverse cardiac events (HR 0.697; 95% CI [0.614, 0.792]). Receiving only anti-tumor necrosis factor (TNF)-&alpha; (HR 0.886; 95% CI [0.807, 0.973]), anti-interleukin (IL)-17 (HR 0.724; 95% CI [0.599, 0.875]), or anti-IL-23 (HR 0.739; 95% CI [0.598, 0.914]) was associated with reduced risks of any CVDs, whereas no significant association was observed for only anti-IL-12/23 (HR 0.915; 95% CI [0.742, 1.128]). This risk reduction remained consistent across various subgroups, including age (&le;45 or &gt;45 years), sex (male or female), regions of research data (the United States, Europe, Middle East and Africa, and Asia-Pacific), and comorbidities (psoriatic arthritis, hypertension, diabetes, hyperlipidemia, overweight or obesity). Eight sensitivity analyses, such as extending the washout period or tightening medication definitions, validated our findings. The main limitation of our study is the observational design, which can only establish associations, not causation.   Conclusions Patients with psoriasis prescribed biologics exhibited a lower risk of CVDs versus those on oral therapy. Anti-TNF-&alpha;, anti-IL-17, and anti-IL-23 were associated with decreased cardiovascular hazards, while anti-IL-12/23 was not.">


  <meta name="keywords" content="Cardiovascular diseases,Cardiovascular disease risk,Cancer risk factors,Cardiovascular therapy,Psoriasis,Medical risk factors,Type 2 diabetes risk,Epidemiology" />


<meta name="citation_doi" content="10.1371/journal.pmed.1004591"/>
<meta name="citation_author" content="Teng-Li Lin"/>
  <meta name="citation_author_institution" content="Department of Dermatology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan"/>
  <meta name="citation_author_institution" content="Ph.D. Program of Interdisciplinary Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan"/>
<meta name="citation_author" content="Yi-Hsuan Fan"/>
  <meta name="citation_author_institution" content="Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan"/>
<meta name="citation_author" content="Kuo-Sheng Fan"/>
  <meta name="citation_author_institution" content="Department of Internal Medicine, Division of Chest Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan"/>
<meta name="citation_author" content="Chao-Kuei Juan"/>
  <meta name="citation_author_institution" content="Department of Dermatology, Taichung Veterans General Hospital, Taichung, Taiwan"/>
<meta name="citation_author" content="Yi-Ju Chen"/>
  <meta name="citation_author_institution" content="Department of Dermatology, Taichung Veterans General Hospital, Taichung, Taiwan"/>
  <meta name="citation_author_institution" content="Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan"/>
  <meta name="citation_author_institution" content="Faculty of Medicine and Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan"/>
<meta name="citation_author" content="Chun-Ying Wu"/>
  <meta name="citation_author_institution" content="Faculty of Medicine and Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan"/>
  <meta name="citation_author_institution" content="Institute of Biomedical Informatics, National Yang Ming Chiao Tung University, Taipei, Taiwan"/>
  <meta name="citation_author_institution" content="Division of Translational Research, Taipei Veterans General Hospital, Taipei, Taiwan"/>
  <meta name="citation_author_institution" content="College of Public Health, China Medical University, Taichung, Taiwan"/>

<meta name="citation_title" content="Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-&alpha;, IL-12/23, IL-17, and IL-23: A population-based retrospective cohort study"/>
<meta itemprop="name" content="Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-&alpha;, IL-12/23, IL-17, and IL-23: A population-based retrospective cohort study"/>
<meta name="citation_journal_title" content="PLOS Medicine"/>
<meta name="citation_journal_abbrev" content="PLOS Medicine"/>
<meta name="citation_date" content="Apr 17, 2025"/>
<meta name="citation_firstpage" content="e1004591"/>
<meta name="citation_issue" content="4"/>
<meta name="citation_volume" content="22"/>
<meta name="citation_issn" content="1549-1676"/>
<meta name="citation_publisher" content="Public Library of Science"/>

  <meta name="citation_pdf_url" content="https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1004591&type=printable">

  <meta name="citation_article_type" content="Research Article">

<meta name="dc.identifier" content="10.1371/journal.pmed.1004591" />


  <meta name="twitter:card" content="summary" />
  <meta name="twitter:site" content="plosmedicine"/>
    <meta name="twitter:title" content="Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-&alpha;, IL-12/23, IL-17, and IL-23: A population-based retrospective cohort study" />
    <meta property="twitter:description" content="Using electronic health records from the TriNetX network, Teng-Li Lin and colleagues compare the risk of cardiovascular disease in patients with psoriasis who were prescribed biologic versus oral therapies." />
    <meta property="twitter:image" content="https://journals.plos.org/plosmedicine/article/figure/image?id=10.1371/journal.pmed.1004591.g004&size=inline" />

<meta property="og:type" content="article" />
<meta property="og:url" content="https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004591"/>
<meta property="og:title" content="Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-&alpha;, IL-12/23, IL-17, and IL-23: A population-based retrospective cohort study"/>
<meta property="og:description" content="Using electronic health records from the TriNetX network, Teng-Li Lin and colleagues compare the risk of cardiovascular disease in patients with psoriasis who were prescribed biologic versus oral therapies."/>
<meta property="og:image" content="https://journals.plos.org/plosmedicine/article/figure/image?id=10.1371/journal.pmed.1004591.g004&size=inline"/>

<meta name="citation_reference" content="citation_title=Risk of myocardial infarction in patients with psoriasis;citation_author=JM Gelfand;citation_author=AL Neimann;citation_author=DB Shin;citation_author=X Wang;citation_author=DJ Margolis;citation_author=AB Troxel;citation_journal_title=JAMA;citation_volume=296;citation_number=296;citation_issue=14;citation_first_page=1735;citation_last_page=41;citation_publication_date=2006;"/>    
<meta name="citation_reference" content="citation_title=Psoriasis and risk of heart failure: a nationwide cohort study;citation_author=U Khalid;citation_author=O Ahlehoff;citation_author=GH Gislason;citation_author=SL Kristensen;citation_author=L Skov;citation_author=C Torp-Pedersen;citation_journal_title=Eur J Heart Fail;citation_volume=16;citation_number=16;citation_issue=7;citation_first_page=743;citation_last_page=8;citation_publication_date=2014;"/>    
<meta name="citation_reference" content="citation_title=Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study;citation_author=O Ahlehoff;citation_author=GH Gislason;citation_author=CH Jørgensen;citation_author=J Lindhardsen;citation_author=M Charlot;citation_author=JB Olesen;citation_journal_title=Eur Heart J;citation_volume=33;citation_number=33;citation_issue=16;citation_first_page=2054;citation_last_page=64;citation_publication_date=2012;"/>    
<meta name="citation_reference" content="citation_title=Psoriasis is associated with a greater risk of incident venous thromboembolism: the Iowa Women’s Health Study;citation_author=PL Lutsey;citation_author=AE Prizment;citation_author=AR Folsom;citation_journal_title=J Thromb Haemost;citation_volume=10;citation_number=10;citation_issue=4;citation_first_page=708;citation_last_page=11;citation_publication_date=2012;"/>    
<meta name="citation_reference" content="citation_title=2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention &amp;amp; Rehabilitation (EACPR);citation_author=MF Piepoli;citation_author=AW Hoes;citation_author=S Agewall;citation_author=C Albus;citation_author=C Brotons;citation_author=AL Catapano;citation_journal_title=Eur Heart J;citation_volume=37;citation_number=37;citation_issue=29;citation_first_page=2315;citation_last_page=81;citation_publication_date=2016;"/>    
<meta name="citation_reference" content="citation_title=Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life;citation_author=M Yoshizumi;citation_author=M Perrella;citation_author=JJ Burnett;citation_author=M Lee;citation_journal_title=Circ Res;citation_volume=73;citation_number=73;citation_issue=1;citation_first_page=205;citation_last_page=9;citation_publication_date=1993;"/>    
<meta name="citation_reference" content="citation_title=Involvement of tumor necrosis factor-alpha in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy;citation_author=S Sriramula;citation_author=M Haque;citation_author=DSA Majid;citation_author=J Francis;citation_journal_title=Hypertension;citation_volume=51;citation_number=51;citation_issue=5;citation_first_page=1345;citation_last_page=51;citation_publication_date=2008;"/>    
<meta name="citation_reference" content="citation_title=The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis;citation_author=A Blauvelt;citation_author=A Chiricozzi;citation_journal_title=Clin Rev Allergy Immunol;citation_volume=55;citation_number=55;citation_issue=3;citation_first_page=379;citation_last_page=90;citation_publication_date=2018;"/>    
<meta name="citation_reference" content="citation_title=Identification of a non-growth factor role for GM-CSF in advanced atherosclerosis: promotion of macrophage apoptosis and plaque necrosis through IL-23 signaling;citation_author=M Subramanian;citation_author=E Thorp;citation_author=I Tabas;citation_journal_title=Circ Res;citation_volume=116;citation_number=116;citation_issue=2;citation_first_page=e13-24;citation_publication_date=2015;"/>    
<meta name="citation_reference" content="citation_title=Interleukin 23 levels are increased in carotid atherosclerosis: possible role for the interleukin 23/interleukin 17 axis;citation_author=A Abbas;citation_author=I Gregersen;citation_author=S Holm;citation_author=I Daissormont;citation_author=V Bjerkeli;citation_author=K Krohg-Sørensen;citation_journal_title=Stroke;citation_volume=46;citation_number=46;citation_issue=3;citation_first_page=793;citation_last_page=9;citation_publication_date=2015;"/>    
<meta name="citation_reference" content="citation_title=Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis;citation_author=B Lockshin;citation_author=Y Balagula;citation_author=JF Merola;citation_journal_title=J Am Acad Dermatol;citation_volume=79;citation_number=79;citation_issue=2;citation_first_page=345;citation_last_page=52;citation_publication_date=2018;"/>    
<meta name="citation_reference" content="citation_title=Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study;citation_author=A Ogdie;citation_author=Y Yu;citation_author=K Haynes;citation_author=TJ Love;citation_author=S Maliha;citation_author=Y Jiang;citation_journal_title=Ann Rheum Dis;citation_volume=74;citation_number=74;citation_issue=2;citation_first_page=326;citation_last_page=32;citation_publication_date=2015;"/>    
<meta name="citation_reference" content="citation_title=Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis;citation_author=S Prodanovich;citation_author=F Ma;citation_author=JR Taylor;citation_author=C Pezon;citation_author=T Fasihi;citation_author=RS Kirsner;citation_journal_title=J Am Acad Dermatol;citation_volume=52;citation_number=52;citation_issue=2;citation_first_page=262;citation_last_page=7;citation_publication_date=2005;"/>    
<meta name="citation_reference" content="citation_title=Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort;citation_author=O Ahlehoff;citation_author=L Skov;citation_author=G Gislason;citation_author=R Gniadecki;citation_author=L Iversen;citation_author=LE Bryld;citation_journal_title=J Eur Acad Dermatol Venereol;citation_volume=29;citation_number=29;citation_issue=6;citation_first_page=1128;citation_last_page=34;citation_publication_date=2015;"/>    
<meta name="citation_reference" content="citation_title=Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial;citation_author=S Boehncke;citation_author=S Fichtlscherer;citation_author=R Salgo;citation_author=J Garbaraviciene;citation_author=H Beschmann;citation_author=S Diehl;citation_journal_title=Arch Dermatol Res;citation_volume=303;citation_number=303;citation_issue=6;citation_first_page=381;citation_last_page=8;citation_publication_date=2011;"/>    
<meta name="citation_reference" content="citation_title=Vitamin A decreases cytotoxicity of oxidized low-density lipoprotein in patients with atherosclerosis;citation_author=MJ Mahmoudi;citation_author=A-A Saboor-Yaraghi;citation_author=F Zabetian-Targhi;citation_author=F Siassi;citation_author=AH Zarnani;citation_author=MR Eshraghian;citation_journal_title=Immunol Invest;citation_volume=45;citation_number=45;citation_issue=1;citation_first_page=52;citation_last_page=62;citation_publication_date=2016;"/>    
<meta name="citation_reference" content="citation_title=Association of biologic therapy with coronary inflammation in patients with psoriasis as assessed by perivascular fat attenuation index;citation_author=YA Elnabawi;citation_author=EK Oikonomou;citation_author=AK Dey;citation_author=J Mancio;citation_author=JA Rodante;citation_author=M Aksentijevich;citation_journal_title=JAMA Cardiol;citation_volume=4;citation_number=4;citation_issue=9;citation_first_page=885;citation_last_page=91;citation_publication_date=2019;"/>    
<meta name="citation_reference" content="citation_title=Antagonization of IL-17A attenuates skin inflammation and vascular dysfunction in mouse models of psoriasis;citation_author=R Schüler;citation_author=A Brand;citation_author=S Klebow;citation_author=J Wild;citation_author=F Veras;citation_author=E Ullmann;citation_journal_title=J Invest Dermatol;citation_volume=139;citation_number=139;citation_issue=3;citation_first_page=638;citation_last_page=47;citation_publication_date=2019;"/>    
<meta name="citation_reference" content="citation_title=Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice;citation_author=E Smith;citation_author=K-MR Prasad;citation_author=M Butcher;citation_author=A Dobrian;citation_author=JK Kolls;citation_author=K Ley;citation_journal_title=Circulation;citation_volume=121;citation_number=121;citation_issue=15;citation_first_page=1746;citation_last_page=55;citation_publication_date=2010;"/>    
<meta name="citation_reference" content="citation_title=Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in psoriasis: results of a pilot study;citation_author=H Jókai;citation_author=J Szakonyi;citation_author=O Kontár;citation_author=M Marschalkó;citation_author=K Szalai;citation_author=S Kárpáti;citation_journal_title=J Am Acad Dermatol;citation_volume=69;citation_number=69;citation_issue=4;citation_first_page=523;citation_last_page=9;citation_publication_date=2013;"/>    
<meta name="citation_reference" content="citation_title=Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks;citation_author=E von Stebut;citation_author=K Reich;citation_author=D Thaçi;citation_author=W Koenig;citation_author=A Pinter;citation_author=A Körber;citation_journal_title=J Invest Dermatol;citation_volume=139;citation_number=139;citation_issue=5;citation_first_page=1054;citation_last_page=62;citation_publication_date=2019;"/>    
<meta name="citation_reference" content="citation_title=Myocardial function and effects of biologic therapy in patients with severe psoriasis: a prospective echocardiographic study;citation_author=O Ahlehoff;citation_author=PR Hansen;citation_author=GH Gislason;citation_author=M Frydland;citation_author=LE Bryld;citation_author=H Elming;citation_journal_title=J Eur Acad Dermatol Venereol;citation_volume=30;citation_number=30;citation_issue=5;citation_first_page=819;citation_last_page=23;citation_publication_date=2016;"/>    
<meta name="citation_reference" content="citation_title=Subclinical cardiovascular disease and it’s improvement after long-term TNF-α inhibitor therapy in severe psoriatic patients;citation_author=E Herédi;citation_author=J Végh;citation_author=L Pogácsás;citation_author=K Gáspár;citation_author=J Varga;citation_author=G Kincse;citation_journal_title=J Eur Acad Dermatol Venereol;citation_volume=30;citation_number=30;citation_issue=9;citation_first_page=1531;citation_last_page=6;citation_publication_date=2016;"/>    
<meta name="citation_reference" content="citation_title=Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis;citation_author=JJ Wu;citation_author=K-YT Poon;citation_author=JC Channual;citation_author=AY-J Shen;citation_journal_title=Arch Dermatol;citation_volume=148;citation_number=148;citation_issue=11;citation_first_page=1244;citation_last_page=50;citation_publication_date=2012;"/>    
<meta name="citation_reference" content="citation_title=Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate;citation_author=JJ Wu;citation_author=A Guérin;citation_author=M Sundaram;citation_author=K Dea;citation_author=M Cloutier;citation_author=P Mulani;citation_journal_title=J Am Acad Dermatol;citation_volume=76;citation_number=76;citation_issue=1;citation_first_page=81;citation_last_page=90;citation_publication_date=2017;"/>    
<meta name="citation_reference" content="citation_title=Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials;citation_author=C Ryan;citation_author=CL Leonardi;citation_author=JG Krueger;citation_author=AB Kimball;citation_author=BE Strober;citation_author=KB Gordon;citation_journal_title=JAMA;citation_volume=306;citation_number=306;citation_issue=8;citation_first_page=864;citation_last_page=71;citation_publication_date=2011;"/>    
<meta name="citation_reference" content="citation_title=Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials;citation_author=T Tzellos;citation_author=A Kyrgidis;citation_author=CC Zouboulis;citation_journal_title=J Eur Acad Dermatol Venereol;citation_volume=27;citation_number=27;citation_issue=5;citation_first_page=622;citation_last_page=7;citation_publication_date=2013;"/>    
<meta name="citation_reference" content="citation_title=Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials;citation_author=W Rungapiromnan;citation_author=ZZN Yiu;citation_author=RB Warren;citation_author=CEM Griffiths;citation_author=DM Ashcroft;citation_journal_title=Br J Dermatol;citation_volume=176;citation_number=176;citation_issue=4;citation_first_page=890;citation_last_page=901;citation_publication_date=2017;"/>    
<meta name="citation_reference" content="citation_title=Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks;citation_author=W Wang;citation_author=C-Y Wang;citation_author=S-I Wang;citation_author=JC-C Wei;citation_journal_title=EClinicalMedicine;citation_volume=53;citation_number=53;citation_first_page=101619;citation_publication_date=2022;"/>    
<meta name="citation_reference" content="citation_title=Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study;citation_author=S Singla;citation_author=M Putman;citation_author=J Liew;citation_author=K Gordon;citation_journal_title=Lancet Rheumatol;citation_volume=5;citation_number=5;citation_issue=4;citation_first_page=e200;citation_last_page=7;citation_publication_date=2023;"/>    
<meta name="citation_reference" content="citation_title=Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in the health improvement network;citation_author=A Ogdie;citation_author=S Alehashemi;citation_author=TJ Love;citation_author=Y Jiang;citation_author=K Haynes;citation_author=S Hennessy;citation_journal_title=Pharmacoepidemiol Drug Saf;citation_volume=23;citation_number=23;citation_issue=9;citation_first_page=918;citation_last_page=22;citation_publication_date=2014;"/>    
<meta name="citation_reference" content="citation_title=Race and ethnicity considerations in patients with coronary artery disease and stroke: JACC focus seminar 3/9;citation_author=R Mital;citation_author=J Bayne;citation_author=F Rodriguez;citation_author=B Ovbiagele;citation_author=DL Bhatt;citation_author=MA Albert;citation_journal_title=J Am Coll Cardiol;citation_volume=78;citation_number=78;citation_issue=24;citation_first_page=2483;citation_last_page=92;citation_publication_date=2021;"/>    
<meta name="citation_reference" content="citation_title=Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis;citation_author=AW Armstrong;citation_author=L Puig;citation_author=A Joshi;citation_author=M Skup;citation_author=D Williams;citation_author=J Li;citation_journal_title=JAMA Dermatol;citation_volume=156;citation_number=156;citation_issue=3;citation_first_page=258;citation_last_page=69;citation_publication_date=2020;"/>    
<meta name="citation_reference" content="citation_title=Criteria for use of composite end points for competing risks—a systematic survey of the literature with recommendations;citation_author=V Manja;citation_author=S AlBashir;citation_author=G Guyatt;citation_journal_title=J Clin Epidemiol;citation_volume=82;citation_number=82;citation_first_page=4;citation_last_page=11;citation_publication_date=2017;"/>    
<meta name="citation_reference" content="citation_title=Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents;citation_author=SB Kaushik;citation_author=MG Lebwohl;citation_journal_title=J Am Acad Dermatol;citation_volume=80;citation_number=80;citation_issue=1;citation_first_page=27;citation_last_page=40;citation_publication_date=2019;"/>    
<meta name="citation_reference" content="citation_title=Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research;citation_author=Y Moride;citation_author=L Abenhaim;citation_journal_title=J Clin Epidemiol;citation_volume=47;citation_number=47;citation_issue=7;citation_first_page=731;citation_last_page=7;citation_publication_date=1994;"/>    
<meta name="citation_reference" content="citation_title=Prevalence of cardiovascular risk factors in patients with psoriasis;citation_author=AL Neimann;citation_author=DB Shin;citation_author=X Wang;citation_author=DJ Margolis;citation_author=AB Troxel;citation_author=JM Gelfand;citation_journal_title=J Am Acad Dermatol;citation_volume=55;citation_number=55;citation_issue=5;citation_first_page=829;citation_last_page=35;citation_publication_date=2006;"/>    
<meta name="citation_reference" content="citation_title=Psoriasis and smoking: a systematic review and meta-analysis;citation_author=A Armstrong;citation_author=C Harskamp;citation_author=J Dhillon;citation_author=E Armstrong;citation_journal_title=Br J Dermatol;citation_volume=170;citation_number=170;citation_issue=2;citation_first_page=304;citation_last_page=14;citation_publication_date=2014;"/>    
<meta name="citation_reference" content="citation_title=Immune-mediated inflammation promotes subclinical atherosclerosis in recent-onset psoriatic arthritis patients without conventional cardiovascular risk factors;citation_author=RA Kolliker Frers;citation_author=V Cosentino;citation_author=J Tau;citation_author=EM Kerzberg;citation_author=A Urdapilleta;citation_author=M Chiocconi;citation_journal_title=Front Immunol;citation_volume=9;citation_number=9;citation_first_page=139;citation_publication_date=2018;"/>    
<meta name="citation_reference" content="citation_title=Studying the effect of systemic and biological drugs on intima-media thickness in patients suffering from moderate and severe psoriasis;citation_author=A Martinez-Lopez;citation_author=G Blasco-Morente;citation_author=I Perez-Lopez;citation_author=J Tercedor-Sanchez;citation_author=S Arias-Santiago;citation_journal_title=J Eur Acad Dermatol Venereol;citation_volume=32;citation_number=32;citation_issue=9;citation_first_page=1492;citation_last_page=8;citation_publication_date=2018;"/>    
<meta name="citation_reference" content="citation_title=Association between changes in coronary artery disease progression and treatment with biologic agents for severe psoriasis;citation_author=KF Hjuler;citation_author=M Bøttcher;citation_author=C Vestergaard;citation_author=HE Bøtker;citation_author=L Iversen;citation_author=K Kragballe;citation_journal_title=JAMA Dermatol;citation_volume=152;citation_number=152;citation_issue=10;citation_first_page=1114;citation_last_page=21;citation_publication_date=2016;"/>    
<meta name="citation_reference" content="citation_title=Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis;citation_author=S Taleb;citation_author=M Romain;citation_author=B Ramkhelawon;citation_author=C Uyttenhove;citation_author=G Pasterkamp;citation_author=O Herbin;citation_journal_title=J Exp Med;citation_volume=206;citation_number=206;citation_issue=10;citation_first_page=2067;citation_last_page=77;citation_publication_date=2009;"/>    
<meta name="citation_reference" content="citation_title=Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice;citation_author=K Danzaki;citation_author=Y Matsui;citation_author=M Ikesue;citation_author=D Ohta;citation_author=K Ito;citation_author=M Kanayama;citation_journal_title=Arterioscler Thromb Vasc Biol;citation_volume=32;citation_number=32;citation_issue=2;citation_first_page=273;citation_last_page=80;citation_publication_date=2012;"/>    
<meta name="citation_reference" content="citation_title=Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study;citation_author=YA Elnabawi;citation_author=AK Dey;citation_author=A Goyal;citation_author=JW Groenendyk;citation_author=JH Chung;citation_author=AD Belur;citation_journal_title=Cardiovasc Res;citation_volume=115;citation_number=115;citation_issue=4;citation_first_page=721;citation_last_page=8;citation_publication_date=2019;"/>    
<meta name="citation_reference" content="citation_title=Effects of Interleukin 17A inhibition on myocardial deformation and vascular function in psoriasis;citation_author=G Makavos;citation_author=I Ikonomidis;citation_author=I Andreadou;citation_author=M Varoudi;citation_author=I Kapniari;citation_author=E Loukeri;citation_journal_title=Can J Cardiol;citation_volume=36;citation_number=36;citation_issue=1;citation_first_page=100;citation_last_page=111;citation_publication_date=2020;"/>    
<meta name="citation_reference" content="citation_title=IL-23R deficiency does not impact atherosclerotic plaque development in mice;citation_author=D Engelbertsen;citation_author=M Depuydt;citation_author=R Verwilligen;citation_author=S Rattik;citation_author=E Levinsohn;citation_author=A Edsfeldt;citation_journal_title=J Am Heart Assoc;citation_volume=7;citation_number=7;citation_issue=8;citation_first_page=e008257;citation_publication_date=2018;"/>    
<meta name="citation_reference" content="citation_title=An Interleukin-23-Interleukin-22 axis regulates intestinal microbial homeostasis to protect from diet-induced atherosclerosis;citation_author=AR Fatkhullina;citation_author=IO Peshkova;citation_author=A Dzutsev;citation_author=T Aghayev;citation_author=JA McCulloch;citation_author=V Thovarai;citation_journal_title=Immunity;citation_volume=49;citation_number=49;citation_issue=5;citation_first_page=943-957.e9;citation_publication_date=2018;"/>    
<meta name="citation_reference" content="citation_title=Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis;citation_author=E Sbidian;citation_author=A Chaimani;citation_author=R Guelimi;citation_author=I Garcia-Doval;citation_author=C Hua;citation_author=C Hughes;citation_journal_title=Cochrane Database Syst Rev;citation_volume=7;citation_number=7;citation_issue=7;citation_first_page=CD011535;citation_publication_date=2023;"/>    
<meta name="citation_reference" content="citation_title=Association between early severe cardiovascular events and the initiation of treatment with the Anti-Interleukin 12/23p40 antibody Ustekinumab;citation_author=F Poizeau;citation_author=E Nowak;citation_author=S Kerbrat;citation_author=B Le Nautout;citation_author=C Droitcourt;citation_author=M-D Drici;citation_journal_title=JAMA Dermatol;citation_volume=156;citation_number=156;citation_issue=11;citation_first_page=1208;citation_last_page=15;citation_publication_date=2020;"/>    
<meta name="citation_reference" content="citation_title=Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters;citation_author=M Reddy;citation_author=G Torres;citation_author=T McCormick;citation_author=C Marano;citation_author=K Cooper;citation_author=N Yeilding;citation_journal_title=J Dermatol;citation_volume=37;citation_number=37;citation_issue=5;citation_first_page=413;citation_last_page=25;citation_publication_date=2010;"/>    
<meta name="citation_reference" content="citation_title=Lowering Interleukin-12 activity improves myocardial and vascular function compared with tumor necrosis factor-a antagonism or cyclosporine in psoriasis;citation_author=I Ikonomidis;citation_author=E Papadavid;citation_author=G Makavos;citation_author=I Andreadou;citation_author=M Varoudi;citation_author=K Gravanis;citation_journal_title=Circ Cardiovasc Imaging;citation_volume=10;citation_number=10;citation_issue=9;citation_first_page=e006283;citation_publication_date=2017;"/>    
<meta name="citation_reference" content="citation_title=Structural basis for how biologic medicines bind their targets in psoriasis therapy;citation_author=SA Eldirany;citation_author=M Ho;citation_author=CG Bunick;citation_journal_title=Yale J Biol Med;citation_volume=93;citation_number=93;citation_issue=1;citation_first_page=19;citation_last_page=27;citation_publication_date=2020;"/>    
<meta name="citation_reference" content="citation_title=Cardiovascular safety of biologics targeting Interleukin (IL)-12 and/or IL-23: what does the evidence say?;citation_author=M de Brito;citation_author=ZZN Yiu;citation_journal_title=Am J Clin Dermatol;citation_volume=22;citation_number=22;citation_issue=5;citation_first_page=587;citation_last_page=601;citation_publication_date=2021;"/>    
<meta name="citation_reference" content="citation_title=Potential cerebrovascular accident signal for risankizumab: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS);citation_author=RH Woods;citation_journal_title=Br J Clin Pharmacol;citation_volume=89;citation_number=89;citation_issue=8;citation_first_page=2386;citation_last_page=95;citation_publication_date=2023;"/>    
<meta name="citation_reference" content="citation_title=Increased reporting of cerebrovascular accidents with use of risankizumab observed in the Food and Drug Administration Adverse Events Reporting System (FAERS);citation_author=A Egeberg;citation_author=JP Thyssen;citation_journal_title=Br J Dermatol;citation_volume=188;citation_number=188;citation_issue=6;citation_first_page=793;citation_last_page=4;citation_publication_date=2023;"/>    


<script type="text/javascript">
    var WombatConfig = WombatConfig || {};
    WombatConfig.journalKey = "PLoSMedicine";
    WombatConfig.journalName = "PLOS Medicine";
    WombatConfig.figurePath = "/plosmedicine/article/figure/image";
    WombatConfig.figShareInstitutionString = "plos";
    WombatConfig.doiResolverPrefix = "https://dx.plos.org/";
</script>

<script type="text/javascript">
  var WombatConfig = WombatConfig || {};
  WombatConfig.metrics = WombatConfig.metrics || {};
  WombatConfig.metrics.referenceUrl      = "http://lagotto.io/plos";
  WombatConfig.metrics.googleScholarUrl  = "https://scholar.google.com/scholar";
  WombatConfig.metrics.googleScholarCitationUrl  = WombatConfig.metrics.googleScholarUrl + "?hl=en&lr=&q=";
  WombatConfig.metrics.crossrefUrl  = "https://www.crossref.org";
</script>
<script defer="defer" src="/resource/js/defer.js?cab1ef1a2bb7cea34f3e"></script><script src="/resource/js/sync.js?cab1ef1a2bb7cea34f3e"></script>
<script src="/resource/js/vendor/jquery.min.js" type="text/javascript"></script>

          <script type="text/javascript" src="https://widgets.figshare.com/static/figshare.js"></script>

<script src="/resource/js/vendor/fastclick/lib/fastclick.js" type="text/javascript"></script>
<script src="/resource/js/vendor/foundation/foundation.js" type="text/javascript"></script>
<script src="/resource/js/vendor/underscore-min.js" type="text/javascript"></script>
<script src="/resource/js/vendor/underscore.string.min.js" type="text/javascript"></script>
<script src="/resource/js/vendor/moment.js" type="text/javascript"></script>


<script src="/resource/js/vendor/jquery-ui-effects.min.js" type="text/javascript"></script>

<script src="/resource/js/vendor/foundation/foundation.tooltip.js" type="text/javascript"></script>
<script src="/resource/js/vendor/foundation/foundation.dropdown.js" type="text/javascript"></script>
<script src="/resource/js/vendor/foundation/foundation.tab.js" type="text/javascript"></script>
<script src="/resource/js/vendor/foundation/foundation.reveal.js" type="text/javascript"></script>
<script src="/resource/js/vendor/foundation/foundation.slider.js" type="text/javascript"></script>

<script src="/resource/js/util/utils.js" type="text/javascript"></script>
<script src="/resource/js/components/toggle.js" type="text/javascript"></script>
<script src="/resource/js/components/truncate_elem.js" type="text/javascript"></script>
<script src="/resource/js/components/tooltip_hover.js" type="text/javascript"></script>
<script src="/resource/js/vendor/jquery.dotdotdot.js" type="text/javascript"></script>


<!-- DoubleClick overall ad setup script -->
<script type='text/javascript'>
  var googletag = googletag || {};
  googletag.cmd = googletag.cmd || [];
  if (window.plosCookieConsent?.hasConsented('advertising')) {
    (function() {
      var gads = document.createElement('script');
      gads.async = true;
      gads.type = 'text/javascript';
      var useSSL = 'https:' == document.location.protocol;
      gads.src = (useSSL ? 'https:' : 'http:') +
          '//www.googletagservices.com/tag/js/gpt.js';
      var node = document.getElementsByTagName('script')[0];
      node.parentNode.insertBefore(gads, node);
    })();
  }
</script>

<!-- DoubleClick ad slot setup script -->

  <script id="doubleClickSetupScript" type='text/javascript'>
    googletag.cmd.push(function() {
  googletag.defineSlot('/75507958/PMED_728x90_ATF', [728, 90], 'div-gpt-ad-1458247671871-0').addService(googletag.pubads());
  googletag.defineSlot('/75507958/PMED_160x600_BTF', [160, 600], 'div-gpt-ad-1458247671871-1').addService(googletag.pubads());
      googletag.pubads().enableSingleRequest();
      googletag.enableServices();
    });
  </script>

<!--For Google Tag manager to be able to track site information  -->
<script>

  dataLayer = [{
    'mobileSite': 'false',
    'desktopSite': 'true'
  }];

</script>

    <title>Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-α, IL-12/23, IL-17, and IL-23: A population-based retrospective cohort study | PLOS Medicine</title>
</head>

<body class="article plosmedicine">


<!-- Google Tag Manager -->
<noscript><iframe src="//www.googletagmanager.com/ns.html?id=GTM-TP26BH"
                  height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<script>
  (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
    new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
    j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
    '//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-TP26BH');
</script>

<noscript><iframe src="//www.googletagmanager.com/ns.html?id=GTM-MQQMGF"
                  height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
    new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
    j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
    '//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-MQQMGF');</script>
<!-- End Google Tag Manager -->

<!-- Start of HubSpot Embed Code -->
<script>
  // from https://developers.hubspot.com/docs/reference/api/analytics-and-events/cookie-banner/cookie-banner-api#example-using-a-third-party-cookie-banner-to-control-hubspot-cookies
  window.disableHubSpotCookieBanner = true;
  window._hsp = window._hsp || [];
  window._hsp.push(['setHubSpotConsent',
      {
        analytics: window.plosCookieConsent?.hasConsented('analytics'),
        advertisement: window.plosCookieConsent?.hasConsented('advertising'),
        functionality: window.plosCookieConsent?.hasConsented('functionality')
      }
    ]);
</script>
<script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/44092021.js"></script>
<!-- End of HubSpot Embed Code -->

<!-- New Relic -->
<script type="text/javascript">
  ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}};
  window.NREUM||(NREUM={}),__nr_require=function(t,e,n){function r(n){if(!e[n]){var o=e[n]={exports:{}};t[n][0].call(o.exports,function(e){var o=t[n][1][e];return r(o||e)},o,o.exports)}return e[n].exports}if("function"==typeof __nr_require)return __nr_require;for(var o=0;o<n.length;o++)r(n[o]);return r}({1:[function(t,e,n){function r(t){try{s.console&&console.log(t)}catch(e){}}var o,i=t("ee"),a=t(32),s={};try{o=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(s.console=!0,o.indexOf("dev")!==-1&&(s.dev=!0),o.indexOf("nr_dev")!==-1&&(s.nrDev=!0))}catch(c){}s.nrDev&&i.on("internal-error",function(t){r(t.stack)}),s.dev&&i.on("fn-err",function(t,e,n){r(n.stack)}),s.dev&&(r("NR AGENT IN DEVELOPMENT MODE"),r("flags: "+a(s,function(t,e){return t}).join(", ")))},{}],2:[function(t,e,n){function r(t,e,n,r,s){try{l?l-=1:o(s||new UncaughtException(t,e,n),!0)}catch(f){try{i("ierr",[f,c.now(),!0])}catch(d){}}return"function"==typeof u&&u.apply(this,a(arguments))}function UncaughtException(t,e,n){this.message=t||"Uncaught error with no additional information",this.sourceURL=e,this.line=n}function o(t,e){var n=e?null:c.now();i("err",[t,n])}var i=t("handle"),a=t(33),s=t("ee"),c=t("loader"),f=t("gos"),u=window.onerror,d=!1,p="nr@seenError";if(!c.disabled){var l=0;c.features.err=!0,t(1),window.onerror=r;try{throw new Error}catch(h){"stack"in h&&(t(14),t(13),"addEventListener"in window&&t(7),c.xhrWrappable&&t(15),d=!0)}s.on("fn-start",function(t,e,n){d&&(l+=1)}),s.on("fn-err",function(t,e,n){d&&!n[p]&&(f(n,p,function(){return!0}),this.thrown=!0,o(n))}),s.on("fn-end",function(){d&&!this.thrown&&l>0&&(l-=1)}),s.on("internal-error",function(t){i("ierr",[t,c.now(),!0])})}},{}],3:[function(t,e,n){var r=t("loader");r.disabled||(r.features.ins=!0)},{}],4:[function(t,e,n){function r(){U++,L=g.hash,this[u]=y.now()}function o(){U--,g.hash!==L&&i(0,!0);var t=y.now();this[h]=~~this[h]+t-this[u],this[d]=t}function i(t,e){E.emit("newURL",[""+g,e])}function a(t,e){t.on(e,function(){this[e]=y.now()})}var s="-start",c="-end",f="-body",u="fn"+s,d="fn"+c,p="cb"+s,l="cb"+c,h="jsTime",m="fetch",v="addEventListener",w=window,g=w.location,y=t("loader");if(w[v]&&y.xhrWrappable&&!y.disabled){var x=t(11),b=t(12),E=t(9),R=t(7),O=t(14),T=t(8),P=t(15),S=t(10),M=t("ee"),N=M.get("tracer"),C=t(23);t(17),y.features.spa=!0;var L,U=0;M.on(u,r),b.on(p,r),S.on(p,r),M.on(d,o),b.on(l,o),S.on(l,o),M.buffer([u,d,"xhr-resolved"]),R.buffer([u]),O.buffer(["setTimeout"+c,"clearTimeout"+s,u]),P.buffer([u,"new-xhr","send-xhr"+s]),T.buffer([m+s,m+"-done",m+f+s,m+f+c]),E.buffer(["newURL"]),x.buffer([u]),b.buffer(["propagate",p,l,"executor-err","resolve"+s]),N.buffer([u,"no-"+u]),S.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"]),a(T,m+s),a(T,m+"-done"),a(S,"new-jsonp"),a(S,"jsonp-end"),a(S,"cb-start"),E.on("pushState-end",i),E.on("replaceState-end",i),w[v]("hashchange",i,C(!0)),w[v]("load",i,C(!0)),w[v]("popstate",function(){i(0,U>1)},C(!0))}},{}],5:[function(t,e,n){function r(){var t=new PerformanceObserver(function(t,e){var n=t.getEntries();s(v,[n])});try{t.observe({entryTypes:["resource"]})}catch(e){}}function o(t){if(s(v,[window.performance.getEntriesByType(w)]),window.performance["c"+p])try{window.performance[h](m,o,!1)}catch(t){}else try{window.performance[h]("webkit"+m,o,!1)}catch(t){}}function i(t){}if(window.performance&&window.performance.timing&&window.performance.getEntriesByType){var a=t("ee"),s=t("handle"),c=t(14),f=t(13),u=t(6),d=t(23),p="learResourceTimings",l="addEventListener",h="removeEventListener",m="resourcetimingbufferfull",v="bstResource",w="resource",g="-start",y="-end",x="fn"+g,b="fn"+y,E="bstTimer",R="pushState",O=t("loader");if(!O.disabled){O.features.stn=!0,t(9),"addEventListener"in window&&t(7);var T=NREUM.o.EV;a.on(x,function(t,e){var n=t[0];n instanceof T&&(this.bstStart=O.now())}),a.on(b,function(t,e){var n=t[0];n instanceof T&&s("bst",[n,e,this.bstStart,O.now()])}),c.on(x,function(t,e,n){this.bstStart=O.now(),this.bstType=n}),c.on(b,function(t,e){s(E,[e,this.bstStart,O.now(),this.bstType])}),f.on(x,function(){this.bstStart=O.now()}),f.on(b,function(t,e){s(E,[e,this.bstStart,O.now(),"requestAnimationFrame"])}),a.on(R+g,function(t){this.time=O.now(),this.startPath=location.pathname+location.hash}),a.on(R+y,function(t){s("bstHist",[location.pathname+location.hash,this.startPath,this.time])}),u()?(s(v,[window.performance.getEntriesByType("resource")]),r()):l in window.performance&&(window.performance["c"+p]?window.performance[l](m,o,d(!1)):window.performance[l]("webkit"+m,o,d(!1))),document[l]("scroll",i,d(!1)),document[l]("keypress",i,d(!1)),document[l]("click",i,d(!1))}}},{}],6:[function(t,e,n){e.exports=function(){return"PerformanceObserver"in window&&"function"==typeof window.PerformanceObserver}},{}],7:[function(t,e,n){function r(t){for(var e=t;e&&!e.hasOwnProperty(u);)e=Object.getPrototypeOf(e);e&&o(e)}function o(t){s.inPlace(t,[u,d],"-",i)}function i(t,e){return t[1]}var a=t("ee").get("events"),s=t("wrap-function")(a,!0),c=t("gos"),f=XMLHttpRequest,u="addEventListener",d="removeEventListener";e.exports=a,"getPrototypeOf"in Object?(r(document),r(window),r(f.prototype)):f.prototype.hasOwnProperty(u)&&(o(window),o(f.prototype)),a.on(u+"-start",function(t,e){var n=t[1];if(null!==n&&("function"==typeof n||"object"==typeof n)){var r=c(n,"nr@wrapped",function(){function t(){if("function"==typeof n.handleEvent)return n.handleEvent.apply(n,arguments)}var e={object:t,"function":n}[typeof n];return e?s(e,"fn-",null,e.name||"anonymous"):n});this.wrapped=t[1]=r}}),a.on(d+"-start",function(t){t[1]=this.wrapped||t[1]})},{}],8:[function(t,e,n){function r(t,e,n){var r=t[e];"function"==typeof r&&(t[e]=function(){var t=i(arguments),e={};o.emit(n+"before-start",[t],e);var a;e[m]&&e[m].dt&&(a=e[m].dt);var s=r.apply(this,t);return o.emit(n+"start",[t,a],s),s.then(function(t){return o.emit(n+"end",[null,t],s),t},function(t){throw o.emit(n+"end",[t],s),t})})}var o=t("ee").get("fetch"),i=t(33),a=t(32);e.exports=o;var s=window,c="fetch-",f=c+"body-",u=["arrayBuffer","blob","json","text","formData"],d=s.Request,p=s.Response,l=s.fetch,h="prototype",m="nr@context";d&&p&&l&&(a(u,function(t,e){r(d[h],e,f),r(p[h],e,f)}),r(s,"fetch",c),o.on(c+"end",function(t,e){var n=this;if(e){var r=e.headers.get("content-length");null!==r&&(n.rxSize=r),o.emit(c+"done",[null,e],n)}else o.emit(c+"done",[t],n)}))},{}],9:[function(t,e,n){var r=t("ee").get("history"),o=t("wrap-function")(r);e.exports=r;var i=window.history&&window.history.constructor&&window.history.constructor.prototype,a=window.history;i&&i.pushState&&i.replaceState&&(a=i),o.inPlace(a,["pushState","replaceState"],"-")},{}],10:[function(t,e,n){function r(t){function e(){f.emit("jsonp-end",[],l),t.removeEventListener("load",e,c(!1)),t.removeEventListener("error",n,c(!1))}function n(){f.emit("jsonp-error",[],l),f.emit("jsonp-end",[],l),t.removeEventListener("load",e,c(!1)),t.removeEventListener("error",n,c(!1))}var r=t&&"string"==typeof t.nodeName&&"script"===t.nodeName.toLowerCase();if(r){var o="function"==typeof t.addEventListener;if(o){var a=i(t.src);if(a){var d=s(a),p="function"==typeof d.parent[d.key];if(p){var l={};u.inPlace(d.parent,[d.key],"cb-",l),t.addEventListener("load",e,c(!1)),t.addEventListener("error",n,c(!1)),f.emit("new-jsonp",[t.src],l)}}}}}function o(){return"addEventListener"in window}function i(t){var e=t.match(d);return e?e[1]:null}function a(t,e){var n=t.match(l),r=n[1],o=n[3];return o?a(o,e[r]):e[r]}function s(t){var e=t.match(p);return e&&e.length>=3?{key:e[2],parent:a(e[1],window)}:{key:t,parent:window}}var c=t(23),f=t("ee").get("jsonp"),u=t("wrap-function")(f);if(e.exports=f,o()){var d=/[?&](?:callback|cb)=([^&#]+)/,p=/(.*)\.([^.]+)/,l=/^(\w+)(\.|$)(.*)$/,h=["appendChild","insertBefore","replaceChild"];Node&&Node.prototype&&Node.prototype.appendChild?u.inPlace(Node.prototype,h,"dom-"):(u.inPlace(HTMLElement.prototype,h,"dom-"),u.inPlace(HTMLHeadElement.prototype,h,"dom-"),u.inPlace(HTMLBodyElement.prototype,h,"dom-")),f.on("dom-start",function(t){r(t[0])})}},{}],11:[function(t,e,n){var r=t("ee").get("mutation"),o=t("wrap-function")(r),i=NREUM.o.MO;e.exports=r,i&&(window.MutationObserver=function(t){return this instanceof i?new i(o(t,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype)},{}],12:[function(t,e,n){function r(t){var e=i.context(),n=s(t,"executor-",e,null,!1),r=new f(n);return i.context(r).getCtx=function(){return e},r}var o=t("wrap-function"),i=t("ee").get("promise"),a=t("ee").getOrSetContext,s=o(i),c=t(32),f=NREUM.o.PR;e.exports=i,f&&(window.Promise=r,["all","race"].forEach(function(t){var e=f[t];f[t]=function(n){function r(t){return function(){i.emit("propagate",[null,!o],a,!1,!1),o=o||!t}}var o=!1;c(n,function(e,n){Promise.resolve(n).then(r("all"===t),r(!1))});var a=e.apply(f,arguments),s=f.resolve(a);return s}}),["resolve","reject"].forEach(function(t){var e=f[t];f[t]=function(t){var n=e.apply(f,arguments);return t!==n&&i.emit("propagate",[t,!0],n,!1,!1),n}}),f.prototype["catch"]=function(t){return this.then(null,t)},f.prototype=Object.create(f.prototype,{constructor:{value:r}}),c(Object.getOwnPropertyNames(f),function(t,e){try{r[e]=f[e]}catch(n){}}),o.wrapInPlace(f.prototype,"then",function(t){return function(){var e=this,n=o.argsToArray.apply(this,arguments),r=a(e);r.promise=e,n[0]=s(n[0],"cb-",r,null,!1),n[1]=s(n[1],"cb-",r,null,!1);var c=t.apply(this,n);return r.nextPromise=c,i.emit("propagate",[e,!0],c,!1,!1),c}}),i.on("executor-start",function(t){t[0]=s(t[0],"resolve-",this,null,!1),t[1]=s(t[1],"resolve-",this,null,!1)}),i.on("executor-err",function(t,e,n){t[1](n)}),i.on("cb-end",function(t,e,n){i.emit("propagate",[n,!0],this.nextPromise,!1,!1)}),i.on("propagate",function(t,e,n){this.getCtx&&!e||(this.getCtx=function(){if(t instanceof Promise)var e=i.context(t);return e&&e.getCtx?e.getCtx():this})}),r.toString=function(){return""+f})},{}],13:[function(t,e,n){var r=t("ee").get("raf"),o=t("wrap-function")(r),i="equestAnimationFrame";e.exports=r,o.inPlace(window,["r"+i,"mozR"+i,"webkitR"+i,"msR"+i],"raf-"),r.on("raf-start",function(t){t[0]=o(t[0],"fn-")})},{}],14:[function(t,e,n){function r(t,e,n){t[0]=a(t[0],"fn-",null,n)}function o(t,e,n){this.method=n,this.timerDuration=isNaN(t[1])?0:+t[1],t[0]=a(t[0],"fn-",this,n)}var i=t("ee").get("timer"),a=t("wrap-function")(i),s="setTimeout",c="setInterval",f="clearTimeout",u="-start",d="-";e.exports=i,a.inPlace(window,[s,"setImmediate"],s+d),a.inPlace(window,[c],c+d),a.inPlace(window,[f,"clearImmediate"],f+d),i.on(c+u,r),i.on(s+u,o)},{}],15:[function(t,e,n){function r(t,e){d.inPlace(e,["onreadystatechange"],"fn-",s)}function o(){var t=this,e=u.context(t);t.readyState>3&&!e.resolved&&(e.resolved=!0,u.emit("xhr-resolved",[],t)),d.inPlace(t,y,"fn-",s)}function i(t){x.push(t),m&&(E?E.then(a):w?w(a):(R=-R,O.data=R))}function a(){for(var t=0;t<x.length;t++)r([],x[t]);x.length&&(x=[])}function s(t,e){return e}function c(t,e){for(var n in t)e[n]=t[n];return e}t(7);var f=t("ee"),u=f.get("xhr"),d=t("wrap-function")(u),p=t(23),l=NREUM.o,h=l.XHR,m=l.MO,v=l.PR,w=l.SI,g="readystatechange",y=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],x=[];e.exports=u;var b=window.XMLHttpRequest=function(t){var e=new h(t);try{u.emit("new-xhr",[e],e),e.addEventListener(g,o,p(!1))}catch(n){try{u.emit("internal-error",[n])}catch(r){}}return e};if(c(h,b),b.prototype=h.prototype,d.inPlace(b.prototype,["open","send"],"-xhr-",s),u.on("send-xhr-start",function(t,e){r(t,e),i(e)}),u.on("open-xhr-start",r),m){var E=v&&v.resolve();if(!w&&!v){var R=1,O=document.createTextNode(R);new m(a).observe(O,{characterData:!0})}}else f.on("fn-end",function(t){t[0]&&t[0].type===g||a()})},{}],16:[function(t,e,n){function r(t){if(!s(t))return null;var e=window.NREUM;if(!e.loader_config)return null;var n=(e.loader_config.accountID||"").toString()||null,r=(e.loader_config.agentID||"").toString()||null,f=(e.loader_config.trustKey||"").toString()||null;if(!n||!r)return null;var h=l.generateSpanId(),m=l.generateTraceId(),v=Date.now(),w={spanId:h,traceId:m,timestamp:v};return(t.sameOrigin||c(t)&&p())&&(w.traceContextParentHeader=o(h,m),w.traceContextStateHeader=i(h,v,n,r,f)),(t.sameOrigin&&!u()||!t.sameOrigin&&c(t)&&d())&&(w.newrelicHeader=a(h,m,v,n,r,f)),w}function o(t,e){return"00-"+e+"-"+t+"-01"}function i(t,e,n,r,o){var i=0,a="",s=1,c="",f="";return o+"@nr="+i+"-"+s+"-"+n+"-"+r+"-"+t+"-"+a+"-"+c+"-"+f+"-"+e}function a(t,e,n,r,o,i){var a="btoa"in window&&"function"==typeof window.btoa;if(!a)return null;var s={v:[0,1],d:{ty:"Browser",ac:r,ap:o,id:t,tr:e,ti:n}};return i&&r!==i&&(s.d.tk=i),btoa(JSON.stringify(s))}function s(t){return f()&&c(t)}function c(t){var e=!1,n={};if("init"in NREUM&&"distributed_tracing"in NREUM.init&&(n=NREUM.init.distributed_tracing),t.sameOrigin)e=!0;else if(n.allowed_origins instanceof Array)for(var r=0;r<n.allowed_origins.length;r++){var o=h(n.allowed_origins[r]);if(t.hostname===o.hostname&&t.protocol===o.protocol&&t.port===o.port){e=!0;break}}return e}function f(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&!!NREUM.init.distributed_tracing.enabled}function u(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&!!NREUM.init.distributed_tracing.exclude_newrelic_header}function d(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&NREUM.init.distributed_tracing.cors_use_newrelic_header!==!1}function p(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&!!NREUM.init.distributed_tracing.cors_use_tracecontext_headers}var l=t(29),h=t(18);e.exports={generateTracePayload:r,shouldGenerateTrace:s}},{}],17:[function(t,e,n){function r(t){var e=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var r=0;r<p;r++)t.removeEventListener(d[r],this.listener,!1);e.aborted||(n.duration=a.now()-this.startTime,this.loadCaptureCalled||4!==t.readyState?null==e.status&&(e.status=0):i(this,t),n.cbTime=this.cbTime,s("xhr",[e,n,this.startTime,this.endTime,"xhr"],this))}}function o(t,e){var n=c(e),r=t.params;r.hostname=n.hostname,r.port=n.port,r.protocol=n.protocol,r.host=n.hostname+":"+n.port,r.pathname=n.pathname,t.parsedOrigin=n,t.sameOrigin=n.sameOrigin}function i(t,e){t.params.status=e.status;var n=v(e,t.lastSize);if(n&&(t.metrics.rxSize=n),t.sameOrigin){var r=e.getResponseHeader("X-NewRelic-App-Data");r&&(t.params.cat=r.split(", ").pop())}t.loadCaptureCalled=!0}var a=t("loader");if(a.xhrWrappable&&!a.disabled){var s=t("handle"),c=t(18),f=t(16).generateTracePayload,u=t("ee"),d=["load","error","abort","timeout"],p=d.length,l=t("id"),h=t(24),m=t(22),v=t(19),w=t(23),g=NREUM.o.REQ,y=window.XMLHttpRequest;a.features.xhr=!0,t(15),t(8),u.on("new-xhr",function(t){var e=this;e.totalCbs=0,e.called=0,e.cbTime=0,e.end=r,e.ended=!1,e.xhrGuids={},e.lastSize=null,e.loadCaptureCalled=!1,e.params=this.params||{},e.metrics=this.metrics||{},t.addEventListener("load",function(n){i(e,t)},w(!1)),h&&(h>34||h<10)||t.addEventListener("progress",function(t){e.lastSize=t.loaded},w(!1))}),u.on("open-xhr-start",function(t){this.params={method:t[0]},o(this,t[1]),this.metrics={}}),u.on("open-xhr-end",function(t,e){"loader_config"in NREUM&&"xpid"in NREUM.loader_config&&this.sameOrigin&&e.setRequestHeader("X-NewRelic-ID",NREUM.loader_config.xpid);var n=f(this.parsedOrigin);if(n){var r=!1;n.newrelicHeader&&(e.setRequestHeader("newrelic",n.newrelicHeader),r=!0),n.traceContextParentHeader&&(e.setRequestHeader("traceparent",n.traceContextParentHeader),n.traceContextStateHeader&&e.setRequestHeader("tracestate",n.traceContextStateHeader),r=!0),r&&(this.dt=n)}}),u.on("send-xhr-start",function(t,e){var n=this.metrics,r=t[0],o=this;if(n&&r){var i=m(r);i&&(n.txSize=i)}this.startTime=a.now(),this.listener=function(t){try{"abort"!==t.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==t.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof e.onload))&&o.end(e)}catch(n){try{u.emit("internal-error",[n])}catch(r){}}};for(var s=0;s<p;s++)e.addEventListener(d[s],this.listener,w(!1))}),u.on("xhr-cb-time",function(t,e,n){this.cbTime+=t,e?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof n.onload||this.end(n)}),u.on("xhr-load-added",function(t,e){var n=""+l(t)+!!e;this.xhrGuids&&!this.xhrGuids[n]&&(this.xhrGuids[n]=!0,this.totalCbs+=1)}),u.on("xhr-load-removed",function(t,e){var n=""+l(t)+!!e;this.xhrGuids&&this.xhrGuids[n]&&(delete this.xhrGuids[n],this.totalCbs-=1)}),u.on("xhr-resolved",function(){this.endTime=a.now()}),u.on("addEventListener-end",function(t,e){e instanceof y&&"load"===t[0]&&u.emit("xhr-load-added",[t[1],t[2]],e)}),u.on("removeEventListener-end",function(t,e){e instanceof y&&"load"===t[0]&&u.emit("xhr-load-removed",[t[1],t[2]],e)}),u.on("fn-start",function(t,e,n){e instanceof y&&("onload"===n&&(this.onload=!0),("load"===(t[0]&&t[0].type)||this.onload)&&(this.xhrCbStart=a.now()))}),u.on("fn-end",function(t,e){this.xhrCbStart&&u.emit("xhr-cb-time",[a.now()-this.xhrCbStart,this.onload,e],e)}),u.on("fetch-before-start",function(t){function e(t,e){var n=!1;return e.newrelicHeader&&(t.set("newrelic",e.newrelicHeader),n=!0),e.traceContextParentHeader&&(t.set("traceparent",e.traceContextParentHeader),e.traceContextStateHeader&&t.set("tracestate",e.traceContextStateHeader),n=!0),n}var n,r=t[1]||{};"string"==typeof t[0]?n=t[0]:t[0]&&t[0].url?n=t[0].url:window.URL&&t[0]&&t[0]instanceof URL&&(n=t[0].href),n&&(this.parsedOrigin=c(n),this.sameOrigin=this.parsedOrigin.sameOrigin);var o=f(this.parsedOrigin);if(o&&(o.newrelicHeader||o.traceContextParentHeader))if("string"==typeof t[0]||window.URL&&t[0]&&t[0]instanceof URL){var i={};for(var a in r)i[a]=r[a];i.headers=new Headers(r.headers||{}),e(i.headers,o)&&(this.dt=o),t.length>1?t[1]=i:t.push(i)}else t[0]&&t[0].headers&&e(t[0].headers,o)&&(this.dt=o)}),u.on("fetch-start",function(t,e){this.params={},this.metrics={},this.startTime=a.now(),this.dt=e,t.length>=1&&(this.target=t[0]),t.length>=2&&(this.opts=t[1]);var n,r=this.opts||{},i=this.target;"string"==typeof i?n=i:"object"==typeof i&&i instanceof g?n=i.url:window.URL&&"object"==typeof i&&i instanceof URL&&(n=i.href),o(this,n);var s=(""+(i&&i instanceof g&&i.method||r.method||"GET")).toUpperCase();this.params.method=s,this.txSize=m(r.body)||0}),u.on("fetch-done",function(t,e){this.endTime=a.now(),this.params||(this.params={}),this.params.status=e?e.status:0;var n;"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var r={txSize:this.txSize,rxSize:n,duration:a.now()-this.startTime};s("xhr",[this.params,r,this.startTime,this.endTime,"fetch"],this)})}},{}],18:[function(t,e,n){var r={};e.exports=function(t){if(t in r)return r[t];var e=document.createElement("a"),n=window.location,o={};e.href=t,o.port=e.port;var i=e.href.split("://");!o.port&&i[1]&&(o.port=i[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===i[0]?"443":"80"),o.hostname=e.hostname||n.hostname,o.pathname=e.pathname,o.protocol=i[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var a=!e.protocol||":"===e.protocol||e.protocol===n.protocol,s=e.hostname===document.domain&&e.port===n.port;return o.sameOrigin=a&&(!e.hostname||s),"/"===o.pathname&&(r[t]=o),o}},{}],19:[function(t,e,n){function r(t,e){var n=t.responseType;return"json"===n&&null!==e?e:"arraybuffer"===n||"blob"===n||"json"===n?o(t.response):"text"===n||""===n||void 0===n?o(t.responseText):void 0}var o=t(22);e.exports=r},{}],20:[function(t,e,n){function r(){}function o(t,e,n,r){return function(){return u.recordSupportability("API/"+e+"/called"),i(t+e,[f.now()].concat(s(arguments)),n?null:this,r),n?void 0:this}}var i=t("handle"),a=t(32),s=t(33),c=t("ee").get("tracer"),f=t("loader"),u=t(25),d=NREUM;"undefined"==typeof window.newrelic&&(newrelic=d);var p=["setPageViewName","setCustomAttribute","setErrorHandler","finished","addToTrace","inlineHit","addRelease"],l="api-",h=l+"ixn-";a(p,function(t,e){d[e]=o(l,e,!0,"api")}),d.addPageAction=o(l,"addPageAction",!0),d.setCurrentRouteName=o(l,"routeName",!0),e.exports=newrelic,d.interaction=function(){return(new r).get()};var m=r.prototype={createTracer:function(t,e){var n={},r=this,o="function"==typeof e;return i(h+"tracer",[f.now(),t,n],r),function(){if(c.emit((o?"":"no-")+"fn-start",[f.now(),r,o],n),o)try{return e.apply(this,arguments)}catch(t){throw c.emit("fn-err",[arguments,this,t],n),t}finally{c.emit("fn-end",[f.now()],n)}}}};a("actionText,setName,setAttribute,save,ignore,onEnd,getContext,end,get".split(","),function(t,e){m[e]=o(h,e)}),newrelic.noticeError=function(t,e){"string"==typeof t&&(t=new Error(t)),u.recordSupportability("API/noticeError/called"),i("err",[t,f.now(),!1,e])}},{}],21:[function(t,e,n){function r(t){if(NREUM.init){for(var e=NREUM.init,n=t.split("."),r=0;r<n.length-1;r++)if(e=e[n[r]],"object"!=typeof e)return;return e=e[n[n.length-1]]}}e.exports={getConfiguration:r}},{}],22:[function(t,e,n){e.exports=function(t){if("string"==typeof t&&t.length)return t.length;if("object"==typeof t){if("undefined"!=typeof ArrayBuffer&&t instanceof ArrayBuffer&&t.byteLength)return t.byteLength;if("undefined"!=typeof Blob&&t instanceof Blob&&t.size)return t.size;if(!("undefined"!=typeof FormData&&t instanceof FormData))try{return JSON.stringify(t).length}catch(e){return}}}},{}],23:[function(t,e,n){var r=!1;try{var o=Object.defineProperty({},"passive",{get:function(){r=!0}});window.addEventListener("testPassive",null,o),window.removeEventListener("testPassive",null,o)}catch(i){}e.exports=function(t){return r?{passive:!0,capture:!!t}:!!t}},{}],24:[function(t,e,n){var r=0,o=navigator.userAgent.match(/Firefox[\/\s](\d+\.\d+)/);o&&(r=+o[1]),e.exports=r},{}],25:[function(t,e,n){function r(t,e){var n=[a,t,{name:t},e];return i("storeMetric",n,null,"api"),n}function o(t,e){var n=[s,t,{name:t},e];return i("storeEventMetrics",n,null,"api"),n}var i=t("handle"),a="sm",s="cm";e.exports={constants:{SUPPORTABILITY_METRIC:a,CUSTOM_METRIC:s},recordSupportability:r,recordCustom:o}},{}],26:[function(t,e,n){function r(){return s.exists&&performance.now?Math.round(performance.now()):(i=Math.max((new Date).getTime(),i))-a}function o(){return i}var i=(new Date).getTime(),a=i,s=t(34);e.exports=r,e.exports.offset=a,e.exports.getLastTimestamp=o},{}],27:[function(t,e,n){function r(t){return!(!t||!t.protocol||"file:"===t.protocol)}e.exports=r},{}],28:[function(t,e,n){function r(t,e){var n=t.getEntries();n.forEach(function(t){"first-paint"===t.name?p("timing",["fp",Math.floor(t.startTime)]):"first-contentful-paint"===t.name&&p("timing",["fcp",Math.floor(t.startTime)])})}function o(t,e){var n=t.getEntries();if(n.length>0){var r=n[n.length-1];if(c&&c<r.startTime)return;p("lcp",[r])}}function i(t){t.getEntries().forEach(function(t){t.hadRecentInput||p("cls",[t])})}function a(t){if(t instanceof v&&!g){var e=Math.round(t.timeStamp),n={type:t.type};e<=l.now()?n.fid=l.now()-e:e>l.offset&&e<=Date.now()?(e-=l.offset,n.fid=l.now()-e):e=l.now(),g=!0,p("timing",["fi",e,n])}}function s(t){"hidden"===t&&(c=l.now(),p("pageHide",[c]))}if(!("init"in NREUM&&"page_view_timing"in NREUM.init&&"enabled"in NREUM.init.page_view_timing&&NREUM.init.page_view_timing.enabled===!1)){var c,f,u,d,p=t("handle"),l=t("loader"),h=t(31),m=t(23),v=NREUM.o.EV;if("PerformanceObserver"in window&&"function"==typeof window.PerformanceObserver){f=new PerformanceObserver(r);try{f.observe({entryTypes:["paint"]})}catch(w){}u=new PerformanceObserver(o);try{u.observe({entryTypes:["largest-contentful-paint"]})}catch(w){}d=new PerformanceObserver(i);try{d.observe({type:"layout-shift",buffered:!0})}catch(w){}}if("addEventListener"in document){var g=!1,y=["click","keydown","mousedown","pointerdown","touchstart"];y.forEach(function(t){document.addEventListener(t,a,m(!1))})}h(s)}},{}],29:[function(t,e,n){function r(){function t(){return e?15&e[n++]:16*Math.random()|0}var e=null,n=0,r=window.crypto||window.msCrypto;r&&r.getRandomValues&&(e=r.getRandomValues(new Uint8Array(31)));for(var o,i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx",a="",s=0;s<i.length;s++)o=i[s],"x"===o?a+=t().toString(16):"y"===o?(o=3&t()|8,a+=o.toString(16)):a+=o;return a}function o(){return a(16)}function i(){return a(32)}function a(t){function e(){return n?15&n[r++]:16*Math.random()|0}var n=null,r=0,o=window.crypto||window.msCrypto;o&&o.getRandomValues&&Uint8Array&&(n=o.getRandomValues(new Uint8Array(31)));for(var i=[],a=0;a<t;a++)i.push(e().toString(16));return i.join("")}e.exports={generateUuid:r,generateSpanId:o,generateTraceId:i}},{}],30:[function(t,e,n){function r(t,e){if(!o)return!1;if(t!==o)return!1;if(!e)return!0;if(!i)return!1;for(var n=i.split("."),r=e.split("."),a=0;a<r.length;a++)if(r[a]!==n[a])return!1;return!0}var o=null,i=null,a=/Version\/(\S+)\s+Safari/;if(navigator.userAgent){var s=navigator.userAgent,c=s.match(a);c&&s.indexOf("Chrome")===-1&&s.indexOf("Chromium")===-1&&(o="Safari",i=c[1])}e.exports={agent:o,version:i,match:r}},{}],31:[function(t,e,n){function r(t){function e(){t(s&&document[s]?document[s]:document[i]?"hidden":"visible")}"addEventListener"in document&&a&&document.addEventListener(a,e,o(!1))}var o=t(23);e.exports=r;var i,a,s;"undefined"!=typeof document.hidden?(i="hidden",a="visibilitychange",s="visibilityState"):"undefined"!=typeof document.msHidden?(i="msHidden",a="msvisibilitychange"):"undefined"!=typeof document.webkitHidden&&(i="webkitHidden",a="webkitvisibilitychange",s="webkitVisibilityState")},{}],32:[function(t,e,n){function r(t,e){var n=[],r="",i=0;for(r in t)o.call(t,r)&&(n[i]=e(r,t[r]),i+=1);return n}var o=Object.prototype.hasOwnProperty;e.exports=r},{}],33:[function(t,e,n){function r(t,e,n){e||(e=0),"undefined"==typeof n&&(n=t?t.length:0);for(var r=-1,o=n-e||0,i=Array(o<0?0:o);++r<o;)i[r]=t[e+r];return i}e.exports=r},{}],34:[function(t,e,n){e.exports={exists:"undefined"!=typeof window.performance&&window.performance.timing&&"undefined"!=typeof window.performance.timing.navigationStart}},{}],ee:[function(t,e,n){function r(){}function o(t){function e(t){return t&&t instanceof r?t:t?f(t,c,a):a()}function n(n,r,o,i,a){if(a!==!1&&(a=!0),!l.aborted||i){t&&a&&t(n,r,o);for(var s=e(o),c=m(n),f=c.length,u=0;u<f;u++)c[u].apply(s,r);var p=d[y[n]];return p&&p.push([x,n,r,s]),s}}function i(t,e){g[t]=m(t).concat(e)}function h(t,e){var n=g[t];if(n)for(var r=0;r<n.length;r++)n[r]===e&&n.splice(r,1)}function m(t){return g[t]||[]}function v(t){return p[t]=p[t]||o(n)}function w(t,e){l.aborted||u(t,function(t,n){e=e||"feature",y[n]=e,e in d||(d[e]=[])})}var g={},y={},x={on:i,addEventListener:i,removeEventListener:h,emit:n,get:v,listeners:m,context:e,buffer:w,abort:s,aborted:!1};return x}function i(t){return f(t,c,a)}function a(){return new r}function s(){(d.api||d.feature)&&(l.aborted=!0,d=l.backlog={})}var c="nr@context",f=t("gos"),u=t(32),d={},p={},l=e.exports=o();e.exports.getOrSetContext=i,l.backlog=d},{}],gos:[function(t,e,n){function r(t,e,n){if(o.call(t,e))return t[e];var r=n();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(t,e,{value:r,writable:!0,enumerable:!1}),r}catch(i){}return t[e]=r,r}var o=Object.prototype.hasOwnProperty;e.exports=r},{}],handle:[function(t,e,n){function r(t,e,n,r){o.buffer([t],r),o.emit(t,e,n)}var o=t("ee").get("handle");e.exports=r,r.ee=o},{}],id:[function(t,e,n){function r(t){var e=typeof t;return!t||"object"!==e&&"function"!==e?-1:t===window?0:a(t,i,function(){return o++})}var o=1,i="nr@id",a=t("gos");e.exports=r},{}],loader:[function(t,e,n){function r(){if(!P++){var t=T.info=NREUM.info,e=v.getElementsByTagName("script")[0];if(setTimeout(f.abort,3e4),!(t&&t.licenseKey&&t.applicationID&&e))return f.abort();c(R,function(e,n){t[e]||(t[e]=n)});var n=a();s("mark",["onload",n+T.offset],null,"api"),s("timing",["load",n]);var r=v.createElement("script");0===t.agent.indexOf("http://")||0===t.agent.indexOf("https://")?r.src=t.agent:r.src=h+"://"+t.agent,e.parentNode.insertBefore(r,e)}}function o(){"complete"===v.readyState&&i()}function i(){s("mark",["domContent",a()+T.offset],null,"api")}var a=t(26),s=t("handle"),c=t(32),f=t("ee"),u=t(30),d=t(27),p=t(21),l=t(23),h=p.getConfiguration("ssl")===!1?"http":"https",m=window,v=m.document,w="addEventListener",g="attachEvent",y=m.XMLHttpRequest,x=y&&y.prototype,b=!d(m.location);NREUM.o={ST:setTimeout,SI:m.setImmediate,CT:clearTimeout,XHR:y,REQ:m.Request,EV:m.Event,PR:m.Promise,MO:m.MutationObserver};var E=""+location,R={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-spa-1212.min.js"},O=y&&x&&x[w]&&!/CriOS/.test(navigator.userAgent),T=e.exports={offset:a.getLastTimestamp(),now:a,origin:E,features:{},xhrWrappable:O,userAgent:u,disabled:b};if(!b){t(20),t(28),v[w]?(v[w]("DOMContentLoaded",i,l(!1)),m[w]("load",r,l(!1))):(v[g]("onreadystatechange",o),m[g]("onload",r)),s("mark",["firstbyte",a.getLastTimestamp()],null,"api");var P=0}},{}],"wrap-function":[function(t,e,n){function r(t,e){function n(e,n,r,c,f){function nrWrapper(){var i,a,u,p;try{a=this,i=d(arguments),u="function"==typeof r?r(i,a):r||{}}catch(l){o([l,"",[i,a,c],u],t)}s(n+"start",[i,a,c],u,f);try{return p=e.apply(a,i)}catch(h){throw s(n+"err",[i,a,h],u,f),h}finally{s(n+"end",[i,a,p],u,f)}}return a(e)?e:(n||(n=""),nrWrapper[p]=e,i(e,nrWrapper,t),nrWrapper)}function r(t,e,r,o,i){r||(r="");var s,c,f,u="-"===r.charAt(0);for(f=0;f<e.length;f++)c=e[f],s=t[c],a(s)||(t[c]=n(s,u?c+r:r,o,c,i))}function s(n,r,i,a){if(!h||e){var s=h;h=!0;try{t.emit(n,r,i,e,a)}catch(c){o([c,n,r,i],t)}h=s}}return t||(t=u),n.inPlace=r,n.flag=p,n}function o(t,e){e||(e=u);try{e.emit("internal-error",t)}catch(n){}}function i(t,e,n){if(Object.defineProperty&&Object.keys)try{var r=Object.keys(t);return r.forEach(function(n){Object.defineProperty(e,n,{get:function(){return t[n]},set:function(e){return t[n]=e,e}})}),e}catch(i){o([i],n)}for(var a in t)l.call(t,a)&&(e[a]=t[a]);return e}function a(t){return!(t&&t instanceof Function&&t.apply&&!t[p])}function s(t,e){var n=e(t);return n[p]=t,i(t,n,u),n}function c(t,e,n){var r=t[e];t[e]=s(r,n)}function f(){for(var t=arguments.length,e=new Array(t),n=0;n<t;++n)e[n]=arguments[n];return e}var u=t("ee"),d=t(33),p="nr@original",l=Object.prototype.hasOwnProperty,h=!1;e.exports=r,e.exports.wrapFunction=s,e.exports.wrapInPlace=c,e.exports.argsToArray=f},{}]},{},["loader",2,17,5,3,4]);
  ;NREUM.loader_config={accountID:"804283",trustKey:"804283",agentID:"402703674",licenseKey:"cf99e8d2a3",applicationID:"402703674"}
  ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"cf99e8d2a3",
    // Modified this value from the generated script, to pass prod vs dev
    applicationID: window.location.hostname.includes('journals.plos.org') ? "402703674" : "402694889",
    sa:1}
</script>
<!-- End New Relic -->



<header>
  <div id="topslot" class="head-top">
  <a id="skip-to-content" tabindex="0" class="button" href="#main-content">
    Skip to main content
  </a>

<div class="center">
<div class="title">Advertisement</div>
<!-- DoubleClick Ad Zone -->
  <div class='advertisement' id='div-gpt-ad-1458247671871-0' style='width:728px; height:90px;'>
    <script type='text/javascript'>
      googletag.cmd.push(function() { googletag.display('div-gpt-ad-1458247671871-0'); });
    </script>
  </div>
</div>
  </div>

  <div id="user" class="nav" data-user-management-url="https://community.plos.org">
  </div>
  <div id="pagehdr">

    <nav class="nav-main">




<h1 class="logo">
  <a href="/plosmedicine/.">PLOS Medicine</a>
</h1>

<section class="top-bar-section"> 

<ul class="nav-elements">



  <li class="menu-section-header has-dropdown " id="browse">
    <span class="menu-section-header-title">  Browse </span>

    <ul class="menu-section dropdown "
        id="browse-dropdown-list">
      <li>
    <a href="/plosmedicine/issue" >Current Issue</a>
  </li>

      <li>
    <a href="/plosmedicine/volume" >Journal Archive</a>
  </li>

      <li>
    <a href="https://collections.plos.org/s/plos-medicine-special-issues" >Special Issues</a>
  </li>

      <li>
    <a href="/plosmedicine/s/collections" >Collections</a>
  </li>

      <li>
    <a href="/plosmedicine/s/find-and-read-articles" >Find and Read Articles</a>
  </li>

    </ul>

  </li>


    <li class="multi-col-parent menu-section-header has-dropdown" id="publish">
    Publish
      <div class="dropdown mega ">
        <ul class="multi-col" id="publish-dropdown-list">

  <li class="menu-section-header " id="submissions">
    <span class="menu-section-header-title">  Submissions </span>

    <ul class="menu-section "
        id="submissions-dropdown-list">
      <li>
    <a href="/plosmedicine/s/getting-started" >Getting Started</a>
  </li>

      <li>
    <a href="/plosmedicine/s/submission-guidelines" >Submission Guidelines</a>
  </li>

      <li>
    <a href="/plosmedicine/s/figures" >Figures</a>
  </li>

      <li>
    <a href="/plosmedicine/s/tables" >Tables</a>
  </li>

      <li>
    <a href="/plosmedicine/s/supporting-information" >Supporting Information</a>
  </li>

      <li>
    <a href="/plosmedicine/s/latex" >LaTeX</a>
  </li>

      <li>
    <a href="/plosmedicine/s/other-article-types" >Other Article Types</a>
  </li>

      <li>
    <a href="/plosmedicine/s/preprints" >Preprints</a>
  </li>

      <li>
    <a href="/plosmedicine/s/revising-your-manuscript" >Revising Your Manuscript</a>
  </li>

      <li>
    <a href="/plosmedicine/s/submit-now" >Submit Now</a>
  </li>

    </ul>

  </li>


  <li class="menu-section-header " id="policies">
    <span class="menu-section-header-title">  Policies </span>

    <ul class="menu-section "
        id="policies-dropdown-list">
      <li>
    <a href="/plosmedicine/s/best-practices-in-research-reporting" >Best Practices in Research Reporting</a>
  </li>

      <li>
    <a href="/plosmedicine/s/human-subjects-research" >Human Subjects Research</a>
  </li>

      <li>
    <a href="/plosmedicine/s/animal-research" >Animal Research</a>
  </li>

      <li>
    <a href="/plosmedicine/s/competing-interests" >Competing Interests</a>
  </li>

      <li>
    <a href="/plosmedicine/s/disclosure-of-funding-sources" >Disclosure of Funding Sources</a>
  </li>

      <li>
    <a href="/plosmedicine/s/licenses-and-copyright" >Licenses and Copyright</a>
  </li>

      <li>
    <a href="/plosmedicine/s/data-availability" >Data Availability</a>
  </li>

      <li>
    <a href="/plosmedicine/s/complementary-research" >Complementary Research</a>
  </li>

      <li>
    <a href="/plosmedicine/s/materials-software-and-code-sharing" >Materials, Software and Code Sharing</a>
  </li>

      <li>
    <a href="/plosmedicine/s/ethical-publishing-practice" >Ethical Publishing Practice</a>
  </li>

      <li>
    <a href="/plosmedicine/s/authorship" >Authorship</a>
  </li>

      <li>
    <a href="/plosmedicine/s/corrections-expressions-of-concern-and-retractions" >Corrections, Expressions of Concern, and Retractions</a>
  </li>

    </ul>

  </li>


  <li class="menu-section-header " id="manuscript-review-and-publication">
    <span class="menu-section-header-title">  Manuscript Review and Publication </span>

    <ul class="menu-section "
        id="manuscript-review-and-publication-dropdown-list">
      <li>
    <a href="/plosmedicine/s/editorial-and-peer-review-process" >Editorial and Peer Review Process</a>
  </li>

      <li>
    <a href="/plosmedicine/s/reviewer-guidelines" >Guidelines for Reviewers</a>
  </li>

      <li>
    <a href="/plosmedicine/s/accepted-manuscripts" >Accepted Manuscripts</a>
  </li>

      <li>
    <a href="/plosmedicine/s/comments" >Comments</a>
  </li>

    </ul>

  </li>
        </ul>
          <div class="calloutcontainer">


  <h3 class="callout-headline">Submit Your Manuscript</h3>

  <div class="action-contain">
  <p class="callout-content">
<em>PLOS Medicine</em> publishes research and commentary of general interest with clear implications for patient care, public policy or clinical research agendas.
  </p>
  <p class="button-contain">
    <a class="button button-default" href="/plosmedicine/s/submit-now">
Get Started
    </a>
  </p>
  </div> <!-- opens in siteMenuCalloutDescription -->
          </div>
      </div>
    </li>



  <li class="menu-section-header has-dropdown " id="about">
    <span class="menu-section-header-title">  About </span>

    <ul class="menu-section dropdown "
        id="about-dropdown-list">
      <li>
    <a href="/plosmedicine/s/journal-information" >Journal Information</a>
  </li>

      <li>
    <a href="/plosmedicine/s/staff-editors" >Staff Editors</a>
  </li>

      <li>
    <a href="/plosmedicine/s/editorial-board" >Editorial Board</a>
  </li>

      <li>
    <a href="/plosmedicine/s/publishing-information" >Publishing Information</a>
  </li>

      <li>
    <a href="https://plos.org/publication-fees" >Publication Fees</a>
  </li>

      <li>
    <a href="https://plos.org/press-and-media" >Press and Media</a>
  </li>

      <li>
    <a href="/plosmedicine/s/resources" >Resources</a>
  </li>

      <li>
    <a href="/plosmedicine/s/contact" >Contact</a>
  </li>

    </ul>

  </li>


<script src="/resource/js/vendor/jquery.hoverIntent.js" type="text/javascript"></script>
<script src="/resource/js/components/menu_drop.js" type="text/javascript"></script>
<script src="/resource/js/components/hover_delay.js" type="text/javascript"></script>
      <li id="navsearch" class="head-search">


    <form name="searchForm" action="/plosmedicine/search" method="get">
      <fieldset>
        <legend>Search</legend>
        <label for="search">Search</label>
        <div class="search-contain">
          <input id="search" type="text" name="q" placeholder="SEARCH" required/>
          <button id="headerSearchButton" type="submit" aria-label="Submit search">
            <i title="Submit search" class="search-icon"></i>
          </button>
        </div>
      </fieldset>
      <input type="hidden" name="filterJournals" value="PLoSMedicine"/>
    </form>

    <a id="advSearch"
       href="/plosmedicine/search">
      advanced search
    </a>




<script src="/resource/js/components/placeholder_style.js" type="text/javascript"></script>
      </li>

      </ul>     
      </section>  
    </nav>
  </div>

</header>
<main id="main-content"> <div class="set-grid">

<header class="title-block">



<script src="/resource/js/components/signposts.js" type="text/javascript"></script>

<ul id="almSignposts" class="signposts">
  <li id="loadingMetrics">
    <p>Loading metrics</p>
  </li>
</ul>

<script type="text/template" id="signpostsGeneralErrorTemplate">
  <li id="metricsError">Article metrics are unavailable at this time. Please try again later.</li>
</script>

<script type="text/template" id="signpostsNewArticleErrorTemplate">
  <li></li><li></li><li id="tooSoon">Article metrics are unavailable for recently published articles.</li>
</script>

<script type="text/template" id="signpostsTemplate">
    <li id="almSaves">
      <%= s.numberFormat(saveCount, 0) %>
      <div class="tools" data-js-tooltip-hover="trigger">
        <a class="metric-term" href="/plosmedicine/article/metrics?id=10.1371/journal.pmed.1004591#savedHeader">Save</a>
        <p class="saves-tip" data-js-tooltip-hover="target"><a href="/plosmedicine/article/metrics?id=10.1371/journal.pmed.1004591#savedHeader">Total Mendeley and Citeulike bookmarks.</a></p>
      </div>
    </li>

    <li id="almCitations">
      <%= s.numberFormat(citationCount, 0) %>
      <div class="tools" data-js-tooltip-hover="trigger">
        <a class="metric-term" href="/plosmedicine/article/metrics?id=10.1371/journal.pmed.1004591#citedHeader">Citation</a>
        <p class="citations-tip" data-js-tooltip-hover="target"><a href="/plosmedicine/article/metrics?id=10.1371/journal.pmed.1004591#citedHeader">Paper's citation count computed by Dimensions.</a></p>
      </div>
    </li>

    <li id="almViews">
      <%= s.numberFormat(viewCount, 0) %>
      <div class="tools" data-js-tooltip-hover="trigger">
        <a class="metric-term" href="/plosmedicine/article/metrics?id=10.1371/journal.pmed.1004591#viewedHeader">View</a>
        <p class="views-tip" data-js-tooltip-hover="target"><a href="/plosmedicine/article/metrics?id=10.1371/journal.pmed.1004591#viewedHeader">PLOS views and downloads.</a></p>
      </div>
    </li>

    <li id="almShares">
      <%= s.numberFormat(shareCount, 0) %>
      <div class="tools" data-js-tooltip-hover="trigger">
        <a class="metric-term" href="/plosmedicine/article/metrics?id=10.1371/journal.pmed.1004591#discussedHeader">Share</a>
        <p class="shares-tip" data-js-tooltip-hover="target"><a href="/plosmedicine/article/metrics?id=10.1371/journal.pmed.1004591#discussedHeader">Sum of Facebook, Twitter, Reddit and Wikipedia activity.</a></p>
      </div>
    </li>
</script>

    <div class="article-meta">

<div class="classifications">
  <p class="license-short" id="licenseShort">Open Access</p>
  <p class="peer-reviewed" id="peerReviewed">Peer-reviewed</p>

<div class="article-type" >
  <p class="type-article" id="artType">Research Article</p>
</div>


</div>
    </div>
    <div class="article-title-etc">



<div class="title-authors">
  <h1 id="artTitle"><?xml version="1.0" encoding="UTF-8"?>Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-α, IL-12/23, IL-17, and IL-23: A population-based retrospective cohort study</h1>

<ul class="author-list clearfix"  data-js-tooltip="tooltip_container" id="author-list">



<li
  data-js-tooltip="tooltip_trigger"
  
>
   <a  data-author-id="0" class="author-name" >
Teng-Li Lin,</a>    <div id="author-meta-0" class="author-info" data-js-tooltip="tooltip_target">

  
  <p class="roles" id="authRoles">
    <span class="type">Roles</span>
    Conceptualization,

    Data curation,

    Formal analysis,

    Investigation,

    Methodology,

    Project administration,

    Software,

    Validation,

    Writing – original draft
  </p>
  
  <p id="authAffiliations-0"><span class="type">Affiliations</span>
    Department of Dermatology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan, 
    Ph.D. Program of Interdisciplinary Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
  </p>

      <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose0"> &#x02A2F; </a>
    </div>
</li>

<li
  data-js-tooltip="tooltip_trigger"
  
>
   <a  data-author-id="1" class="author-name" >
Yi-Hsuan Fan,</a>    <div id="author-meta-1" class="author-info" data-js-tooltip="tooltip_target">

  
  <p class="roles" id="authRoles">
    <span class="type">Roles</span>
    Data curation,

    Formal analysis,

    Investigation,

    Methodology,

    Software
  </p>
  
  <p id="authAffiliations-1"><span class="type">Affiliation</span>
    Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan
  </p>

      <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose1"> &#x02A2F; </a>
    </div>
</li>

<li
  data-js-tooltip="tooltip_trigger"
  
>
   <a  data-author-id="2" class="author-name" >
Kuo-Sheng Fan,</a>    <div id="author-meta-2" class="author-info" data-js-tooltip="tooltip_target">

  
  <p class="roles" id="authRoles">
    <span class="type">Roles</span>
    Conceptualization,

    Methodology
  </p>
  
  <p id="authAffiliations-2"><span class="type">Affiliation</span>
    Department of Internal Medicine, Division of Chest Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan
  </p>

      <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose2"> &#x02A2F; </a>
    </div>
</li>

<li
  data-js-tooltip="tooltip_trigger"
  
>
   <a  data-author-id="3" class="author-name" >
Chao-Kuei Juan,</a>    <div id="author-meta-3" class="author-info" data-js-tooltip="tooltip_target">

  
  <p class="roles" id="authRoles">
    <span class="type">Roles</span>
    Resources
  </p>
  
  <p id="authAffiliations-3"><span class="type">Affiliation</span>
    Department of Dermatology, Taichung Veterans General Hospital, Taichung, Taiwan
  </p>

      <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose3"> &#x02A2F; </a>
    </div>
</li>

<li
  data-js-tooltip="tooltip_trigger"
  
>
   <a  data-author-id="4" class="author-name" >
Yi-Ju Chen <span class="email">  </span>,</a>    <div id="author-meta-4" class="author-info" data-js-tooltip="tooltip_target">

  
  <p class="roles" id="authRoles">
    <span class="type">Roles</span>
    Conceptualization,

    Funding acquisition,

    Project administration,

    Resources,

    Supervision,

    Validation,

    Writing – review & editing
  </p>
  <p id="authCorresponding-4"> <span class="email">* E-mail:</span> <a href="mailto:yjchenmd@vghtc.gov.tw">yjchenmd@vghtc.gov.tw</a> (YJC); <a href="mailto:cywu4@ym.edu.tw">cywu4@ym.edu.tw</a> (CYW)</p>
  <p id="authAffiliations-4"><span class="type">Affiliations</span>
    Department of Dermatology, Taichung Veterans General Hospital, Taichung, Taiwan, 
    Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan, 
    Faculty of Medicine and Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
  </p>
  <div>
  <p class="orcid" id="authOrcid-4">
    <span>
      <a id="connect-orcid-link" href="https://orcid.org/0000-0002-0639-3533" target="_blank" title="ORCID Registry">
        <img id="orcid-id-logo" src="/resource/img/orcid_16x16.png" width="16" height="16" alt="ORCID logo"/>
        https://orcid.org/0000-0002-0639-3533
      </a>
    </span>
  </p>
  </div>

      <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose4"> &#x02A2F; </a>
    </div>
</li>

<li
  data-js-tooltip="tooltip_trigger"
  
>
   <a  data-author-id="5" class="author-name" >
Chun-Ying Wu <span class="email">  </span></a>    <div id="author-meta-5" class="author-info" data-js-tooltip="tooltip_target">

  
  <p class="roles" id="authRoles">
    <span class="type">Roles</span>
    Methodology,

    Supervision,

    Validation,

    Writing – review & editing
  </p>
  <p id="authCorresponding-5"> <span class="email">* E-mail:</span> <a href="mailto:yjchenmd@vghtc.gov.tw">yjchenmd@vghtc.gov.tw</a> (YJC); <a href="mailto:cywu4@ym.edu.tw">cywu4@ym.edu.tw</a> (CYW)</p>
  <p id="authAffiliations-5"><span class="type">Affiliations</span>
    Faculty of Medicine and Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, 
    Institute of Biomedical Informatics, National Yang Ming Chiao Tung University, Taipei, Taiwan, 
    Division of Translational Research, Taipei Veterans General Hospital, Taipei, Taiwan, 
    College of Public Health, China Medical University, Taichung, Taiwan
  </p>

      <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose5"> &#x02A2F; </a>
    </div>
</li>

</ul>
<script src="/resource/js/components/tooltip.js" type="text/javascript"></script>

</div>


<div id="floatTitleTop" data-js-floater="title_author" class="float-title" role="presentation">
  <div class="set-grid">
    <div class="float-title-inner">
      <h1><?xml version="1.0" encoding="UTF-8"?>Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-α, IL-12/23, IL-17, and IL-23: A population-based retrospective cohort study</h1>

<ul id="floatAuthorList" data-js-floater="floated_authors">

  <li data-float-index="1">Teng-Li Lin,&nbsp;

  </li>
  <li data-float-index="2">Yi-Hsuan Fan,&nbsp;

  </li>
  <li data-float-index="3">Kuo-Sheng Fan,&nbsp;

  </li>
  <li data-float-index="4">Chao-Kuei Juan,&nbsp;

  </li>
  <li data-float-index="5">Yi-Ju Chen,&nbsp;

  </li>
  <li data-float-index="6">Chun-Ying Wu

  </li>

</ul>



    </div>
    <div class="logo-close" id="titleTopCloser">
      <img src="/resource/img/logo-plos-full-color.svg" style="height: 2em" alt="PLOS" />
      <div class="close-floater" title="close">x</div>
    </div>
  </div>
</div>

      <ul class="date-doi">
          <li class="revisionList">

<script src="/resource/js/components/revision_menu.js" type="text/javascript"></script>


<!-- make ascending order in the FTL -->
<div id="revisionMenu">
  <form>
   <select name="revisionLink" id="revisionLink">
        <option value="/plosmedicine/article?id=10.1371/journal.pmed.1004591&rev=2" selected>
          Version 2 
        </option>
        <option value="/plosmedicine/article?id=10.1371/journal.pmed.1004591&rev=1" >
          Version 1     Uncorrected Proof

        </option>
    </select>
  </form>
</div>

          </li>
        <li id="artPubDate">Published: April 17, 2025</li>
        <li id="artDoi">
<a   href="https://doi.org/10.1371/journal.pmed.1004591">https://doi.org/10.1371/journal.pmed.1004591</a>
        </li>
        <li class="flex-spacer"></li>
      </ul>

    </div>
  <div>

  </div>
</header>
  <section class="article-body">



<ul class="article-tabs">

          <li class="tab-title active" id="tabArticle">
            <a href="/plosmedicine/article?id=10.1371/journal.pmed.1004591" class="article-tab-1">Article</a>
        </li>


              <li class="tab-title " id="tabAuthors">
            <a href="/plosmedicine/article/authors?id=10.1371/journal.pmed.1004591" class="article-tab-2">Authors</a>
        </li>


          <li class="tab-title " id="tabMetrics">
            <a href="/plosmedicine/article/metrics?id=10.1371/journal.pmed.1004591" class="article-tab-3">Metrics</a>
        </li>


          <li class="tab-title " id="tabComments">
            <a href="/plosmedicine/article/comments?id=10.1371/journal.pmed.1004591" class="article-tab-4">Comments</a>
        </li>

  <li class="tab-title" id="tabRelated">
    <a class="article-tab-5" id="tabRelated-link">Media Coverage</a> 
    <script>$(document).ready(function() { $.getMediaLink("10.1371/journal.pmed.1004591").then(function (url) { $("#tabRelated-link").attr("href", url) } ) })</script>
  </li>
</ul>

    <div class="article-container">


<div id="nav-article">
  <ul class="nav-secondary">

    <li class="nav-comments" id="nav-comments">
      <a href="article/comments?id=10.1371/journal.pmed.1004591">Reader Comments</a>
    </li>

    <li id="nav-figures"><a href="#" data-doi="10.1371/journal.pmed.1004591">Figures</a></li>
  </ul>
  <div id="nav-data-linking" data-data-url="">
  </div>
</div>
<script src="/resource/js/components/scroll.js" type="text/javascript"></script>
<script src="/resource/js/components/nav_builder.js" type="text/javascript"></script>
<script src="/resource/js/components/floating_nav.js" type="text/javascript"></script>

<div id="figure-lightbox-container"></div>

<script id="figure-lightbox-template" type="text/template">
  <div id="figure-lightbox" class="reveal-modal full" data-reveal aria-hidden="true"
       role="dialog">
    <div class="lb-header">
      <h1 id="lb-title"><%= articleTitle %></h1>

      <div id="lb-authors">
              <span>Teng-Li Lin</span>
              <span>Yi-Hsuan Fan</span>
          <a class="more-authors" href="/plosmedicine/article/authors?id=10.1371/journal.pmed.1004591">...</a>
          <span>Chun-Ying Wu</span>
      </div>

      <div class="lb-close" title="close">&nbsp;</div>
    </div>
    <div class="img-container">
      <div class="loader"> <i class="fa-spinner"></i> </div>
      <img class="main-lightbox-image" src=""/>
      <aside id="figures-list">
        <% figureList.each(function (ix, figure) { %>
        <div class="change-img" data-doi="<%= figure.getAttribute('data-doi') %>">
          <img class="aside-figure" src="/plosmedicine/article/figure/image?size=inline&id=<%= figure.getAttribute('data-doi') %>" />
        </div>
        <% }) %>
        <div class="dummy-figure">
        </div>
      </aside>
    </div>
    <div id="lightbox-footer">

      <div id="btns-container" class="lightbox-row <% if(figureList.length <= 1) { print('one-figure-only') } %>">
        <div class="fig-btns-container reset-zoom-wrapper left">
          <span class="fig-btn reset-zoom-btn">Reset zoom</span>
        </div>
        <div class="zoom-slider-container">
          <div class="range-slider-container">
            <span id="lb-zoom-min"></span>
            <div class="range-slider round" data-slider data-options="start: 20; end: 200; initial: 20;">
              <span class="range-slider-handle" role="slider" tabindex="0"></span>
              <span class="range-slider-active-segment"></span>
              <input type="hidden">
            </div>
            <span id="lb-zoom-max"></span>
          </div>
        </div>
        <% if(figureList.length > 1) { %>
        <div class="fig-btns-container">
          <span class="fig-btn all-fig-btn"><i class="icon icon-all"></i> All Figures</span>
          <span class="fig-btn next-fig-btn"><i class="icon icon-next"></i> Next</span>
          <span class="fig-btn prev-fig-btn"><i class="icon icon-prev"></i> Previous</span>
        </div>
        <% } %>
      </div>
      <div id="image-context">
      </div>
    </div>
  </div>
</script>

<script id="image-context-template" type="text/template">
  <div class="footer-text">
    <div id="figure-description-wrapper">
      <div id="view-more-wrapper" style="<% descriptionExpanded? print('display:none;') : '' %>">
        <span id="figure-title"><%= title %></span>
        <p id="figure-description">
          <%= description %>&nbsp;&nbsp;
        </p>
        <span id="view-more">show more<i class="icon-arrow-right"></i></span>

      </div>
      <div id="view-less-wrapper" style="<% descriptionExpanded? print('display:inline-block;') : '' %>" >
        <span id="figure-title"><%= title %></span>
        <p id="full-figure-description">
          <%= description %>&nbsp;&nbsp;
          <span id="view-less">show less<i class="icon-arrow-left"></i></span>
        </p>
      </div>
    </div>
  </div>
  <div id="show-context-container">
    <a class="btn show-context" href="<%= showInContext(strippedDoi) %>">Show in Context</a>
  </div>
  <div id="download-buttons">
    <h3>Download:</h3>
    <div class="item">
      <a href="/plosmedicine/article/figure/image?size=original&download=&id=<%= doi %>" title="original image">
        <span class="download-btn">TIFF</span>
      </a>
      <span class="file-size"><%= fileSizes.original %></span>
    </div>
    <div class="item">
      <a href="/plosmedicine/article/figure/image?size=large&download=&id=<%= doi %>" title="large image">
        <span class="download-btn">PNG</span>
      </a>
      <span class="file-size"><%= fileSizes.large %></span>
    </div>
    <div class="item">
      <a href="/plosmedicine/article/figure/powerpoint?id=<%= doi %>" title="PowerPoint slide">
        <span class="download-btn">PPT</span>
      </a>
    </div>

  </div>
</script>
      <div class="article-content">






<div id="figure-carousel-section">
  <h2>Figures</h2>

  <div id="figure-carousel">

    <div class="carousel-wrapper">
      <div class="slider">

          <div class="carousel-item lightbox-figure" data-doi="10.1371/journal.pmed.1004591.t001">

                <img src="/plosmedicine/article/figure/image?size=inline&amp;id=10.1371/journal.pmed.1004591.t001"
                     loading="lazy"
                     alt="Table 1"
                />

            </div>

          <div class="carousel-item lightbox-figure" data-doi="10.1371/journal.pmed.1004591.g001">

                <img src="/plosmedicine/article/figure/image?size=inline&amp;id=10.1371/journal.pmed.1004591.g001"
                     loading="lazy"
                     alt="Fig 1"
                />

            </div>

          <div class="carousel-item lightbox-figure" data-doi="10.1371/journal.pmed.1004591.g002">

                <img src="/plosmedicine/article/figure/image?size=inline&amp;id=10.1371/journal.pmed.1004591.g002"
                     loading="lazy"
                     alt="Fig 2"
                />

            </div>

          <div class="carousel-item lightbox-figure" data-doi="10.1371/journal.pmed.1004591.g003">

                <img src="/plosmedicine/article/figure/image?size=inline&amp;id=10.1371/journal.pmed.1004591.g003"
                     loading="lazy"
                     alt="Fig 3"
                />

            </div>

          <div class="carousel-item lightbox-figure" data-doi="10.1371/journal.pmed.1004591.g004">

                <img src="/plosmedicine/article/figure/image?size=inline&amp;id=10.1371/journal.pmed.1004591.g004"
                     loading="lazy"
                     alt="Fig 4"
                />

            </div>
      </div>
    </div>

    <div class="carousel-control">
      <span class="button previous"></span>
      <span class="button next"></span>
    </div>
    <div class="carousel-page-buttons">

    </div>
  </div>
</div>
<script src="/resource/js/vendor/jquery.touchswipe.js" type="text/javascript"></script>
<script src="/resource/js/components/figure_carousel.js" type="text/javascript"></script>
<script src="/resource/js/vendor/jquery.dotdotdot.js" type="text/javascript"></script>


        <div class="article-text" id="artText">
          



<div xmlns:plos="http://plos.org" class="abstract toc-section abstract-type-"><a id="abstract0" name="abstract0" data-toc="abstract0" class="link-target" title="Abstract"></a><h2>Abstract</h2><div class="abstract-content">
<div id="section1" class="section toc-section"><a id="sec001" name="sec001" class="link-target" title="Background"></a>
<h3>Background</h3>
<a id="article1.front1.article-meta1.abstract1.sec1.p1" name="article1.front1.article-meta1.abstract1.sec1.p1" class="link-target"></a><p>Psoriasis is associated with various cardiovascular diseases (CVDs). The aim of this study was to compare the risk of CVD in patients with psoriasis who were prescribed biologics or oral therapies, and to assess the association between different classes of biologics and CVD risk.</p>
</div>

<div id="section2" class="section toc-section"><a id="sec002" name="sec002" class="link-target" title="Methods and Findings"></a>
<h3>Methods and Findings</h3>
<a id="article1.front1.article-meta1.abstract1.sec2.p1" name="article1.front1.article-meta1.abstract1.sec2.p1" class="link-target"></a><p>This retrospective cohort study utilized the TriNetX Global Collaborative Network (2014–2025). Patients with psoriasis newly prescribed biologics (BIO-cohort) and those newly initiating oral anti-psoriatic drugs without biologic exposure (Non-BIO-cohort) were enrolled. A propensity score-matched analysis was conducted, accounting for age, sex, race, comorbidities, body mass index, serum lipid profile, and inflammatory marker levels. Cardiovascular risk was compared between the BIO- and Non-BIO-cohorts using Cox regression to calculate hazard ratios (HRs) with 95% confidence intervals (CIs). After matching, each cohort comprised 12,732 patients, with approximately 50% being female, a mean age of 57 years, and 55% identifying as White. The 5-year cumulative incidence of any CVDs was significantly lower in the BIO-cohort (10.68%; 95% CI [10.03%, 11.36%]) than in the Non-BIO-cohort (16.17%; 95% CI: [15.34%, 17.05%]) (<em>p</em> &lt; 0.001). The BIO-cohort had attenuated risks of any CVDs (HR 0.621; 95% CI [0.571, 0.676]), cerebrovascular diseases (HR 0.616; 95% CI [0.519, 0.731]), arrhythmias (HR 0.632; 95% CI [0.565, 0.706]), inflammatory heart diseases (HR 0.566; 95% CI [0.360, 0.891]), ischemic heart diseases (HR 0.579; 95% CI [0.465, 0.721]), heart failure (HR 0.637; 95% CI [0.521, 0.780]), non-ischemic cardiomyopathy (HR 0.654; 95% CI [0.466, 0.918]), thrombotic disorders (HR 0.570; 95% CI [0.444, 0.733]), peripheral arterial occlusive diseases (HR 0.501; 95% CI [0.383, 0.656]), and major adverse cardiac events (HR 0.697; 95% CI [0.614, 0.792]). Receiving only anti-tumor necrosis factor (TNF)-α (HR 0.886; 95% CI [0.807, 0.973]), anti-interleukin (IL)-17 (HR 0.724; 95% CI [0.599, 0.875]), or anti-IL-23 (HR 0.739; 95% CI [0.598, 0.914]) was associated with reduced risks of any CVDs, whereas no significant association was observed for only anti-IL-12/23 (HR 0.915; 95% CI [0.742, 1.128]). This risk reduction remained consistent across various subgroups, including age (≤45 or &gt;45 years), sex (male or female), regions of research data (the United States, Europe, Middle East and Africa, and Asia-Pacific), and comorbidities (psoriatic arthritis, hypertension, diabetes, hyperlipidemia, overweight or obesity). Eight sensitivity analyses, such as extending the washout period or tightening medication definitions, validated our findings. The main limitation of our study is the observational design, which can only establish associations, not causation.</p>
</div>

<div id="section3" class="section toc-section"><a id="sec003" name="sec003" class="link-target" title="Conclusions"></a>
<h3>Conclusions</h3>
<a id="article1.front1.article-meta1.abstract1.sec3.p1" name="article1.front1.article-meta1.abstract1.sec3.p1" class="link-target"></a><p>Patients with psoriasis prescribed biologics exhibited a lower risk of CVDs versus those on oral therapy. Anti-TNF-α, anti-IL-17, and anti-IL-23 were associated with decreased cardiovascular hazards, while anti-IL-12/23 was not.</p>
</div>
</div></div><div xmlns:plos="http://plos.org" class="abstract toc-section abstract-type-summary"><a id="abstract1" name="abstract1" data-toc="abstract1" class="link-target" title="Author summary"></a>
<h2>Author summary</h2>
<div class="abstract-content">
<div id="section1" class="section toc-section"><a id="sec004" name="sec004" class="link-target" title="Why was this study done?"></a>
<h3>Why was this study done?</h3>


<ul class="bulleted">

<li>People with psoriasis have a higher risk of heart disease, possibly due to inflammation caused by certain proteins in the body, such as tumor necrosis factor (TNF)-α, interleukin (IL)-23, and IL-17.</li>

<li>Biologics used to treat psoriasis, which inhibit TNF-α or the IL-23/IL-17 pathway, have been shown to improve heart health.</li>

</ul></div>

<div id="section2" class="section toc-section"><a id="sec005" name="sec005" class="link-target" title="What did the researchers do and find?"></a>
<h3>What did the researchers do and find?</h3>


<ul class="bulleted">

<li>We analyzed electronic health records from the TriNetX Network, which includes data from 156 million patients across 142 healthcare organizations in 18 countries.</li>

<li>We included 12,732 patients with psoriasis on biologics and 12,732 on oral psoriasis drugs, and found that those on biologics had a lower risk of heart diseases over a five-year follow-up period.</li>

<li>This lower risk was seen across different heart conditions, including stroke, arrhythmias, inflammatory heart diseases, ischemic heart diseases, heart failure, non-ischemic cardiomyopathy, thrombotic disorders, peripheral arterial occlusive diseases, and major adverse cardiac events.</li>

<li>Patients receiving anti-TNF-α, anti-IL-17, or anti-IL-23 alone had a lower risk of heart disease, while no association was observed for those receiving anti-IL-12/23 alone.</li>

</ul></div>

<div id="section3" class="section toc-section"><a id="sec006" name="sec006" class="link-target" title="What do these findings mean?"></a>
<h3>What do these findings mean?</h3>


<ul class="bulleted">

<li>Biologic treatment may help protect patients with psoriasis from heart diseases.</li>

<li>More research is needed to understand how biologics targeting TNF-α, IL-17, or IL-23 might reduce heart disease risk and whether this benefit applies to a broader population.</li>

<li>While this study shows an association between biologics commonly in psoriasis treatment and lower heart disease risk, it does not establish causality.</li>

</ul></div>
</div></div>


<div xmlns:plos="http://plos.org" class="articleinfo"><p><strong>Citation: </strong>Lin T-L, Fan Y-H, Fan K-S, Juan C-K, Chen Y-J, Wu C-Y (2025) Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-α, IL-12/23, IL-17, and IL-23: A population-based retrospective cohort study. PLoS Med 22(4):
           e1004591.
        
        https://doi.org/10.1371/journal.pmed.1004591</p><p><strong>Academic Editor: </strong>Tom W. J. Huizinga, Leiden University Medical Centre, NETHERLANDS, KINGDOM OF THE</p><p><strong>Received: </strong>November 5, 2024; <strong>Accepted: </strong>March 25, 2025; <strong>Published: </strong> April 17, 2025</p><p><strong>Copyright: </strong> © 2025 Lin et al. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</p><p><strong>Data Availability: </strong>Data Sharing Statement: The data used for this article were acquired from TriNetX. The TriNetX system returned the results of these analyses as .csv files, which were downloaded and archived. This study had no special privileges. Inclusion criteria specified in the Methods would allow other researchers to identify similar cohorts of patients as we used here for these analyses; however, TriNetX is a live platform with new data being added daily so exact counts will vary. To gain access to the data, a request can be made to TriNetX (<a href="mailto:join@trinetx.com">join@trinetx.com</a>), but costs might be incurred, and a data-sharing agreement would be necessary.</p><p><strong>Funding: </strong>This work was supported by the National Science Technology Council, Taiwan (NSTC 111-2314-B-075A-001-MY3 to YJC) and Taichung Veterans General Hospital (TCVGH 1126801C to YJC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p><p><strong>Competing interests: </strong> The authors have declared that no competing interests exist.</p><p><strong>Abbreviations:
          </strong>CIs,
            confidence intervals; CVDs,
            cardiovascular diseases; EMEA,
            Europe, the Middle East, Africa; HRs,
            hazard ratios; IL,
            interleukin; MACEs,
            major adverse cardiac events; MI,
            myocardial infarction; PSM,
            propensity score matching; PsO,
            psoriasis; SD,
            standard deviation; STROBE,
            Strengthening the Reporting of Observational Studies in Epidemiology; TNF-α,
            tumor necrosis factor-α</p></div>





<div xmlns:plos="http://plos.org" id="section1" class="section toc-section"><a id="sec007" name="sec007" data-toc="sec007" class="link-target" title="Introduction"></a><h2>Introduction</h2><a id="article1.body1.sec1.p1" name="article1.body1.sec1.p1" class="link-target"></a><p>Psoriasis (PsO) is a chronic dermatosis characterized by systemic inflammation, which can drive dysfunction in organs beyond the skin. Cardiovascular diseases (CVDs) frequently accompany PsO as comorbidities. Research indicates elevated risks of various CVDs in PsO, including stroke, myocardial infarction (MI), heart failure, atrial fibrillation, and vascular disorders [<a href="#pmed.1004591.ref001" class="ref-tip">1</a>–<a href="#pmed.1004591.ref004" class="ref-tip">4</a>]. In the European guideline for CVD prevention, PsO has been recognized as a contributing risk factor, amplifying cardiovascular hazard by 1.5 times [<a href="#pmed.1004591.ref005" class="ref-tip">5</a>].</p>
<a id="article1.body1.sec1.p2" name="article1.body1.sec1.p2" class="link-target"></a><p>The shared immunoinflammatory mechanism underlies the association between PsO and CVDs. The upstream pathogenic cytokine of PsO, tumor necrosis factor-α (TNF-α), can trigger oxidative stress and augment angiotensin effects, resulting in endothelial damage and vasomotor disruption [<a href="#pmed.1004591.ref006" class="ref-tip">6</a>,<a href="#pmed.1004591.ref007" class="ref-tip">7</a>]. Aberrantly activated interleukin (IL)-23/IL-17 axis, the key factor in PsO [<a href="#pmed.1004591.ref008" class="ref-tip">8</a>], is also implicated in atherosclerosis and atheroma instability, thereby causing vessel stiffness and thrombosis [<a href="#pmed.1004591.ref009" class="ref-tip">9</a>–<a href="#pmed.1004591.ref011" class="ref-tip">11</a>]. The particularly high cardiovascular risk in severe PsO echoes the contribution of psoriatic inflammation to CVD development [<a href="#pmed.1004591.ref001" class="ref-tip">1</a>,<a href="#pmed.1004591.ref012" class="ref-tip">12</a>].</p>
<a id="article1.body1.sec1.p3" name="article1.body1.sec1.p3" class="link-target"></a><p>Evidence suggests that controlling inflammation in PsO with conventional systemic anti-psoriatic drugs could alleviate CVD risk [<a href="#pmed.1004591.ref013" class="ref-tip">13</a>–<a href="#pmed.1004591.ref016" class="ref-tip">16</a>]. By targeting key psoriatic effectors, biologics offer enhanced efficacy against PsO and potentially heightened benefits in reducing subsequent CVDs. Inhibiting TNF-α or the IL-23/IL-17 pathway has demonstrated improvements in various cardiovascular health indicators [<a href="#pmed.1004591.ref017" class="ref-tip">17</a>–<a href="#pmed.1004591.ref023" class="ref-tip">23</a>]. Consistent with this, biologic treatment for PsO is linked to a greater mitigation in CVD risk in certain investigations [<a href="#pmed.1004591.ref014" class="ref-tip">14</a>,<a href="#pmed.1004591.ref024" class="ref-tip">24</a>,<a href="#pmed.1004591.ref025" class="ref-tip">25</a>]. Nevertheless, conflicting results also exist across the literature [<a href="#pmed.1004591.ref026" class="ref-tip">26</a>–<a href="#pmed.1004591.ref028" class="ref-tip">28</a>]. Moreover, the role of newly developed biologics targeting IL-17 or IL-23 on CVDs remains understudied. Another gap is the limited exploration of CVD risk beyond stroke and MI in patients with PsO receiving biologics [<a href="#pmed.1004591.ref014" class="ref-tip">14</a>,<a href="#pmed.1004591.ref024" class="ref-tip">24</a>–<a href="#pmed.1004591.ref028" class="ref-tip">28</a>].</p>
<a id="article1.body1.sec1.p4" name="article1.body1.sec1.p4" class="link-target"></a><p>This study aimed to assess the association between biologics and CVD risk in patients with PsO compared to oral anti-psoriatic drugs. We hypothesized that biologic treatments would be associated with a lower risk of CVDs in patients with PsO compared to those on oral therapy.</p>
</div>

<div xmlns:plos="http://plos.org" id="section2" class="section toc-section"><a id="sec008" name="sec008" data-toc="sec008" class="link-target" title="Methods"></a><h2>Methods</h2>
<div id="section1" class="section toc-section"><a id="sec009" name="sec009" class="link-target" title="Data source"></a>
<h3>Data source</h3>
<a id="article1.body1.sec2.sec1.p1" name="article1.body1.sec2.sec1.p1" class="link-target"></a><p>This retrospective cohort study utilized data from the Global Collaborative Network within the TriNetX database, spanning 2014–2025. TriNetX is a research platform gathering anonymized, real-time data from multiple healthcare organizations worldwide, with records updated approximately every two weeks. The Global Collaborative Network, a subset of TriNetX, comprises around 156 million patients from 142 healthcare organizations across 18 countries (<a href="#pmed.1004591.s001">S1 Text</a>). Available data includes demographics, diagnoses, measurements, medications, and procedures, which are extensively utilized in epidemiologic research [<a href="#pmed.1004591.ref029" class="ref-tip">29</a>,<a href="#pmed.1004591.ref030" class="ref-tip">30</a>]. Details about the standardized codes used in this study are available in the online <a href="#pmed.1004591.s004">S1 Table</a>. Data analysis was concluded on February 6, 2025. Ethical approval was granted by Taichung Veterans General Hospital, Taiwan (No. CE23353C), with informed consent waived due to data de-identification.</p>
</div>

<div id="section2" class="section toc-section"><a id="sec010" name="sec010" class="link-target" title="Study design and population"></a>
<h3>Study design and population</h3>
<a id="article1.body1.sec2.sec2.p1" name="article1.body1.sec2.sec2.p1" class="link-target"></a><p>Patients aged 18 years or older with two separate PsO diagnoses, spaced at least 30 days apart, were eligible. This approach, validated in electronic health record databases, helps reduce misclassification and has been used in other high-quality studies [<a href="#pmed.1004591.ref030" class="ref-tip">30</a>,<a href="#pmed.1004591.ref031" class="ref-tip">31</a>]. The biologic cohort (BIO-cohort) comprised patients prescribed biologics, including anti-TNF-α (infliximab, adalimumab, etanercept, golimumab, and certolizumab), anti-IL-12/23 (ustekinumab), anti-IL-17 (secukinumab, ixekizumab, and brodalimumab), or anti-IL-23 (guselkumab, risankizumab, and tildrakizumab), for a minimum of three times following their PsO diagnosis. Since biologics are typically later-line treatments compared to oral anti-psoriatic drugs, we did not exclude BIO-cohort patients who had previously used oral therapies. The non-biologic cohort (Non-BIO-cohort) encompassed patients prescribed oral anti-psoriatic drugs, including methotrexate, cyclosporin, acitretin, and apremilast, for at least 3 times post-PsO diagnosis, but never biologic use. The 3-treatment minimum aimed to reduce the inclusion of patients with poor adherence. The index date was defined as the initial prescription date of either biologics for the BIO-cohort or oral anti-psoriatic drugs for the Non-BIO-cohort.</p>
<a id="article1.body1.sec2.sec2.p2" name="article1.body1.sec2.sec2.p2" class="link-target"></a><p>We excluded patients with non-psoriatic conditions indicating anti-TNF-α, anti-IL-12/23, anti-IL-17, or anti-IL-23 treatments, such as rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, inflammatory bowel diseases, hidradenitis suppurativa, and uveitis. Patients with CVDs (designated as outcomes of interest) before the index date were excluded. After exclusions, both cohorts underwent 1:1 propensity score matching (PSM) based on current age, age at index, sex, race, comorbidities, and laboratory measurements.</p>
<a id="article1.body1.sec2.sec2.p3" name="article1.body1.sec2.sec2.p3" class="link-target"></a><p>This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (<a href="#pmed.1004591.s013">S1 Checklist</a>).</p>
</div>

<div id="section3" class="section toc-section"><a id="sec011" name="sec011" class="link-target" title="Covariates"></a>
<h3>Covariates</h3>
<a id="article1.body1.sec2.sec3.p1" name="article1.body1.sec2.sec3.p1" class="link-target"></a><p>Demographic data, including current age, age at the index date, and sex, were collected. Due to the existence of racial differences in CVD epidemiology, potentially driven by genetic, clinical, and social factors [<a href="#pmed.1004591.ref032" class="ref-tip">32</a>], race (but not ethnicity) was accounted to reduce confounding. Race data were obtained through patient self-report or healthcare provider observation and subsequently submitted to the TriNetX Network by healthcare organizations. Comorbidities were analyzed over the 3 years preceding the index date, including hypertension, chronic obstructive pulmonary disease, liver diseases, chronic kidney disease, type 2 diabetes mellitus, hyperlipidemia, depression, sleep disorders, and overweight or obesity. Socioeconomic health hazards and smoking habits were also identified. Measurements were sourced from the TriNetX database, which provides the most recent data before the index date. Cutoff values for various measurement results were set, and TriNetX’s statistical analysis treats these values as categorical covariates. Body mass index (≥27 kg/m²) and laboratory measurements, including triglycerides (≥500 mg/dL), low-density lipoprotein cholesterol (≥190 mg/dL), high-density lipoprotein cholesterol (&lt;40 mg/dL), C-reactive protein (&gt;3 mg/L), and erythrocyte sedimentation rate (&gt;25 mm/h) in blood, were assessed. Both current age and age at index were included as continuous variables in the matching process to mitigate period effects. Other categorical covariates with &gt;3% prevalence in either cohort were incorporated into the PSM to retain as many participants as possible while ensuring proper matching and avoiding overfitting.</p>
</div>

<div id="section4" class="section toc-section"><a id="sec012" name="sec012" class="link-target" title="Outcomes"></a>
<h3>Outcomes</h3>
<a id="article1.body1.sec2.sec4.p1" name="article1.body1.sec2.sec4.p1" class="link-target"></a><p>The primary outcome was the first incident of any CVDs within the TriNetX network, defined as the composite of various categories of cardiovascular complications, including: (1) cerebrovascular diseases (stroke and transient ischemic attacks), (2) arrhythmias (atrial fibrillation, atrial flutter, tachycardia, bradycardia, and ventricular arrhythmias), (3) inflammatory heart diseases (pericarditis and myocarditis), (4) ischemic heart diseases (acute coronary disease, MI, ischemic cardiomyopathy, and angina), (5) heart failure, (6) non-ischemic cardiomyopathy, (7) thrombotic disorders (pulmonary embolism and superficial or deep vein thrombosis), (8) peripheral arterial occlusive disease, and (9) cardiac arrest or cardiogenic shock. Additionally, we separately analyzed these disease categories and the major adverse cardiac events (MACEs), described as instances of MI, stroke, heart failure, ventricular arrhythmia, and cardiac arrest.</p>
<a id="article1.body1.sec2.sec4.p2" name="article1.body1.sec2.sec4.p2" class="link-target"></a><p>As a secondary outcome, we examined medications commonly used for these CVDs within the database, including thrombolytics, antiplatelets, anticoagulants, antiarrhythmics, antianginals, vasodilators, <em>β</em>-blockers, cardiac-selective calcium channel blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, diuretics, sympathomimetics, digitalis glycoside, and cilostazol. Cardiovascular procedures, such as cardiac catheterization, coronary artery bypass graft, and pacemaker implantation, were also analyzed.</p>
<a id="article1.body1.sec2.sec4.p3" name="article1.body1.sec2.sec4.p3" class="link-target"></a><p>In clinical practice, a 3–4-month treatment period is generally considered a reasonable timeframe for PsO treatments to show efficacy, as reflected in pivotal trials for biologics, where primary efficacy endpoints are typically assessed at 12–16 weeks [<a href="#pmed.1004591.ref033" class="ref-tip">33</a>]. To evaluate the role of treatment on CVDs in patients with PsO, we implemented a 6-month washout period after the index date, during which outcomes were not considered. Participants were followed for up to five years or until experiencing the outcomes of interest, death, or their last database entry.</p>
</div>

<div id="section5" class="section toc-section"><a id="sec013" name="sec013" class="link-target" title="Subgroup analyses"></a>
<h3>Subgroup analyses</h3>
<a id="article1.body1.sec2.sec5.p1" name="article1.body1.sec2.sec5.p1" class="link-target"></a><p>To assess the relationship between different biologic mechanisms and CVD risk, we categorized patients prescribed only one class of biologics: either anti-TNF-α, anti-IL-12/23, anti-IL-17, or anti-IL-23. Those prescribed two different classes of biologics were not included. These patients were compared separately to those on oral therapy for the risk of CVDs. Since different biologics, even within the same class, can still result in varying therapeutic responses, we further applied an individual comparator-restricted approach, comparing each biologic separately with oral anti-psoriatic drugs. Patients who had used two or more different biologics were excluded from this analysis.</p>
<a id="article1.body1.sec2.sec5.p2" name="article1.body1.sec2.sec5.p2" class="link-target"></a><p>We also examined the association between biologics and CVDs versus oral therapy across subgroups distinguished by age (≤45 years or &gt;45 years), sex (male or female), and presence of comorbidities such as psoriatic arthritis (PsA), hypertension, type 2 diabetes mellitus, hyperlipidemia, and overweight or obesity. Moreover, we analyzed data from different regions: the United States of America (USA), Europe, the Middle East, Africa (EMEA), and the Asia-Pacific region (<a href="#pmed.1004591.s001">S1 Text</a>).</p>
</div>

<div id="section6" class="section toc-section"><a id="sec014" name="sec014" class="link-target" title="Sensitivity analyses"></a>
<h3>Sensitivity analyses</h3>
<a id="article1.body1.sec2.sec6.p1" name="article1.body1.sec2.sec6.p1" class="link-target"></a><p>To reinforce our primary results, we employed eight sensitivity analyses. Model 1 extended the washout period to 1 year, mitigating the influence of delayed coding of CVDs and potential protopathic bias. Model 2 included death as part of each outcome to address the competing risk of mortality [<a href="#pmed.1004591.ref034" class="ref-tip">34</a>]. Model 3 excluded BIO-cohort patients ever prescribed oral anti-psoriatic drugs, ensuring that the primary analysis results genuinely reflect the association between biologics and CVD risk. Model 4 excluded Non-BIO-cohort patients who used cyclosporine, which is associated with dyslipidemia and hypertension side effects, known to increase CVD risk [<a href="#pmed.1004591.ref014" class="ref-tip">14</a>,<a href="#pmed.1004591.ref035" class="ref-tip">35</a>]. Model 5 excluded patients with apremilast use from the Non-BIO-cohort, limiting this group to conventional anti-psoriatic drugs. Model 6 required at least two prescriptions spaced 6 months apart in both cohorts, in addition to the initial three prescription records, to further improve treatment adherence among included patients. Model 7 additionally included prior use of CVD medications—including thrombolytics, platelet aggregation inhibitors, antiarrhythmics, antianginals, vasodilators, beta-blockers, calcium channel blockers, diuretics, sympathomimetics, digitalis glycosides, and cilostazol—as a matching criterion to reduce confounding. In Model 8, patients with prior CVDs were retained, incorporating these diseases as an additional matching criterion. This approach minimizes bias resulting from the selection of inherently less susceptible patients in either cohort [<a href="#pmed.1004591.ref036" class="ref-tip">36</a>].</p>
</div>

<div id="section7" class="section toc-section"><a id="sec015" name="sec015" class="link-target" title="Statistical analysis"></a>
<h3>Statistical analysis</h3>
<a id="article1.body1.sec2.sec7.p1" name="article1.body1.sec2.sec7.p1" class="link-target"></a><p>We employed PSM on the TriNetX platform to adjust for cohort differences without replacement (<a href="#pmed.1004591.s002">S2 Text</a>). The propensity scores were computed using logistic regression in scikit-learn, yielding values between 0 and 1. To match participants, greedy nearest neighbor matching was applied with a caliper of 0.1 of the pooled standard deviation, and cohorts were considered adequately matched when the standardized differences were less than 0.1. Outcome incidence was evaluated using the Kaplan–Meier estimator and differences assessed via the log-rank test. Hazard ratios (HRs) for outcomes were determined using the Cox regression. Missing data were handled in accordance with TriNetX platform protocols, which include specific imputations for encounter identifiers, encounter start and end dates, estimated glomerular filtration rate, and oncology diagnoses, with all other missing values remaining unaltered (<a href="#pmed.1004591.s003">S3 Text</a>). Computational tasks were performed in R (version 4.3.1), except for PSM and the log-rank test, which were conducted in TriNetX. Statistical significance was set at a two-sided <em>p</em>-value &lt;  0.05, with 95% confidence intervals (CIs) excluding 1.</p>
</div>
</div>

<div xmlns:plos="http://plos.org" id="section3" class="section toc-section"><a id="sec016" name="sec016" data-toc="sec016" class="link-target" title="Results"></a><h2>Results</h2>
<div id="section1" class="section toc-section"><a id="sec017" name="sec017" class="link-target" title="Demographic characteristics"></a>
<h3>Demographic characteristics</h3>
<a id="article1.body1.sec3.sec1.p1" name="article1.body1.sec3.sec1.p1" class="link-target"></a><p><a href="#pmed-1004591-g001">Fig 1</a> illustrates our cohort selection process. Within the TriNetX Global Collaborative Network, we identified 52,181 patients with PsO-prescribed biologics and 22,304 receiving oral anti-psoriatic drugs without biologic exposure. After exclusions and PSM, both the BIO- and the Non-BIO-cohort comprised 12,732 patients. The demographic data before and after matching are presented in <a href="#pmed-1004591-t001">Tables 1</a> and <a href="#pmed.1004591.s002">S2</a>, respectively.</p>
<a class="link-target" id="pmed-1004591-t001" name="pmed-1004591-t001"></a><div class="figure" data-doi="10.1371/journal.pmed.1004591.t001"><div class="img-box"><a title="Click for larger image" href="article/figure/image?size=medium&amp;id=10.1371/journal.pmed.1004591.t001" data-doi="10.1371/journal.pmed.1004591" data-uri="10.1371/journal.pmed.1004591.t001"><img src="article/figure/image?size=inline&amp;id=10.1371/journal.pmed.1004591.t001" alt="thumbnail" class="thumbnail" loading="lazy"></a><div class="expand"></div></div><div class="figure-inline-download">
          Download:
          <ul><li><a href="article/figure/powerpoint?id=10.1371/journal.pmed.1004591.t001"><div class="definition-label">PPT</div><div class="definition-description">PowerPoint slide</div></a></li><li><a href="article/figure/image?download&amp;size=large&amp;id=10.1371/journal.pmed.1004591.t001"><div class="definition-label">PNG</div><div class="definition-description">larger image</div></a></li><li><a href="article/figure/image?download&amp;size=original&amp;id=10.1371/journal.pmed.1004591.t001"><div class="definition-label">TIFF</div><div class="definition-description">original image</div></a></li></ul></div><div class="figcaption"><span>Table 1. </span> Demographic characteristics of study subjects after PSM <span class="xref"><sup><sup>*</sup></sup></span> .</div><p class="caption_target"></p><p class="caption_object"><a href="https://doi.org/10.1371/journal.pmed.1004591.t001">
              https://doi.org/10.1371/journal.pmed.1004591.t001</a></p></div><a class="link-target" id="pmed-1004591-g001" name="pmed-1004591-g001"></a><div class="figure" data-doi="10.1371/journal.pmed.1004591.g001"><div class="img-box"><a title="Click for larger image" href="article/figure/image?size=medium&amp;id=10.1371/journal.pmed.1004591.g001" data-doi="10.1371/journal.pmed.1004591" data-uri="10.1371/journal.pmed.1004591.g001"><img src="article/figure/image?size=inline&amp;id=10.1371/journal.pmed.1004591.g001" alt="thumbnail" class="thumbnail" loading="lazy"></a><div class="expand"></div></div><div class="figure-inline-download">
          Download:
          <ul><li><a href="article/figure/powerpoint?id=10.1371/journal.pmed.1004591.g001"><div class="definition-label">PPT</div><div class="definition-description">PowerPoint slide</div></a></li><li><a href="article/figure/image?download&amp;size=large&amp;id=10.1371/journal.pmed.1004591.g001"><div class="definition-label">PNG</div><div class="definition-description">larger image</div></a></li><li><a href="article/figure/image?download&amp;size=original&amp;id=10.1371/journal.pmed.1004591.g001"><div class="definition-label">TIFF</div><div class="definition-description">original image</div></a></li></ul></div><div class="figcaption"><span>Fig 1. </span> Flow chart of the patient selection.</div><p class="caption_target"><a id="article1.body1.sec3.sec1.fig1.caption1.p1" name="article1.body1.sec3.sec1.fig1.caption1.p1" class="link-target"></a><p>Abbreviation: PsO, psoriasis; RA, rheumatoid arthritis; AS, ankylosing spondylitis; JIA, juvenile idiopathic arthritis; IBD, inflammatory bowel diseases; HS, hidradenitis suppurativa; CVDs, cardiovascular diseases; HCOs, healthcare organizations.</p>
</p><p class="caption_object"><a href="https://doi.org/10.1371/journal.pmed.1004591.g001">
              https://doi.org/10.1371/journal.pmed.1004591.g001</a></p></div><a id="article1.body1.sec3.sec1.p2" name="article1.body1.sec3.sec1.p2" class="link-target"></a><p>For the BIO-cohort, the mean ages were 56.7 years (standard deviation [SD] 15.2) currently and 50.2 years (SD 14.8) at the index; the Non-BIO-cohort had respective averages of 57.3 (SD 16.4) and 50.8 (SD 15.9) years. The mean follow-up duration was 4.8 years (SD 0.9) for the BIO-cohort and 4.6 years (SD 1.1) for the Non-BIO-cohort. Both cohorts exhibited similar sex and racial distributions, with approximately half of the patients being female and 55% being White. Well-matched characteristics in comorbidities, smoking status, socioeconomic challenges, and laboratory results were observed. Hypertension, hyperlipidemia, and overweight or obesity were the most prevalent conditions.</p>
</div>

<div id="section2" class="section toc-section"><a id="sec018" name="sec018" class="link-target" title="Incidence and risk of CVDs and associated therapy utilization"></a>
<h3>Incidence and risk of CVDs and associated therapy utilization</h3>
<a id="article1.body1.sec3.sec2.p1" name="article1.body1.sec3.sec2.p1" class="link-target"></a><p>During observation, 950 patients (7.5%) in the BIO-cohort and 1,281 patients (10.1%) in the Non-BIO-cohort developed CVDs (<em>p</em> &lt; 0.001) (<a href="#pmed.1004591.s006">S3 Table</a>). The BIO-cohort demonstrated a significantly lower 5-year cumulative incidence of any CVDs (10.68%; 95% CI [10.03%, 11.36%]) compared to the Non-BIO-cohort (16.17%; 95% CI [15.34%, 17.05%]) (<em>p</em> &lt;  0.001) (<a href="#pmed-1004591-g002">Fig 2</a>). There were also lower occurrences of nearly all categories of CVDs in the BIO-cohort, with 12 out of 14 CVD-associated treatments showing fewer events, 6 of which demonstrated a significant reduction in utilization compared to the Non-BIO-cohort (<a href="#pmed.1004591.s006">S3 Table</a> and <a href="#pmed.1004591.s009">S1 Fig</a>).</p>
<a class="link-target" id="pmed-1004591-g002" name="pmed-1004591-g002"></a><div class="figure" data-doi="10.1371/journal.pmed.1004591.g002"><div class="img-box"><a title="Click for larger image" href="article/figure/image?size=medium&amp;id=10.1371/journal.pmed.1004591.g002" data-doi="10.1371/journal.pmed.1004591" data-uri="10.1371/journal.pmed.1004591.g002"><img src="article/figure/image?size=inline&amp;id=10.1371/journal.pmed.1004591.g002" alt="thumbnail" class="thumbnail" loading="lazy"></a><div class="expand"></div></div><div class="figure-inline-download">
          Download:
          <ul><li><a href="article/figure/powerpoint?id=10.1371/journal.pmed.1004591.g002"><div class="definition-label">PPT</div><div class="definition-description">PowerPoint slide</div></a></li><li><a href="article/figure/image?download&amp;size=large&amp;id=10.1371/journal.pmed.1004591.g002"><div class="definition-label">PNG</div><div class="definition-description">larger image</div></a></li><li><a href="article/figure/image?download&amp;size=original&amp;id=10.1371/journal.pmed.1004591.g002"><div class="definition-label">TIFF</div><div class="definition-description">original image</div></a></li></ul></div><div class="figcaption"><span>Fig 2. </span> Cumulative incidence of any cardiovascular diseases in the BIO-cohort vs. the Non-BIO-cohort.</div><p class="caption_target"><a id="article1.body1.sec3.sec2.fig1.caption1.p1" name="article1.body1.sec3.sec2.fig1.caption1.p1" class="link-target"></a><p>The differences between the two study cohorts were determined by log-rank test. Abbreviation: BIO., biologic cohort; Non-BIO., non-biologic cohort.</p>
</p><p class="caption_object"><a href="https://doi.org/10.1371/journal.pmed.1004591.g002">
              https://doi.org/10.1371/journal.pmed.1004591.g002</a></p></div><a id="article1.body1.sec3.sec2.p2" name="article1.body1.sec3.sec2.p2" class="link-target"></a><p>In Cox regression, the BIO-cohort had significantly attenuated risks of any CVDs (HR 0.621; 95% CI [0.571, 0.676]), cerebrovascular diseases (HR 0.616; 95% CI [0.519, 0.731]), arrythmias (HR 0.632; 95% CI [0.565, 0.706]), inflammatory heart diseases (HR 0.566; 95% CI [0.360, 0.891]), ischemic heart diseases (HR 0.579; 95% CI [0.465, 0.721]), heart failure (HR 0.637; 95% CI [0.521, 0.780]), non-ischemic cardiomyopathy (HR 0.654; 95% CI [0.466, 0.918]), thrombotic disorders (HR 0.570; 95% CI [0.444, 0.733]), peripheral arterial occlusive diseases (HR 0.501; 95% CI [0.383, 0.656]), and MACEs (HR 0.697; 95% CI [0.14, 0.792]) (<a href="#pmed-1004591-g003">Fig 3</a>). The risk of cardiac arrest or cardiogenic shock (HR 0.850; 95% CI [0.477, 1.516]) was lower with biologics than oral therapy, though the 95% CIs included 1. Furthermore, reduced risks in utilizing CVD-associated treatments were also observed in the BIO-cohort versus the Non-BIO-cohort, with significant differences found in antiplatelets (HR 0.769; 95% CI [0.698, 0.848]), anticoagulants (HR 0.848; 95% CI [0.794, 0.906]), antiarrhythmics (HR 0.661; 95% CI [0.485, 0.900]), antianginals (HR 0.663; 95% CI [0.549, 0.801]), vasodilators for cardiac diseases (HR 0.659; 95% CI [0.546, 0.796]), β-blockers (HR 0.795; 95% CI [0.727, 0.869]), cardiac-selective calcium channel blockers (HR 0.545; 95% CI [0.418, 0.711]), diuretics (HR 0.865; 95% CI [0.801, 0.935]), and cilostazol (HR 0.240; 95% CI [0.089, 0.646]) (<a href="#pmed.1004591.s010">S2 Fig</a>).</p>
<a class="link-target" id="pmed-1004591-g003" name="pmed-1004591-g003"></a><div class="figure" data-doi="10.1371/journal.pmed.1004591.g003"><div class="img-box"><a title="Click for larger image" href="article/figure/image?size=medium&amp;id=10.1371/journal.pmed.1004591.g003" data-doi="10.1371/journal.pmed.1004591" data-uri="10.1371/journal.pmed.1004591.g003"><img src="article/figure/image?size=inline&amp;id=10.1371/journal.pmed.1004591.g003" alt="thumbnail" class="thumbnail" loading="lazy"></a><div class="expand"></div></div><div class="figure-inline-download">
          Download:
          <ul><li><a href="article/figure/powerpoint?id=10.1371/journal.pmed.1004591.g003"><div class="definition-label">PPT</div><div class="definition-description">PowerPoint slide</div></a></li><li><a href="article/figure/image?download&amp;size=large&amp;id=10.1371/journal.pmed.1004591.g003"><div class="definition-label">PNG</div><div class="definition-description">larger image</div></a></li><li><a href="article/figure/image?download&amp;size=original&amp;id=10.1371/journal.pmed.1004591.g003"><div class="definition-label">TIFF</div><div class="definition-description">original image</div></a></li></ul></div><div class="figcaption"><span>Fig 3. </span> Forest plot depicting hazard ratios for the development of cardiovascular diseases.</div><p class="caption_target"><a id="article1.body1.sec3.sec2.fig2.caption1.p1" name="article1.body1.sec3.sec2.fig2.caption1.p1" class="link-target"></a><p>Among patients with psoriasis, biologic treatment was found to be associated with a decreased risk of any cardiovascular diseases and almost all categories of cardiovascular diseases. Abbreviation: BIO., biologic cohort; Non-BIO., non-biologic cohort; CI, confidence interval.</p>
</p><p class="caption_object"><a href="https://doi.org/10.1371/journal.pmed.1004591.g003">
              https://doi.org/10.1371/journal.pmed.1004591.g003</a></p></div></div>

<div id="section3" class="section toc-section"><a id="sec019" name="sec019" class="link-target" title="Subgroup analyses"></a>
<h3>Subgroup analyses</h3>
<a id="article1.body1.sec3.sec3.p1" name="article1.body1.sec3.sec3.p1" class="link-target"></a><p>The cumulative incidence of any CVDs over 5 years for patients prescribed different classes of biologics versus oral anti-psoriatic drugs is presented in <a href="#pmed.1004591.s011">S3 Fig</a>. Patients receiving only anti-TNF-α (HR 0.886; 95% CI [0.807, 0.973]), anti-IL-17 (HR 0.724; 95% CI [0.599, 0.875]), or anti-IL-23 (HR 0.739; 95% CI [0.598, 0.914]) all showed significantly lower risks of any CVDs. However, no significant association was observed for only anti-IL-12/23 (HR 0.915; 95% CI [0.742, 1.128]) (<a href="#pmed-1004591-g004">Fig 4</a>). Risk was generally lower for specific category of CVDs within these subgroups of single-class biologics, though the case numbers were limited, with statistical significance observed in just a small subset of events (<a href="#pmed.1004591.s007">S4 Table</a>). When comparing individual biologics separately with oral anti-psoriatic drugs, the sample sizes were further reduced. Only a few outcomes showed significant differences, accompanied by wide CIs (<a href="#pmed.1004591.s008">S5 Table</a>).</p>
<a class="link-target" id="pmed-1004591-g004" name="pmed-1004591-g004"></a><div class="figure" data-doi="10.1371/journal.pmed.1004591.g004"><div class="img-box"><a title="Click for larger image" href="article/figure/image?size=medium&amp;id=10.1371/journal.pmed.1004591.g004" data-doi="10.1371/journal.pmed.1004591" data-uri="10.1371/journal.pmed.1004591.g004"><img src="article/figure/image?size=inline&amp;id=10.1371/journal.pmed.1004591.g004" alt="thumbnail" class="thumbnail" loading="lazy"></a><div class="expand"></div></div><div class="figure-inline-download">
          Download:
          <ul><li><a href="article/figure/powerpoint?id=10.1371/journal.pmed.1004591.g004"><div class="definition-label">PPT</div><div class="definition-description">PowerPoint slide</div></a></li><li><a href="article/figure/image?download&amp;size=large&amp;id=10.1371/journal.pmed.1004591.g004"><div class="definition-label">PNG</div><div class="definition-description">larger image</div></a></li><li><a href="article/figure/image?download&amp;size=original&amp;id=10.1371/journal.pmed.1004591.g004"><div class="definition-label">TIFF</div><div class="definition-description">original image</div></a></li></ul></div><div class="figcaption"><span>Fig 4. </span> Forest plot depicting hazard ratios for the development of any cardiovascular diseases stratified by biologic classes, demographics, regions of data source, and comorbidities.</div><p class="caption_target"><a id="article1.body1.sec3.sec3.fig1.caption1.p1" name="article1.body1.sec3.sec3.fig1.caption1.p1" class="link-target"></a><p>Patients with psoriasis prescribed only anti-TNF-α, anti-IL-17, or anti-IL-23 showed lower cardiovascular disease risks, while no significant reduction was seen with anti-IL-12/23 alone. This risk reduction remained significant across diverse demographics and comorbidities with biologic prescriptions. Abbreviation: BIO., biologic cohort; Non-BIO., non-biologic cohort; CI, confidence interval.</p>
</p><p class="caption_object"><a href="https://doi.org/10.1371/journal.pmed.1004591.g004">
              https://doi.org/10.1371/journal.pmed.1004591.g004</a></p></div><a id="article1.body1.sec3.sec3.p2" name="article1.body1.sec3.sec3.p2" class="link-target"></a><p>Subgroup analyses across demographic and clinical categories uniformly demonstrated the association of biologic therapy with reduced CVD risk, even among individuals older than 45 years (HR 0.699; 95% CI [0.641, 0.762]), males (HR 0.621; 95% CI [0.548, 0.704]), patients with coexisting PsA (HR 0.686; 95% CI [0.596, 0.790]), or those with comorbid hypertension (HR 0.692; 95% CI [0.612, 0.782]), type 2 diabetes mellitus (HR 0.716; 95% CI [0.597, 0.859]), hyperlipidemia (HR 0.757; 95% CI [0.651, 0.881]), or overweight or obesity (HR 0.675; 95% CI [0.557, 0.817]) (<a href="#pmed-1004591-g004">Fig 4</a>). This reduction in risk was also consistent across patient data from the USA (HR 0.682; 95% CI [0.624, 0.746]), EMEA (HR 0.523; 95% CI [0.297, 0.922]), and the Asia-Pacific region (HR 0.499; 95% CI [0.330, 0.755]).</p>
</div>

<div id="section4" class="section toc-section"><a id="sec020" name="sec020" class="link-target" title="Sensitivity analyses"></a>
<h3>Sensitivity analyses</h3>
<a id="article1.body1.sec3.sec4.p1" name="article1.body1.sec3.sec4.p1" class="link-target"></a><p>All sensitivity analyses corroborated the primary findings (<a href="#pmed.1004591.s012">S4 Fig</a>). From Models 1 to 7, each respectively representing extending the washout period (HR 0.628; 95% CI [0.575, 0.686]), accounting for competing mortality (HR 0.600; 95% CI [0.554, 0.650]), excluding BIO-cohort patients previously prescribed oral therapies (HR 0.654; 95% CI [0.595, 0.718]), excluding cyclosporine users from the Non-BIO-cohort (HR 0.667; 95% CI [0.611, 0.729]), restricting the Non-BIO-cohort to conventional drugs (HR 0.627; 95% CI [0.568, 0.692]), refining prescription criteria to include patients with better adherence (HR 0.621; 95% CI [0.571, 0.676]), and additionally matching for prior CVD medication use (HR 0.651; 95% CI [0.600, 0.708]), biologics were associated with a decreased risk of any CVDs. Notably, in Model 8, by including patients with prior CVDs as an additional matching criterion, the significant risk reduction (HR 0.830; 95% CI [0.790, 0.871]) should be interpreted as alleviating CVD exacerbations or newly occurring events necessitating medical visits.</p>
</div>
</div>

<div xmlns:plos="http://plos.org" id="section4" class="section toc-section"><a id="sec021" name="sec021" data-toc="sec021" class="link-target" title="Discussions"></a><h2>Discussions</h2><a id="article1.body1.sec4.p1" name="article1.body1.sec4.p1" class="link-target"></a><p>In this cohort study using a global health research network, patients with PsO-prescribed biologics exhibited a reduced risk of incident CVDs compared to those receiving oral anti-psoriatic drugs. Anti-TNF-α, anti-IL-17, and anti-IL-23 were associated with decreased cardiovascular hazards, while the anti-IL-12/23 was not. The biologic benefits against CVDs were consistent across patients with PsO of different age groups, sexes, regions, and comorbidities.</p>
<a id="article1.body1.sec4.p2" name="article1.body1.sec4.p2" class="link-target"></a><p>Meta-analyses of randomized controlled trials have demonstrated no difference or even an increased risk of CVDs in patients with PsO receiving biologic treatment [<a href="#pmed.1004591.ref026" class="ref-tip">26</a>–<a href="#pmed.1004591.ref028" class="ref-tip">28</a>]. However, the result may not reflect real-world scenarios due to short controlled periods in trials and the inclusion of non-licensed biologics in the analyses. In contrast, cohort studies suggested a neutral or protective association between biologics and CVDs in PsO [<a href="#pmed.1004591.ref014" class="ref-tip">14</a>,<a href="#pmed.1004591.ref024" class="ref-tip">24</a>,<a href="#pmed.1004591.ref025" class="ref-tip">25</a>], but limitations included small sample sizes and lack of confounders such as body fat and laboratory measurements. In this study, we compared 12,732 patients with PsO-prescribed biologics to those receiving oral therapy. Comorbidities, smoking status, body mass index, lipid profiles, and inflammation biomarkers, all related to CVD development [<a href="#pmed.1004591.ref037" class="ref-tip">37</a>–<a href="#pmed.1004591.ref039" class="ref-tip">39</a>], were well-matched. Patients on biologics had a 38% reduced risk of CVDs over the 5-year follow-up. The results support the link between psoriatic inflammation and CVDs, highlighting the potential of targeted anti-inflammatory therapy for cardiovascular protection.</p>
<a id="article1.body1.sec4.p3" name="article1.body1.sec4.p3" class="link-target"></a><p>Despite the known association of PsO with various CVDs [<a href="#pmed.1004591.ref001" class="ref-tip">1</a>–<a href="#pmed.1004591.ref004" class="ref-tip">4</a>], previous literature mainly focused on the relationship between biologic use and stroke or MI [<a href="#pmed.1004591.ref014" class="ref-tip">14</a>,<a href="#pmed.1004591.ref024" class="ref-tip">24</a>–<a href="#pmed.1004591.ref028" class="ref-tip">28</a>]. Our study further demonstrated the attenuated risk of multiple CVD categories with biologics. Research has indicated alleviated atherosclerosis and coronary inflammation in biologic-treated patients [<a href="#pmed.1004591.ref017" class="ref-tip">17</a>,<a href="#pmed.1004591.ref020" class="ref-tip">20</a>,<a href="#pmed.1004591.ref040" class="ref-tip">40</a>,<a href="#pmed.1004591.ref041" class="ref-tip">41</a>], aligning with our findings of decreased risk of cerebrovascular diseases, ischemic heart diseases, and peripheral arterial occlusive disease in the BIO-cohort. Diminished oxidative stress and improved endothelial function after initiating biologics in PsO mouse models and humans may explain the reduced risk of arrhythmias and thrombotic disorders in our study [<a href="#pmed.1004591.ref018" class="ref-tip">18</a>,<a href="#pmed.1004591.ref021" class="ref-tip">21</a>]. Additionally, biologics have been shown to enhance myocardial function in echocardiography [<a href="#pmed.1004591.ref022" class="ref-tip">22</a>, <a href="#pmed.1004591.ref023" class="ref-tip">23</a>], reinforcing their link to the mitigated risk of inflammatory heart diseases, heart failure, and cardiomyopathy. The decreased use of various CVD-associated therapies in the BIO-cohort may also reflect a potential relationship between biologics and a lower risk across multiple CVD categories.</p>
<a id="article1.body1.sec4.p4" name="article1.body1.sec4.p4" class="link-target"></a><p>This study investigates the association between novel biologics targeting IL-17 and IL-23 and CVD risk in PsO, alongside earlier agents targeting TNF-α and IL-12/23, in comparison to oral therapies. Patients solely prescribed anti-TNF-α had an 11% lower CVD risk, contrasting with previous findings of a 40%–50% reduction [<a href="#pmed.1004591.ref014" class="ref-tip">14</a>,<a href="#pmed.1004591.ref024" class="ref-tip">24</a>,<a href="#pmed.1004591.ref025" class="ref-tip">25</a>]. The numerical discrepancy may result from past research defining non-systemic therapy as the reference group or focusing only on MI as the outcome. Nonetheless, anti-TNF-α consistently demonstrated significant advantages in reducing CVDs. While IL-17 confers pro-atherosclerotic functions [<a href="#pmed.1004591.ref010" class="ref-tip">10</a>,<a href="#pmed.1004591.ref011" class="ref-tip">11</a>], experimental investigations also observed its anti-atherosclerotic effects, both in animal models and humans [<a href="#pmed.1004591.ref042" class="ref-tip">42</a>,<a href="#pmed.1004591.ref043" class="ref-tip">43</a>]. However, in patients with PsO, IL-17 inhibition is generally associated with improvements in cardiovascular soft endpoints regarding endothelial health, atheroma burden, and myocardial function [<a href="#pmed.1004591.ref021" class="ref-tip">21</a>,<a href="#pmed.1004591.ref044" class="ref-tip">44</a>,<a href="#pmed.1004591.ref045" class="ref-tip">45</a>]. Our result also suggests a lower risk of CVDs in PsO among patients receiving anti-IL-17. Information about CVD risk in the context of IL-23 inhibition remains scarce. Although IL-23 promotes oxidative stress and atherosclerosis [<a href="#pmed.1004591.ref009" class="ref-tip">9</a>,<a href="#pmed.1004591.ref010" class="ref-tip">10</a>], limited animal studies have not shown benefits in ameliorating atheroma from IL-23 blockage [<a href="#pmed.1004591.ref046" class="ref-tip">46</a>,<a href="#pmed.1004591.ref047" class="ref-tip">47</a>]. Our findings show a link between anti-IL-23 and a lower CVD risk in PsO clinically, but its precise mechanism requires clarification.</p>
<a id="article1.body1.sec4.p5" name="article1.body1.sec4.p5" class="link-target"></a><p>In this study, patients prescribed anti-IL-12/23 did not exhibit a significant reduction in CVD risk compared to those on oral therapy, consistent with prior research [<a href="#pmed.1004591.ref014" class="ref-tip">14</a>,<a href="#pmed.1004591.ref026" class="ref-tip">26</a>]. Given the postulated association between psoriatic inflammation and CVD development, the decreased CVD risk with anti-IL-23, but not anti-IL-12/23, may stem from the superior efficacy of anti-IL-23 in treating PsO compared to anti-IL-12/23 [<a href="#pmed.1004591.ref033" class="ref-tip">33</a>,<a href="#pmed.1004591.ref048" class="ref-tip">48</a>]. Another possibility could be the destabilization of atheroma during the initial phase of anti-IL-12/23 therapy [<a href="#pmed.1004591.ref049" class="ref-tip">49</a>]. However, this temporary pro-atherogenic response diminishes with continued treatment [<a href="#pmed.1004591.ref050" class="ref-tip">50</a>]. Clinical evidence also shows improvements in arterial and myocardial function in patients with PsO receiving ustekinumab [<a href="#pmed.1004591.ref040" class="ref-tip">40</a>,<a href="#pmed.1004591.ref051" class="ref-tip">51</a>]. Overall, anti-IL-12/23 is still considered potentially cardioprotective for patients with PsO [<a href="#pmed.1004591.ref035" class="ref-tip">35</a>], and our results suggest its protection is comparable to oral anti-psoriatic drugs.</p>
<a id="article1.body1.sec4.p6" name="article1.body1.sec4.p6" class="link-target"></a><p>Different biologics, even within the same class, vary in origin, structure, and pharmacokinetics, resulting in differences in immunogenicity, efficacy, and adverse effects, which may be associated with varying cardiovascular risks among their users. [<a href="#pmed.1004591.ref052" class="ref-tip">52</a>]. For instance, while ustekinumab has shown no link to MACE risk in literature or our study, another anti-IL-12/23 [<a href="#pmed.1004591.ref014" class="ref-tip">14</a>,<a href="#pmed.1004591.ref026" class="ref-tip">26</a>], briakinumab, was discontinued in 2011 due to MACE concerns in early trials [<a href="#pmed.1004591.ref053" class="ref-tip">53</a>]. Current evidence supports the cardiovascular safety of anti-IL-23 [<a href="#pmed.1004591.ref053" class="ref-tip">53</a>]. However, a recent FDA Adverse Event Reporting System analysis suggested a potential cerebrovascular risk with risankizumab, possibly due to impaired anti-atherosclerotic activity from reduced IL-17 levels following anti-IL-23 [<a href="#pmed.1004591.ref054" class="ref-tip">54</a>,<a href="#pmed.1004591.ref055" class="ref-tip">55</a>]. In our study, a comparator-restricted analysis showed a significant reduction in cerebrovascular diseases among risankizumab users versus oral therapy. Nevertheless, the wide CI reflects limited sample size and reduced estimate precision, highlighting the need for larger studies. Beyond drug class and mechanism, subgroup analyses consistently showed reduced CVD risk across demographics, regions, and comorbidities, supporting the generalizability of this association.</p>
<a id="article1.body1.sec4.p7" name="article1.body1.sec4.p7" class="link-target"></a><p>Our study has several strengths. Utilizing a large real-world database mitigates selection bias and enhances statistical robustness. The study design adopts a new-user, active comparator approach, considers detailed confounder information, and performs multiple subgroup analyses. Sensitivity tests bolster confidence in the decreased CVD risk associated with biologics: extending the washout period and accounting for competing mortality reinforce the temporal relationship; excluding oral therapy users from the BIO-cohort and cyclosporine or apremilast users from the Non-BIO-cohort increases specificity and provides more clinically insights; tightening medication definitions and considering other CVD drugs supports the validity; incorporating CVDs as matching criteria prevents the depletion of susceptible effect [<a href="#pmed.1004591.ref036" class="ref-tip">36</a>].</p>
<a id="article1.body1.sec4.p8" name="article1.body1.sec4.p8" class="link-target"></a><p>Our study has several limitations. Firstly, as an observational study, we cannot establish direct causality but only report a lower CVD risk in patients with PsO-prescribed biologic versus oral therapy. Secondly, information such as PsO severity, the basis for treatment selection, and medical records from institutions outside the TriNetX system were unavailable. To address this, we chose patients receiving oral therapy as the reference group to ensure comparable PsO severity between cohorts, aided by the matching to balance their characteristics. The large-scale nature of this big data analysis also helps reduce bias from differences in treatment selection rationale and unrecorded medical interventions outside the database. However, since biologics are often a later line of therapy, the BIO-cohort may have had higher PsO severity than the Non-BIO-cohort. If so, considering the link between PsO severity and CVD risk [<a href="#pmed.1004591.ref001" class="ref-tip">1</a>,<a href="#pmed.1004591.ref012" class="ref-tip">12</a>], the current study may underestimate the protective benefit of biologics in reducing CVD risk. Thirdly, coding errors could exist in the database, but we sought to limit misclassification by including only patients with two PsO diagnoses separated by at least a month. Moreover, we evaluated not just CVDs but also CVD-associated treatments. Fourthly, multiple comparisons may increase the risk of chance outcomes, and statistical corrections are not applicable due to the constraints of the TriNetX database’s analytical methods. Nevertheless, the observed reduced CVD risk in biologic-treated patients is biologically plausible and consistent with existing evidence, supporting the reliability of our findings. Finally, the TriNetX database cannot capture time-related dynamics such as treatment duration, cumulative dosage, timing of intervention, or treatment response. Despite this limitation to time-fixed medication exposure analyses, this study provides preliminary but valuable evidence linking biologic therapy to reduced CVD risk in PsO. However, the findings should be interpreted cautiously, as the primary results reflect the overall association of any biologics ever used with subsequent cardiovascular risk, and the study does not compare the relative association of different biologic classes with this risk. Further research is needed to evaluate the impact of dosage, duration, and treatment sequencing across biologic therapies.</p>
<a id="article1.body1.sec4.p9" name="article1.body1.sec4.p9" class="link-target"></a><p>In conclusion, this observational study revealed a reduced risk of CVDs in patients with PsO-prescribed biologics versus oral therapy. The risk reduction persisted with anti-TNF-α, anti-IL-17, and anti-IL-23 alone, but not with anti-IL-12/23.</p>
</div>

<div xmlns:plos="http://plos.org" id="section5" class="section toc-section"><a id="sec022" name="sec022" data-toc="sec022" class="link-target" title="Supporting information"></a><h2>Supporting information</h2><div class="figshare_widget" doi="10.1371/journal.pmed.1004591"></div><div class="supplementary-material"><a name="pmed.1004591.s001" id="pmed.1004591.s001" class="link-target"></a><h3 class="siTitle title-small"><a href="article/file?type=supplementary&amp;id=10.1371/journal.pmed.1004591.s001">S1 Text. </a>Data acquisition.</h3><p class="siDoi"><a href="https://doi.org/10.1371/journal.pmed.1004591.s001">https://doi.org/10.1371/journal.pmed.1004591.s001</a></p><a id="article1.body1.sec5.supplementary-material1.caption1.p1" name="article1.body1.sec5.supplementary-material1.caption1.p1" class="link-target"></a><p class="postSiDOI">(PDF)</p>
</div><div class="supplementary-material"><a name="pmed.1004591.s002" id="pmed.1004591.s002" class="link-target"></a><h3 class="siTitle title-small"><a href="article/file?type=supplementary&amp;id=10.1371/journal.pmed.1004591.s002">S2 Text. </a>Propensity score matching.</h3><p class="siDoi"><a href="https://doi.org/10.1371/journal.pmed.1004591.s002">https://doi.org/10.1371/journal.pmed.1004591.s002</a></p><a id="article1.body1.sec5.supplementary-material2.caption1.p1" name="article1.body1.sec5.supplementary-material2.caption1.p1" class="link-target"></a><p class="postSiDOI">(PDF)</p>
</div><div class="supplementary-material"><a name="pmed.1004591.s003" id="pmed.1004591.s003" class="link-target"></a><h3 class="siTitle title-small"><a href="article/file?type=supplementary&amp;id=10.1371/journal.pmed.1004591.s003">S3 Text. </a>Handling of missing data.</h3><p class="siDoi"><a href="https://doi.org/10.1371/journal.pmed.1004591.s003">https://doi.org/10.1371/journal.pmed.1004591.s003</a></p><a id="article1.body1.sec5.supplementary-material3.caption1.p1" name="article1.body1.sec5.supplementary-material3.caption1.p1" class="link-target"></a><p class="postSiDOI">(PDF)</p>
</div><div class="supplementary-material"><a name="pmed.1004591.s004" id="pmed.1004591.s004" class="link-target"></a><h3 class="siTitle title-small"><a href="article/file?type=supplementary&amp;id=10.1371/journal.pmed.1004591.s004">S1 Table. </a>Codes for all diagnoses, laboratory tests, and medications in our analysis.</h3><p class="siDoi"><a href="https://doi.org/10.1371/journal.pmed.1004591.s004">https://doi.org/10.1371/journal.pmed.1004591.s004</a></p><a id="article1.body1.sec5.supplementary-material4.caption1.p1" name="article1.body1.sec5.supplementary-material4.caption1.p1" class="link-target"></a><p class="postSiDOI">(PDF)</p>
</div><div class="supplementary-material"><a name="pmed.1004591.s005" id="pmed.1004591.s005" class="link-target"></a><h3 class="siTitle title-small"><a href="article/file?type=supplementary&amp;id=10.1371/journal.pmed.1004591.s005">S2 Table. </a>Demographic characteristics of study subjects before propensity score matching (PSM).</h3><p class="siDoi"><a href="https://doi.org/10.1371/journal.pmed.1004591.s005">https://doi.org/10.1371/journal.pmed.1004591.s005</a></p><a id="article1.body1.sec5.supplementary-material5.caption1.p1" name="article1.body1.sec5.supplementary-material5.caption1.p1" class="link-target"></a><p class="postSiDOI">(PDF)</p>
</div><div class="supplementary-material"><a name="pmed.1004591.s006" id="pmed.1004591.s006" class="link-target"></a><h3 class="siTitle title-small"><a href="article/file?type=supplementary&amp;id=10.1371/journal.pmed.1004591.s006">S3 Table. </a>Outcome events among patients in the BIO-cohort and Non-BIO-cohort.</h3><p class="siDoi"><a href="https://doi.org/10.1371/journal.pmed.1004591.s006">https://doi.org/10.1371/journal.pmed.1004591.s006</a></p><a id="article1.body1.sec5.supplementary-material6.caption1.p1" name="article1.body1.sec5.supplementary-material6.caption1.p1" class="link-target"></a><p class="postSiDOI">(PDF)</p>
</div><div class="supplementary-material"><a name="pmed.1004591.s007" id="pmed.1004591.s007" class="link-target"></a><h3 class="siTitle title-small"><a href="article/file?type=supplementary&amp;id=10.1371/journal.pmed.1004591.s007">S4 Table. </a>Risk of specific category of cardiovascular diseases in subgroups prescribed single class biologics versus those on conventional systemic anti-psoriatic drugs.</h3><p class="siDoi"><a href="https://doi.org/10.1371/journal.pmed.1004591.s007">https://doi.org/10.1371/journal.pmed.1004591.s007</a></p><a id="article1.body1.sec5.supplementary-material7.caption1.p1" name="article1.body1.sec5.supplementary-material7.caption1.p1" class="link-target"></a><p class="postSiDOI">(PDF)</p>
</div><div class="supplementary-material"><a name="pmed.1004591.s008" id="pmed.1004591.s008" class="link-target"></a><h3 class="siTitle title-small"><a href="article/file?type=supplementary&amp;id=10.1371/journal.pmed.1004591.s008">S5 Table. </a>Cardiovascular disease risk in patients with psoriasis receiving a single biologic versus oral anti-psoriatic drugs after 1:1 propensity score matching.</h3><p class="siDoi"><a href="https://doi.org/10.1371/journal.pmed.1004591.s008">https://doi.org/10.1371/journal.pmed.1004591.s008</a></p><a id="article1.body1.sec5.supplementary-material8.caption1.p1" name="article1.body1.sec5.supplementary-material8.caption1.p1" class="link-target"></a><p class="postSiDOI">(PDF)</p>
</div><div class="supplementary-material"><a name="pmed.1004591.s009" id="pmed.1004591.s009" class="link-target"></a><h3 class="siTitle title-small"><a href="article/file?type=supplementary&amp;id=10.1371/journal.pmed.1004591.s009">S1 Fig. </a>Cumulative incidence of specific category of cardiovascular diseases in the BIO-cohort vs. the Non-BIO-cohort.</h3><p class="siDoi"><a href="https://doi.org/10.1371/journal.pmed.1004591.s009">https://doi.org/10.1371/journal.pmed.1004591.s009</a></p><a id="article1.body1.sec5.supplementary-material9.caption1.p1" name="article1.body1.sec5.supplementary-material9.caption1.p1" class="link-target"></a><p class="postSiDOI">(PDF)</p>
</div><div class="supplementary-material"><a name="pmed.1004591.s010" id="pmed.1004591.s010" class="link-target"></a><h3 class="siTitle title-small"><a href="article/file?type=supplementary&amp;id=10.1371/journal.pmed.1004591.s010">S2 Fig. </a>Forest plot depicting hazard ratios for the utilization of cardiovascular disease-associated treatments.</h3><p class="siDoi"><a href="https://doi.org/10.1371/journal.pmed.1004591.s010">https://doi.org/10.1371/journal.pmed.1004591.s010</a></p><a id="article1.body1.sec5.supplementary-material10.caption1.p1" name="article1.body1.sec5.supplementary-material10.caption1.p1" class="link-target"></a><p class="postSiDOI">(PDF)</p>
</div><div class="supplementary-material"><a name="pmed.1004591.s011" id="pmed.1004591.s011" class="link-target"></a><h3 class="siTitle title-small"><a href="article/file?type=supplementary&amp;id=10.1371/journal.pmed.1004591.s011">S3 Fig. </a>Cumulative incidence of any cardiovascular diseases in users of different biologic classes vs. the Non-BIO-cohort.</h3><p class="siDoi"><a href="https://doi.org/10.1371/journal.pmed.1004591.s011">https://doi.org/10.1371/journal.pmed.1004591.s011</a></p><a id="article1.body1.sec5.supplementary-material11.caption1.p1" name="article1.body1.sec5.supplementary-material11.caption1.p1" class="link-target"></a><p class="postSiDOI">(PDF)</p>
</div><div class="supplementary-material"><a name="pmed.1004591.s012" id="pmed.1004591.s012" class="link-target"></a><h3 class="siTitle title-small"><a href="article/file?type=supplementary&amp;id=10.1371/journal.pmed.1004591.s012">S4 Fig. </a>Forest plot depicting hazard ratios for the development of any cardiovascular diseases in eight sensitivity analyses.</h3><p class="siDoi"><a href="https://doi.org/10.1371/journal.pmed.1004591.s012">https://doi.org/10.1371/journal.pmed.1004591.s012</a></p><a id="article1.body1.sec5.supplementary-material12.caption1.p1" name="article1.body1.sec5.supplementary-material12.caption1.p1" class="link-target"></a><p class="postSiDOI">(PDF)</p>
</div><div class="supplementary-material"><a name="pmed.1004591.s013" id="pmed.1004591.s013" class="link-target"></a><h3 class="siTitle title-small"><a href="article/file?type=supplementary&amp;id=10.1371/journal.pmed.1004591.s013">S1 Checklist. </a>STROBE Statement.</h3><p class="siDoi"><a href="https://doi.org/10.1371/journal.pmed.1004591.s013">https://doi.org/10.1371/journal.pmed.1004591.s013</a></p><a id="article1.body1.sec5.supplementary-material13.caption1.p1" name="article1.body1.sec5.supplementary-material13.caption1.p1" class="link-target"></a><p class="postSiDOI">(PDF)</p>
</div></div>



<div xmlns:plos="http://plos.org" class="toc-section"><a id="references" name="references" class="link-target" data-toc="references" title="References"></a><h2>References</h2><ol class="references"><li id="ref1"><span class="order">1.
            </span><a name="pmed.1004591.ref001" id="pmed.1004591.ref001" class="link-target"></a>Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–41.  pmid:17032986 <ul class="reflinks" data-doi="10.1001/jama.296.14.1735"><li><a href="https://doi.org/10.1001/jama.296.14.1735" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/17032986" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Risk+of+myocardial+infarction+in+patients+with+psoriasis+Gelfand+2006" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref2"><span class="order">2.
            </span><a name="pmed.1004591.ref002" id="pmed.1004591.ref002" class="link-target"></a>Khalid U, Ahlehoff O, Gislason GH, Kristensen SL, Skov L, Torp-Pedersen C, et al. Psoriasis and risk of heart failure: a nationwide cohort study. Eur J Heart Fail. 2014;16(7):743–8.  pmid:24903077 <ul class="reflinks" data-doi="10.1002/ejhf.113"><li><a href="https://doi.org/10.1002/ejhf.113" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/24903077" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Psoriasis+and+risk+of+heart+failure%3A+a+nationwide+cohort+study+Khalid+2014" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref3"><span class="order">3.
            </span><a name="pmed.1004591.ref003" id="pmed.1004591.ref003" class="link-target"></a>Ahlehoff O, Gislason GH, Jørgensen CH, Lindhardsen J, Charlot M, Olesen JB, et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. Eur Heart J. 2012;33(16):2054–64.  pmid:21840930 <ul class="reflinks" data-doi="10.1093/eurheartj/ehr285"><li><a href="https://doi.org/10.1093/eurheartj/ehr285" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/21840930" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Psoriasis+and+risk+of+atrial+fibrillation+and+ischaemic+stroke%3A+a+Danish+Nationwide+Cohort+Study+Ahlehoff+2012" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref4"><span class="order">4.
            </span><a name="pmed.1004591.ref004" id="pmed.1004591.ref004" class="link-target"></a>Lutsey PL, Prizment AE, Folsom AR. Psoriasis is associated with a greater risk of incident venous thromboembolism: the Iowa Women’s Health Study. J Thromb Haemost. 2012;10(4):708–11.  pmid:22284895 <ul class="reflinks" data-doi="10.1111/j.1538-7836.2012.04646.x"><li><a href="https://doi.org/10.1111/j.1538-7836.2012.04646.x" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/22284895" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Psoriasis+is+associated+with+a+greater+risk+of+incident+venous+thromboembolism%3A+the+Iowa+Women%E2%80%99s+Health+Study+Lutsey+2012" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref5"><span class="order">5.
            </span><a name="pmed.1004591.ref005" id="pmed.1004591.ref005" class="link-target"></a>Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–81.  pmid:27222591 <ul class="reflinks" data-doi="10.1093/eurheartj/ehw106"><li><a href="https://doi.org/10.1093/eurheartj/ehw106" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/27222591" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=2016+European+Guidelines+on+cardiovascular+disease+prevention+in+clinical+practice%3A+The+Sixth+Joint+Task+Force+of+the+European+Society+of+Cardiology+and+Other+Societies+on+Cardiovascular+Disease+Prevention+in+Clinical+Practice+%28constituted+by+representatives+of+10+societies+and+by+invited+experts%29+Developed+with+the+special+contribution+of+the+European+Association+for+Cardiovascular+Prevention+%26amp%3B+Rehabilitation+%28EACPR%29+Piepoli+2016" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref6"><span class="order">6.
            </span><a name="pmed.1004591.ref006" id="pmed.1004591.ref006" class="link-target"></a>Yoshizumi M, Perrella M, Burnett JJ, Lee M. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res. 1993;73(1):205–9. <ul class="reflinks"><li><a href="#" data-author="Yoshizumi" data-cit="YoshizumiM%2C%20PerrellaM%2C%20BurnettJJ%2C%20LeeM.%20Tumor%20necrosis%20factor%20downregulates%20an%20endothelial%20nitric%20oxide%20synthase%20mRNA%20by%20shortening%20its%20half-life.%20Circ%20Res.%201993%3B73%281%29%3A205%E2%80%939." data-title="Tumor%20necrosis%20factor%20downregulates%20an%20endothelial%20nitric%20oxide%20synthase%20mRNA%20by%20shortening%20its%20half-life" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=Tumor+necrosis+factor+downregulates+an+endothelial+nitric+oxide+synthase+mRNA+by+shortening+its+half-life+Yoshizumi+1993" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref7"><span class="order">7.
            </span><a name="pmed.1004591.ref007" id="pmed.1004591.ref007" class="link-target"></a>Sriramula S, Haque M, Majid DSA, Francis J. Involvement of tumor necrosis factor-alpha in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy. Hypertension. 2008;51(5):1345–51.  pmid:18391105 <ul class="reflinks" data-doi="10.1161/HYPERTENSIONAHA.107.102152"><li><a href="https://doi.org/10.1161/HYPERTENSIONAHA.107.102152" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/18391105" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Involvement+of+tumor+necrosis+factor-alpha+in+angiotensin+II-mediated+effects+on+salt+appetite%2C+hypertension%2C+and+cardiac+hypertrophy+Sriramula+2008" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref8"><span class="order">8.
            </span><a name="pmed.1004591.ref008" id="pmed.1004591.ref008" class="link-target"></a>Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379–90.  pmid:30109481 <ul class="reflinks" data-doi="10.1007/s12016-018-8702-3"><li><a href="https://doi.org/10.1007/s12016-018-8702-3" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/30109481" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=The+immunologic+role+of+IL-17+in+psoriasis+and+psoriatic+arthritis+pathogenesis+Blauvelt+2018" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref9"><span class="order">9.
            </span><a name="pmed.1004591.ref009" id="pmed.1004591.ref009" class="link-target"></a>Subramanian M, Thorp E, Tabas I. Identification of a non-growth factor role for GM-CSF in advanced atherosclerosis: promotion of macrophage apoptosis and plaque necrosis through IL-23 signaling. Circ Res. 2015;116(2):e13-24.  pmid:25348165 <ul class="reflinks" data-doi="10.1161/CIRCRESAHA.116.304794"><li><a href="https://doi.org/10.1161/CIRCRESAHA.116.304794" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/25348165" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Identification+of+a+non-growth+factor+role+for+GM-CSF+in+advanced+atherosclerosis%3A+promotion+of+macrophage+apoptosis+and+plaque+necrosis+through+IL-23+signaling+Subramanian+2015" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref10"><span class="order">10.
            </span><a name="pmed.1004591.ref010" id="pmed.1004591.ref010" class="link-target"></a>Abbas A, Gregersen I, Holm S, Daissormont I, Bjerkeli V, Krohg-Sørensen K, et al. Interleukin 23 levels are increased in carotid atherosclerosis: possible role for the interleukin 23/interleukin 17 axis. Stroke. 2015;46(3):793–9.  pmid:25649806 <ul class="reflinks" data-doi="10.1161/STROKEAHA.114.006516"><li><a href="https://doi.org/10.1161/STROKEAHA.114.006516" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/25649806" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Interleukin+23+levels+are+increased+in+carotid+atherosclerosis%3A+possible+role+for+the+interleukin+23%2Finterleukin+17+axis+Abbas+2015" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref11"><span class="order">11.
            </span><a name="pmed.1004591.ref011" id="pmed.1004591.ref011" class="link-target"></a>Lockshin B, Balagula Y, Merola JF. Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. J Am Acad Dermatol. 2018;79(2):345–52.  pmid:29477740 <ul class="reflinks" data-doi="10.1016/j.jaad.2018.02.040"><li><a href="https://doi.org/10.1016/j.jaad.2018.02.040" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/29477740" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Interleukin+17%2C+inflammation%2C+and+cardiovascular+risk+in+patients+with+psoriasis+Lockshin+2018" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref12"><span class="order">12.
            </span><a name="pmed.1004591.ref012" id="pmed.1004591.ref012" class="link-target"></a>Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74(2):326–32.  pmid:25351522 <ul class="reflinks" data-doi="10.1136/annrheumdis-2014-205675"><li><a href="https://doi.org/10.1136/annrheumdis-2014-205675" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/25351522" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Risk+of+major+cardiovascular+events+in+patients+with+psoriatic+arthritis%2C+psoriasis+and+rheumatoid+arthritis%3A+a+population-based+cohort+study+Ogdie+2015" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref13"><span class="order">13.
            </span><a name="pmed.1004591.ref013" id="pmed.1004591.ref013" class="link-target"></a>Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol. 2005;52(2):262–7.  pmid:15692471 <ul class="reflinks" data-doi="10.1016/j.jaad.2004.06.017"><li><a href="https://doi.org/10.1016/j.jaad.2004.06.017" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/15692471" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Methotrexate+reduces+incidence+of+vascular+diseases+in+veterans+with+psoriasis+or+rheumatoid+arthritis+Prodanovich+2005" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref14"><span class="order">14.
            </span><a name="pmed.1004591.ref014" id="pmed.1004591.ref014" class="link-target"></a>Ahlehoff O, Skov L, Gislason G, Gniadecki R, Iversen L, Bryld LE, et al. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. J Eur Acad Dermatol Venereol. 2015;29(6):1128–34.  pmid:25303139 <ul class="reflinks" data-doi="10.1111/jdv.12768"><li><a href="https://doi.org/10.1111/jdv.12768" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/25303139" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Cardiovascular+outcomes+and+systemic+anti-inflammatory+drugs+in+patients+with+severe+psoriasis%3A+5-year+follow-up+of+a+Danish+nationwide+cohort+Ahlehoff+2015" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref15"><span class="order">15.
            </span><a name="pmed.1004591.ref015" id="pmed.1004591.ref015" class="link-target"></a>Boehncke S, Fichtlscherer S, Salgo R, Garbaraviciene J, Beschmann H, Diehl S, et al. Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial. Arch Dermatol Res. 2011;303(6):381–8.  pmid:21170539 <ul class="reflinks" data-doi="10.1007/s00403-010-1108-6"><li><a href="https://doi.org/10.1007/s00403-010-1108-6" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/21170539" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Systemic+therapy+of+plaque-type+psoriasis+ameliorates+endothelial+cell+function%3A+results+of+a+prospective+longitudinal+pilot+trial+Boehncke+2011" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref16"><span class="order">16.
            </span><a name="pmed.1004591.ref016" id="pmed.1004591.ref016" class="link-target"></a>Mahmoudi MJ, Saboor-Yaraghi A-A, Zabetian-Targhi F, Siassi F, Zarnani AH, Eshraghian MR, et al. Vitamin A decreases cytotoxicity of oxidized low-density lipoprotein in patients with atherosclerosis. Immunol Invest. 2016;45(1):52–62.  pmid:26700065 <ul class="reflinks" data-doi="10.3109/08820139.2015.1095208"><li><a href="https://doi.org/10.3109/08820139.2015.1095208" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/26700065" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Vitamin+A+decreases+cytotoxicity+of+oxidized+low-density+lipoprotein+in+patients+with+atherosclerosis+Mahmoudi+2016" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref17"><span class="order">17.
            </span><a name="pmed.1004591.ref017" id="pmed.1004591.ref017" class="link-target"></a>Elnabawi YA, Oikonomou EK, Dey AK, Mancio J, Rodante JA, Aksentijevich M, et al. Association of biologic therapy with coronary inflammation in patients with psoriasis as assessed by perivascular fat attenuation index. JAMA Cardiol. 2019;4(9):885–91.  pmid:31365032 <ul class="reflinks" data-doi="10.1001/jamacardio.2019.2589"><li><a href="https://doi.org/10.1001/jamacardio.2019.2589" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/31365032" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Association+of+biologic+therapy+with+coronary+inflammation+in+patients+with+psoriasis+as+assessed+by+perivascular+fat+attenuation+index+Elnabawi+2019" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref18"><span class="order">18.
            </span><a name="pmed.1004591.ref018" id="pmed.1004591.ref018" class="link-target"></a>Schüler R, Brand A, Klebow S, Wild J, Veras F, Ullmann E. Antagonization of IL-17A attenuates skin inflammation and vascular dysfunction in mouse models of psoriasis. J Invest Dermatol. 2019;139(3):638–47. <ul class="reflinks"><li><a href="#" data-author="Sch%C3%BCler" data-cit="Sch%C3%BClerR%2C%20BrandA%2C%20KlebowS%2C%20WildJ%2C%20VerasF%2C%20UllmannE.%20Antagonization%20of%20IL-17A%20attenuates%20skin%20inflammation%20and%20vascular%20dysfunction%20in%20mouse%20models%20of%20psoriasis.%20J%20Invest%20Dermatol.%202019%3B139%283%29%3A638%E2%80%9347." data-title="Antagonization%20of%20IL-17A%20attenuates%20skin%20inflammation%20and%20vascular%20dysfunction%20in%20mouse%20models%20of%20psoriasis" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=Antagonization+of+IL-17A+attenuates+skin+inflammation+and+vascular+dysfunction+in+mouse+models+of+psoriasis+Sch%C3%BCler+2019" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref19"><span class="order">19.
            </span><a name="pmed.1004591.ref019" id="pmed.1004591.ref019" class="link-target"></a>Smith E, Prasad K-MR, Butcher M, Dobrian A, Kolls JK, Ley K, et al. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2010;121(15):1746–55.  pmid:20368519 <ul class="reflinks" data-doi="10.1161/CIRCULATIONAHA.109.924886"><li><a href="https://doi.org/10.1161/CIRCULATIONAHA.109.924886" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/20368519" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Blockade+of+interleukin-17A+results+in+reduced+atherosclerosis+in+apolipoprotein+E-deficient+mice+Smith+2010" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref20"><span class="order">20.
            </span><a name="pmed.1004591.ref020" id="pmed.1004591.ref020" class="link-target"></a>Jókai H, Szakonyi J, Kontár O, Marschalkó M, Szalai K, Kárpáti S. Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in psoriasis: results of a pilot study. J Am Acad Dermatol. 2013;69(4):523–9. <ul class="reflinks"><li><a href="#" data-author="J%C3%B3kai" data-cit="J%C3%B3kaiH%2C%20SzakonyiJ%2C%20Kont%C3%A1rO%2C%20Marschalk%C3%B3M%2C%20SzalaiK%2C%20K%C3%A1rp%C3%A1tiS.%20Impact%20of%20effective%20tumor%20necrosis%20factor-alfa%20inhibitor%20treatment%20on%20arterial%20intima-media%20thickness%20in%20psoriasis%3A%20results%20of%20a%20pilot%20study.%20J%20Am%20Acad%20Dermatol.%202013%3B69%284%29%3A523%E2%80%939." data-title="Impact%20of%20effective%20tumor%20necrosis%20factor-alfa%20inhibitor%20treatment%20on%20arterial%20intima-media%20thickness%20in%20psoriasis%3A%20results%20of%20a%20pilot%20study" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=Impact+of+effective+tumor+necrosis+factor-alfa+inhibitor+treatment+on+arterial+intima-media+thickness+in+psoriasis%3A+results+of+a+pilot+study+J%C3%B3kai+2013" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref21"><span class="order">21.
            </span><a name="pmed.1004591.ref021" id="pmed.1004591.ref021" class="link-target"></a>von Stebut E, Reich K, Thaçi D, Koenig W, Pinter A, Körber A. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol. 2019;139(5):1054–62. <ul class="reflinks"><li><a href="#" data-author="von%20Stebut" data-cit="von%20StebutE%2C%20ReichK%2C%20Tha%C3%A7iD%2C%20KoenigW%2C%20PinterA%2C%20K%C3%B6rberA.%20Impact%20of%20secukinumab%20on%20endothelial%20dysfunction%20and%20other%20cardiovascular%20disease%20parameters%20in%20psoriasis%20patients%20over%2052%20weeks.%20J%20Invest%20Dermatol.%202019%3B139%285%29%3A1054%E2%80%9362." data-title="Impact%20of%20secukinumab%20on%20endothelial%20dysfunction%20and%20other%20cardiovascular%20disease%20parameters%20in%20psoriasis%20patients%20over%2052%20weeks" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=Impact+of+secukinumab+on+endothelial+dysfunction+and+other+cardiovascular+disease+parameters+in+psoriasis+patients+over+52+weeks+von+Stebut+2019" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref22"><span class="order">22.
            </span><a name="pmed.1004591.ref022" id="pmed.1004591.ref022" class="link-target"></a>Ahlehoff O, Hansen PR, Gislason GH, Frydland M, Bryld LE, Elming H, et al. Myocardial function and effects of biologic therapy in patients with severe psoriasis: a prospective echocardiographic study. J Eur Acad Dermatol Venereol. 2016;30(5):819–23.  pmid:25845841 <ul class="reflinks" data-doi="10.1111/jdv.13152"><li><a href="https://doi.org/10.1111/jdv.13152" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/25845841" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Myocardial+function+and+effects+of+biologic+therapy+in+patients+with+severe+psoriasis%3A+a+prospective+echocardiographic+study+Ahlehoff+2016" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref23"><span class="order">23.
            </span><a name="pmed.1004591.ref023" id="pmed.1004591.ref023" class="link-target"></a>Herédi E, Végh J, Pogácsás L, Gáspár K, Varga J, Kincse G, et al. Subclinical cardiovascular disease and it’s improvement after long-term TNF-α inhibitor therapy in severe psoriatic patients. J Eur Acad Dermatol Venereol. 2016;30(9):1531–6.  pmid:27393182 <ul class="reflinks" data-doi="10.1111/jdv.13649"><li><a href="https://doi.org/10.1111/jdv.13649" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/27393182" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Subclinical+cardiovascular+disease+and+it%E2%80%99s+improvement+after+long-term+TNF-%CE%B1+inhibitor+therapy+in+severe+psoriatic+patients+Her%C3%A9di+2016" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref24"><span class="order">24.
            </span><a name="pmed.1004591.ref024" id="pmed.1004591.ref024" class="link-target"></a>Wu JJ, Poon K-YT, Channual JC, Shen AY-J. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148(11):1244–50.  pmid:22911151 <ul class="reflinks" data-doi="10.1001/archdermatol.2012.2502"><li><a href="https://doi.org/10.1001/archdermatol.2012.2502" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/22911151" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Association+between+tumor+necrosis+factor+inhibitor+therapy+and+myocardial+infarction+risk+in+patients+with+psoriasis+Wu+2012" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref25"><span class="order">25.
            </span><a name="pmed.1004591.ref025" id="pmed.1004591.ref025" class="link-target"></a>Wu JJ, Guérin A, Sundaram M, Dea K, Cloutier M, Mulani P. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate. J Am Acad Dermatol. 2017;76(1):81–90.  pmid:27894789 <ul class="reflinks" data-doi="10.1016/j.jaad.2016.07.042"><li><a href="https://doi.org/10.1016/j.jaad.2016.07.042" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/27894789" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Cardiovascular+event+risk+assessment+in+psoriasis+patients+treated+with+tumor+necrosis+factor-%CE%B1+inhibitors+versus+methotrexate+Wu+2017" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref26"><span class="order">26.
            </span><a name="pmed.1004591.ref026" id="pmed.1004591.ref026" class="link-target"></a>Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011;306(8):864–71.  pmid:21862748 <ul class="reflinks" data-doi="10.1001/jama.2011.1211"><li><a href="https://doi.org/10.1001/jama.2011.1211" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/21862748" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Association+between+biologic+therapies+for+chronic+plaque+psoriasis+and+cardiovascular+events%3A+a+meta-analysis+of+randomized+controlled+trials+Ryan+2011" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref27"><span class="order">27.
            </span><a name="pmed.1004591.ref027" id="pmed.1004591.ref027" class="link-target"></a>Tzellos T, Kyrgidis A, Zouboulis CC. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2013;27(5):622–7.  pmid:22404103 <ul class="reflinks" data-doi="10.1111/j.1468-3083.2012.04500.x"><li><a href="https://doi.org/10.1111/j.1468-3083.2012.04500.x" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/22404103" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Re-evaluation+of+the+risk+for+major+adverse+cardiovascular+events+in+patients+treated+with+anti-IL-12%2F23+biological+agents+for+chronic+plaque+psoriasis%3A+a+meta-analysis+of+randomized+controlled+trials+Tzellos+2013" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref28"><span class="order">28.
            </span><a name="pmed.1004591.ref028" id="pmed.1004591.ref028" class="link-target"></a>Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM. Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2017;176(4):890–901.  pmid:27518205 <ul class="reflinks" data-doi="10.1111/bjd.14964"><li><a href="https://doi.org/10.1111/bjd.14964" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/27518205" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Impact+of+biologic+therapies+on+risk+of+major+adverse+cardiovascular+events+in+patients+with+psoriasis%3A+systematic+review+and+meta-analysis+of+randomized+controlled+trials+Rungapiromnan+2017" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref29"><span class="order">29.
            </span><a name="pmed.1004591.ref029" id="pmed.1004591.ref029" class="link-target"></a>Wang W, Wang C-Y, Wang S-I, Wei JC-C. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks. EClinicalMedicine. 2022;53:101619.  pmid:35971425 <ul class="reflinks" data-doi="10.1016/j.eclinm.2022.101619"><li><a href="https://doi.org/10.1016/j.eclinm.2022.101619" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/35971425" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Long-term+cardiovascular+outcomes+in+COVID-19+survivors+among+non-vaccinated+population%3A+a+retrospective+cohort+study+from+the+TriNetX+US+collaborative+networks+Wang+2022" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref30"><span class="order">30.
            </span><a name="pmed.1004591.ref030" id="pmed.1004591.ref030" class="link-target"></a>Singla S, Putman M, Liew J, Gordon K. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study. Lancet Rheumatol. 2023;5(4):e200–7.  pmid:38251522 <ul class="reflinks" data-doi="10.1016/S2665-9913(23)00034-6"><li><a href="https://doi.org/10.1016/S2665-9913(23)00034-6" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/38251522" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Association+between+biological+immunotherapy+for+psoriasis+and+time+to+incident+inflammatory+arthritis%3A+a+retrospective+cohort+study+Singla+2023" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref31"><span class="order">31.
            </span><a name="pmed.1004591.ref031" id="pmed.1004591.ref031" class="link-target"></a>Ogdie A, Alehashemi S, Love TJ, Jiang Y, Haynes K, Hennessy S, et al. Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in the health improvement network. Pharmacoepidemiol Drug Saf. 2014;23(9):918–22.  pmid:25044030 <ul class="reflinks" data-doi="10.1002/pds.3677"><li><a href="https://doi.org/10.1002/pds.3677" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/25044030" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Validity+of+psoriatic+arthritis+and+capture+of+disease+modifying+antirheumatic+drugs+in+the+health+improvement+network+Ogdie+2014" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref32"><span class="order">32.
            </span><a name="pmed.1004591.ref032" id="pmed.1004591.ref032" class="link-target"></a>Mital R, Bayne J, Rodriguez F, Ovbiagele B, Bhatt DL, Albert MA. Race and ethnicity considerations in patients with coronary artery disease and stroke: JACC focus seminar 3/9. J Am Coll Cardiol. 2021;78(24):2483–92.  pmid:34886970 <ul class="reflinks" data-doi="10.1016/j.jacc.2021.05.051"><li><a href="https://doi.org/10.1016/j.jacc.2021.05.051" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/34886970" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Race+and+ethnicity+considerations+in+patients+with+coronary+artery+disease+and+stroke%3A+JACC+focus+seminar+3%2F9+Mital+2021" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref33"><span class="order">33.
            </span><a name="pmed.1004591.ref033" id="pmed.1004591.ref033" class="link-target"></a>Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258–69.  pmid:32022825 <ul class="reflinks" data-doi="10.1001/jamadermatol.2019.4029"><li><a href="https://doi.org/10.1001/jamadermatol.2019.4029" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/32022825" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Comparison+of+biologics+and+oral+treatments+for+plaque+psoriasis%3A+a+meta-analysis+Armstrong+2020" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref34"><span class="order">34.
            </span><a name="pmed.1004591.ref034" id="pmed.1004591.ref034" class="link-target"></a>Manja V, AlBashir S, Guyatt G. Criteria for use of composite end points for competing risks—a systematic survey of the literature with recommendations. J Clin Epidemiol. 2017;82:4–11.  pmid:27965044 <ul class="reflinks" data-doi="10.1016/j.jclinepi.2016.12.001"><li><a href="https://doi.org/10.1016/j.jclinepi.2016.12.001" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/27965044" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Criteria+for+use+of+composite+end+points+for+competing+risks%E2%80%94a+systematic+survey+of+the+literature+with+recommendations+Manja+2017" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref35"><span class="order">35.
            </span><a name="pmed.1004591.ref035" id="pmed.1004591.ref035" class="link-target"></a>Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27–40.  pmid:30017705 <ul class="reflinks" data-doi="10.1016/j.jaad.2018.06.057"><li><a href="https://doi.org/10.1016/j.jaad.2018.06.057" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/30017705" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Psoriasis%3A+which+therapy+for+which+patient%3A+psoriasis+comorbidities+and+preferred+systemic+agents+Kaushik+2019" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref36"><span class="order">36.
            </span><a name="pmed.1004591.ref036" id="pmed.1004591.ref036" class="link-target"></a>Moride Y, Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol. 1994;47(7):731–7.  pmid:7722586 <ul class="reflinks" data-doi="10.1016/0895-4356(94)90170-8"><li><a href="https://doi.org/10.1016/0895-4356(94)90170-8" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/7722586" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Evidence+of+the+depletion+of+susceptibles+effect+in+non-experimental+pharmacoepidemiologic+research+Moride+1994" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref37"><span class="order">37.
            </span><a name="pmed.1004591.ref037" id="pmed.1004591.ref037" class="link-target"></a>Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829–35.  pmid:17052489 <ul class="reflinks" data-doi="10.1016/j.jaad.2006.08.040"><li><a href="https://doi.org/10.1016/j.jaad.2006.08.040" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/17052489" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Prevalence+of+cardiovascular+risk+factors+in+patients+with+psoriasis+Neimann+2006" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref38"><span class="order">38.
            </span><a name="pmed.1004591.ref038" id="pmed.1004591.ref038" class="link-target"></a>Armstrong A, Harskamp C, Dhillon J, Armstrong E. Psoriasis and smoking: a systematic review and meta-analysis. Br J Dermatol. 2014;170(2):304–14. <ul class="reflinks"><li><a href="#" data-author="Armstrong" data-cit="ArmstrongA%2C%20HarskampC%2C%20DhillonJ%2C%20ArmstrongE.%20Psoriasis%20and%20smoking%3A%20a%20systematic%20review%20and%20meta-analysis.%20Br%20J%20Dermatol.%202014%3B170%282%29%3A304%E2%80%9314." data-title="Psoriasis%20and%20smoking%3A%20a%20systematic%20review%20and%20meta-analysis" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=Psoriasis+and+smoking%3A+a+systematic+review+and+meta-analysis+Armstrong+2014" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref39"><span class="order">39.
            </span><a name="pmed.1004591.ref039" id="pmed.1004591.ref039" class="link-target"></a>Kolliker Frers RA, Cosentino V, Tau J, Kerzberg EM, Urdapilleta A, Chiocconi M, et al. Immune-mediated inflammation promotes subclinical atherosclerosis in recent-onset psoriatic arthritis patients without conventional cardiovascular risk factors. Front Immunol. 2018;9:139.  pmid:29535705 <ul class="reflinks" data-doi="10.3389/fimmu.2018.00139"><li><a href="https://doi.org/10.3389/fimmu.2018.00139" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/29535705" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Immune-mediated+inflammation+promotes+subclinical+atherosclerosis+in+recent-onset+psoriatic+arthritis+patients+without+conventional+cardiovascular+risk+factors+Kolliker+Frers+2018" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref40"><span class="order">40.
            </span><a name="pmed.1004591.ref040" id="pmed.1004591.ref040" class="link-target"></a>Martinez-Lopez A, Blasco-Morente G, Perez-Lopez I, Tercedor-Sanchez J, Arias-Santiago S. Studying the effect of systemic and biological drugs on intima-media thickness in patients suffering from moderate and severe psoriasis. J Eur Acad Dermatol Venereol. 2018;32(9):1492–8.  pmid:29405437 <ul class="reflinks" data-doi="10.1111/jdv.14841"><li><a href="https://doi.org/10.1111/jdv.14841" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/29405437" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Studying+the+effect+of+systemic+and+biological+drugs+on+intima-media+thickness+in+patients+suffering+from+moderate+and+severe+psoriasis+Martinez-Lopez+2018" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref41"><span class="order">41.
            </span><a name="pmed.1004591.ref041" id="pmed.1004591.ref041" class="link-target"></a>Hjuler KF, Bøttcher M, Vestergaard C, Bøtker HE, Iversen L, Kragballe K. Association between changes in coronary artery disease progression and treatment with biologic agents for severe psoriasis. JAMA Dermatol. 2016;152(10):1114–21.  pmid:27385305 <ul class="reflinks" data-doi="10.1001/jamadermatol.2016.1984"><li><a href="https://doi.org/10.1001/jamadermatol.2016.1984" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/27385305" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Association+between+changes+in+coronary+artery+disease+progression+and+treatment+with+biologic+agents+for+severe+psoriasis+Hjuler+2016" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref42"><span class="order">42.
            </span><a name="pmed.1004591.ref042" id="pmed.1004591.ref042" class="link-target"></a>Taleb S, Romain M, Ramkhelawon B, Uyttenhove C, Pasterkamp G, Herbin O, et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med. 2009;206(10):2067–77.  pmid:19737863 <ul class="reflinks" data-doi="10.1084/jem.20090545"><li><a href="https://doi.org/10.1084/jem.20090545" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/19737863" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Loss+of+SOCS3+expression+in+T+cells+reveals+a+regulatory+role+for+interleukin-17+in+atherosclerosis+Taleb+2009" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref43"><span class="order">43.
            </span><a name="pmed.1004591.ref043" id="pmed.1004591.ref043" class="link-target"></a>Danzaki K, Matsui Y, Ikesue M, Ohta D, Ito K, Kanayama M. Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2012;32(2):273–80. <ul class="reflinks"><li><a href="#" data-author="Danzaki" data-cit="DanzakiK%2C%20MatsuiY%2C%20IkesueM%2C%20OhtaD%2C%20ItoK%2C%20KanayamaM.%20Interleukin-17A%20deficiency%20accelerates%20unstable%20atherosclerotic%20plaque%20formation%20in%20apolipoprotein%20E-deficient%20mice.%20Arterioscler%20Thromb%20Vasc%20Biol.%202012%3B32%282%29%3A273%E2%80%9380." data-title="Interleukin-17A%20deficiency%20accelerates%20unstable%20atherosclerotic%20plaque%20formation%20in%20apolipoprotein%20E-deficient%20mice" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=Interleukin-17A+deficiency+accelerates+unstable+atherosclerotic+plaque+formation+in+apolipoprotein+E-deficient+mice+Danzaki+2012" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref44"><span class="order">44.
            </span><a name="pmed.1004591.ref044" id="pmed.1004591.ref044" class="link-target"></a>Elnabawi YA, Dey AK, Goyal A, Groenendyk JW, Chung JH, Belur AD, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res. 2019;115(4):721–8.  pmid:30721933 <ul class="reflinks" data-doi="10.1093/cvr/cvz009"><li><a href="https://doi.org/10.1093/cvr/cvz009" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/30721933" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Coronary+artery+plaque+characteristics+and+treatment+with+biologic+therapy+in+severe+psoriasis%3A+results+from+a+prospective+observational+study+Elnabawi+2019" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref45"><span class="order">45.
            </span><a name="pmed.1004591.ref045" id="pmed.1004591.ref045" class="link-target"></a>Makavos G, Ikonomidis I, Andreadou I, Varoudi M, Kapniari I, Loukeri E, et al. Effects of Interleukin 17A inhibition on myocardial deformation and vascular function in psoriasis. Can J Cardiol. 2020;36(1):100-111. <ul class="reflinks"><li><a href="#" data-author="Makavos" data-cit="MakavosG%2C%20IkonomidisI%2C%20AndreadouI%2C%20VaroudiM%2C%20KapniariI%2C%20LoukeriE%2C%20et%20al.%20Effects%20of%20Interleukin%2017A%20inhibition%20on%20myocardial%20deformation%20and%20vascular%20function%20in%20psoriasis.%20Can%20J%20Cardiol.%202020%3B36%281%29%3A100-111." data-title="Effects%20of%20Interleukin%2017A%20inhibition%20on%20myocardial%20deformation%20and%20vascular%20function%20in%20psoriasis" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=Effects+of+Interleukin+17A+inhibition+on+myocardial+deformation+and+vascular+function+in+psoriasis+Makavos+2020" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref46"><span class="order">46.
            </span><a name="pmed.1004591.ref046" id="pmed.1004591.ref046" class="link-target"></a>Engelbertsen D, Depuydt M, Verwilligen R, Rattik S, Levinsohn E, Edsfeldt A. IL-23R deficiency does not impact atherosclerotic plaque development in mice. J Am Heart Assoc. 2018;7(8):e008257. <ul class="reflinks"><li><a href="#" data-author="Engelbertsen" data-cit="EngelbertsenD%2C%20DepuydtM%2C%20VerwilligenR%2C%20RattikS%2C%20LevinsohnE%2C%20EdsfeldtA.%20IL-23R%20deficiency%20does%20not%20impact%20atherosclerotic%20plaque%20development%20in%20mice.%20J%20Am%20Heart%20Assoc.%202018%3B7%288%29%3Ae008257." data-title="IL-23R%20deficiency%20does%20not%20impact%20atherosclerotic%20plaque%20development%20in%20mice" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=IL-23R+deficiency+does+not+impact+atherosclerotic+plaque+development+in+mice+Engelbertsen+2018" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref47"><span class="order">47.
            </span><a name="pmed.1004591.ref047" id="pmed.1004591.ref047" class="link-target"></a>Fatkhullina AR, Peshkova IO, Dzutsev A, Aghayev T, McCulloch JA, Thovarai V, et al. An Interleukin-23-Interleukin-22 axis regulates intestinal microbial homeostasis to protect from diet-induced atherosclerosis. Immunity. 2018;49(5):943-957.e9.  pmid:30389414 <ul class="reflinks" data-doi="10.1016/j.immuni.2018.09.011"><li><a href="https://doi.org/10.1016/j.immuni.2018.09.011" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/30389414" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=An+Interleukin-23-Interleukin-22+axis+regulates+intestinal+microbial+homeostasis+to+protect+from+diet-induced+atherosclerosis+Fatkhullina+2018" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref48"><span class="order">48.
            </span><a name="pmed.1004591.ref048" id="pmed.1004591.ref048" class="link-target"></a>Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2023;7(7):CD011535.  pmid:37436070 <ul class="reflinks" data-doi="10.1002/14651858.CD011535.pub6"><li><a href="https://doi.org/10.1002/14651858.CD011535.pub6" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/37436070" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Systemic+pharmacological+treatments+for+chronic+plaque+psoriasis%3A+a+network+meta-analysis+Sbidian+2023" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref49"><span class="order">49.
            </span><a name="pmed.1004591.ref049" id="pmed.1004591.ref049" class="link-target"></a>Poizeau F, Nowak E, Kerbrat S, Le Nautout B, Droitcourt C, Drici M-D, et al. Association between early severe cardiovascular events and the initiation of treatment with the Anti-Interleukin 12/23p40 antibody Ustekinumab. JAMA Dermatol. 2020;156(11):1208–15.  pmid:32902568 <ul class="reflinks" data-doi="10.1001/jamadermatol.2020.2977"><li><a href="https://doi.org/10.1001/jamadermatol.2020.2977" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/32902568" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Association+between+early+severe+cardiovascular+events+and+the+initiation+of+treatment+with+the+Anti-Interleukin+12%2F23p40+antibody+Ustekinumab+Poizeau+2020" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref50"><span class="order">50.
            </span><a name="pmed.1004591.ref050" id="pmed.1004591.ref050" class="link-target"></a>Reddy M, Torres G, McCormick T, Marano C, Cooper K, Yeilding N, et al. Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters. J Dermatol. 2010;37(5):413–25.  pmid:20536646 <ul class="reflinks" data-doi="10.1111/j.1346-8138.2010.00802.x"><li><a href="https://doi.org/10.1111/j.1346-8138.2010.00802.x" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/20536646" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Positive+treatment+effects+of+ustekinumab+in+psoriasis%3A+analysis+of+lesional+and+systemic+parameters+Reddy+2010" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref51"><span class="order">51.
            </span><a name="pmed.1004591.ref051" id="pmed.1004591.ref051" class="link-target"></a>Ikonomidis I, Papadavid E, Makavos G, Andreadou I, Varoudi M, Gravanis K, et al. Lowering Interleukin-12 activity improves myocardial and vascular function compared with tumor necrosis factor-a antagonism or cyclosporine in psoriasis. Circ Cardiovasc Imaging. 2017;10(9):e006283.  pmid:28899951 <ul class="reflinks" data-doi="10.1161/CIRCIMAGING.117.006283"><li><a href="https://doi.org/10.1161/CIRCIMAGING.117.006283" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/28899951" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Lowering+Interleukin-12+activity+improves+myocardial+and+vascular+function+compared+with+tumor+necrosis+factor-a+antagonism+or+cyclosporine+in+psoriasis+Ikonomidis+2017" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref52"><span class="order">52.
            </span><a name="pmed.1004591.ref052" id="pmed.1004591.ref052" class="link-target"></a>Eldirany SA, Ho M, Bunick CG. Structural basis for how biologic medicines bind their targets in psoriasis therapy. Yale J Biol Med. 2020;93(1):19–27. pmid:32226331 <ul class="reflinks"><li><a href="#" data-author="Eldirany" data-cit="EldiranySA%2C%20HoM%2C%20BunickCG.%20Structural%20basis%20for%20how%20biologic%20medicines%20bind%20their%20targets%20in%20psoriasis%20therapy.%20Yale%20J%20Biol%20Med.%202020%3B93%281%29%3A19%E2%80%9327.%2032226331" data-title="Structural%20basis%20for%20how%20biologic%20medicines%20bind%20their%20targets%20in%20psoriasis%20therapy" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/32226331" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Structural+basis+for+how+biologic+medicines+bind+their+targets+in+psoriasis+therapy+Eldirany+2020" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref53"><span class="order">53.
            </span><a name="pmed.1004591.ref053" id="pmed.1004591.ref053" class="link-target"></a>de Brito M, Yiu ZZN. Cardiovascular safety of biologics targeting Interleukin (IL)-12 and/or IL-23: what does the evidence say? Am J Clin Dermatol. 2021;22(5):587–601.  pmid:34292509 <ul class="reflinks" data-doi="10.1007/s40257-021-00612-9"><li><a href="https://doi.org/10.1007/s40257-021-00612-9" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/34292509" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Cardiovascular+safety+of+biologics+targeting+Interleukin+%28IL%29-12+and%2For+IL-23%3A+what+does+the+evidence+say%3F+de+Brito+2021" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref54"><span class="order">54.
            </span><a name="pmed.1004591.ref054" id="pmed.1004591.ref054" class="link-target"></a>Woods RH. Potential cerebrovascular accident signal for risankizumab: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS). Br J Clin Pharmacol. 2023;89(8):2386–95.  pmid:36321844 <ul class="reflinks" data-doi="10.1111/bcp.15581"><li><a href="https://doi.org/10.1111/bcp.15581" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/36321844" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Potential+cerebrovascular+accident+signal+for+risankizumab%3A+a+disproportionality+analysis+of+the+FDA+Adverse+Event+Reporting+System+%28FAERS%29+Woods+2023" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref55"><span class="order">55.
            </span><a name="pmed.1004591.ref055" id="pmed.1004591.ref055" class="link-target"></a>Egeberg A, Thyssen JP. Increased reporting of cerebrovascular accidents with use of risankizumab observed in the Food and Drug Administration Adverse Events Reporting System (FAERS). Br J Dermatol. 2023;188(6):793–4.  pmid:36797979 <ul class="reflinks" data-doi="10.1093/bjd/ljad039"><li><a href="https://doi.org/10.1093/bjd/ljad039" data-author="doi-provided" data-cit="doi-provided" data-title="doi-provided" target="_new" title="Go to article">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/pubmed/36797979" target="_new" title="Go to article in PubMed">
                        PubMed/NCBI
                      </a></li><li><a href="http://scholar.google.com/scholar?q=Increased+reporting+of+cerebrovascular+accidents+with+use+of+risankizumab+observed+in+the+Food+and+Drug+Administration+Adverse+Events+Reporting+System+%28FAERS%29+Egeberg+2023" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li></ol></div>



          <div class="ref-tooltip">
            <div class="ref_tooltip-content">

            </div>
          </div>

        </div>
      </div>
    </div>

  </section>
  <aside class="article-aside">


<!--[if IE 9]>
<style>
.dload-xml {margin-top: 38px}
</style>
<![endif]-->
<div class="dload-menu">
  <div class="dload-pdf">
    <a href="/plosmedicine/article/file?id=10.1371/journal.pmed.1004591&type=printable"
       id="downloadPdf" target="_blank">Download PDF</a>
  </div>
  <div data-js-tooltip-hover="trigger" class="dload-hover">&nbsp;
    <ul class="dload-xml" data-js-tooltip-hover="target">
      <li><a href="/plosmedicine/article/citation?id=10.1371/journal.pmed.1004591"
             id="downloadCitation">Citation</a></li>
      <li><a href="/plosmedicine/article/file?id=10.1371/journal.pmed.1004591&type=manuscript"
             id="downloadXml">XML</a>
      </li>
    </ul>

  </div>
</div>

<div class="aside-container">
  <div class="print-article" id="printArticle" data-js-tooltip-hover="trigger">
    <a href="#" onclick="window.print(); return false;" class="preventDefault" id="printBrowser">Print</a>
  </div>
  <div class="share-article" id="shareArticle" data-js-tooltip-hover="trigger">
    Share
    <ul data-js-tooltip-hover="target" class="share-options" id="share-options">

      <li><a href="https://www.reddit.com/submit?url=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pmed.1004591" id="shareReddit" target="_blank" title="Submit to Reddit"><img src="/resource/img/icon.reddit.16.png" width="16" height="16" alt="Reddit">Reddit</a></li>

      <li><a href="https://www.facebook.com/share.php?u=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pmed.1004591&t=Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-α, IL-12/23, IL-17, and IL-23: A population-based retrospective cohort study" id="shareFacebook" target="_blank" title="Share on Facebook"><img src="/resource/img/icon.fb.16.png" width="16" height="16" alt="Facebook">Facebook</a></li>

      <li><a href="https://www.linkedin.com/shareArticle?url=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pmed.1004591&title=Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-α, IL-12/23, IL-17, and IL-23: A population-based retrospective cohort study&summary=Checkout this article I found at PLOS"  id="shareLinkedIn" target="_blank" title="Add to LinkedIn"><img src="/resource/img/icon.linkedin.16.png" width="16" height="16" alt="LinkedIn">LinkedIn</a></li>

      <li><a href="https://www.mendeley.com/import/?url=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pmed.1004591"  id="shareMendeley" target="_blank" title="Add to Mendeley"><img src="/resource/img/icon.mendeley.16.png" width="16" height="16" alt="Mendeley">Mendeley</a></li>

      <li><a href="https://bsky.app/intent/compose?text=Checkout%20this%20article%20I%20found%20at%20PLOS:%20https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pmed.1004591"  id="shareBluesky" target="_blank" title="Share on Bluesky"><img src="/resource/img/icon.bluesky.light.png" width="16" height="16" alt="Bluesky">Bluesky</a></li>

      <li><a href="mailto:?subject=Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-α, IL-12/23, IL-17, and IL-23: A population-based retrospective cohort study&body=I%20thought%20you%20would%20find%20this%20article%20interesting.%20From%20PLOS Medicine:%20https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pmed.1004591"  id="shareEmail" rel="noreferrer" aria-label="Email"><img src="/resource/img/icon.email.16.png" width="16" height="16" alt="Email">Email</a></li>
    </ul>
  </div>
</div>


     <!-- Crossmark 2.0 widget -->
    <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script>
    <a aria-label="Check for updates via CrossMark" data-target="crossmark">
      <img alt="Check for updates via CrossMark" width="150" src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_BW_horizontal.svg">
    </a>
    <!-- End Crossmark 2.0 widget -->



<div class="aside-container collections-aside-container"><!-- React Magic --></div>


<div class="skyscraper-container">
  <div class="title">Advertisement</div>
<!-- DoubleClick Ad Zone -->
  <div class='advertisement' id='div-gpt-ad-1458247671871-1' style='width:160px; height:600px;'>
    <script type='text/javascript'>
      googletag.cmd.push(function() { googletag.display('div-gpt-ad-1458247671871-1'); });
    </script>
  </div>
</div>




<div class="subject-areas-container">
  <h3>Subject Areas <div id="subjInfo">?</div>
    <div id="subjInfoText">
      <p>For more information about PLOS Subject Areas, click
        <a href="https://github.com/PLOS/plos-thesaurus/blob/master/README.md" target="_blank" title="Link opens in new window">here</a>.</p>
      <span class="inline-intro">We want your feedback.</span> Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!


    </div>
  </h3>
  <ul id="subjectList">
      <li>
              <a class="taxo-term" title="Search for articles about Cardiovascular diseases"
                 href="/plosmedicine/search?filterSubjects=Cardiovascular+diseases&filterJournals=PLoSMedicine&q=">Cardiovascular diseases</a>
        <span class="taxo-flag">&nbsp;</span>
        <div class="taxo-tooltip" data-categoryname="Cardiovascular diseases"><p class="taxo-explain">Is the Subject Area <strong>"Cardiovascular diseases"</strong> applicable to this article?
          <button id="noFlag" data-action="remove">Yes</button>
          <button id="flagIt" value="flagno" data-action="add">No</button></p>
          <p class="taxo-confirm">Thanks for your feedback.</p>
        </div>
      </li>
      <li>
              <a class="taxo-term" title="Search for articles about Cardiovascular disease risk"
                 href="/plosmedicine/search?filterSubjects=Cardiovascular+disease+risk&filterJournals=PLoSMedicine&q=">Cardiovascular disease risk</a>
        <span class="taxo-flag">&nbsp;</span>
        <div class="taxo-tooltip" data-categoryname="Cardiovascular disease risk"><p class="taxo-explain">Is the Subject Area <strong>"Cardiovascular disease risk"</strong> applicable to this article?
          <button id="noFlag" data-action="remove">Yes</button>
          <button id="flagIt" value="flagno" data-action="add">No</button></p>
          <p class="taxo-confirm">Thanks for your feedback.</p>
        </div>
      </li>
      <li>
              <a class="taxo-term" title="Search for articles about Cancer risk factors"
                 href="/plosmedicine/search?filterSubjects=Cancer+risk+factors&filterJournals=PLoSMedicine&q=">Cancer risk factors</a>
        <span class="taxo-flag">&nbsp;</span>
        <div class="taxo-tooltip" data-categoryname="Cancer risk factors"><p class="taxo-explain">Is the Subject Area <strong>"Cancer risk factors"</strong> applicable to this article?
          <button id="noFlag" data-action="remove">Yes</button>
          <button id="flagIt" value="flagno" data-action="add">No</button></p>
          <p class="taxo-confirm">Thanks for your feedback.</p>
        </div>
      </li>
      <li>
              <a class="taxo-term" title="Search for articles about Cardiovascular therapy"
                 href="/plosmedicine/search?filterSubjects=Cardiovascular+therapy&filterJournals=PLoSMedicine&q=">Cardiovascular therapy</a>
        <span class="taxo-flag">&nbsp;</span>
        <div class="taxo-tooltip" data-categoryname="Cardiovascular therapy"><p class="taxo-explain">Is the Subject Area <strong>"Cardiovascular therapy"</strong> applicable to this article?
          <button id="noFlag" data-action="remove">Yes</button>
          <button id="flagIt" value="flagno" data-action="add">No</button></p>
          <p class="taxo-confirm">Thanks for your feedback.</p>
        </div>
      </li>
      <li>
              <a class="taxo-term" title="Search for articles about Psoriasis"
                 href="/plosmedicine/search?filterSubjects=Psoriasis&filterJournals=PLoSMedicine&q=">Psoriasis</a>
        <span class="taxo-flag">&nbsp;</span>
        <div class="taxo-tooltip" data-categoryname="Psoriasis"><p class="taxo-explain">Is the Subject Area <strong>"Psoriasis"</strong> applicable to this article?
          <button id="noFlag" data-action="remove">Yes</button>
          <button id="flagIt" value="flagno" data-action="add">No</button></p>
          <p class="taxo-confirm">Thanks for your feedback.</p>
        </div>
      </li>
      <li>
              <a class="taxo-term" title="Search for articles about Medical risk factors"
                 href="/plosmedicine/search?filterSubjects=Medical+risk+factors&filterJournals=PLoSMedicine&q=">Medical risk factors</a>
        <span class="taxo-flag">&nbsp;</span>
        <div class="taxo-tooltip" data-categoryname="Medical risk factors"><p class="taxo-explain">Is the Subject Area <strong>"Medical risk factors"</strong> applicable to this article?
          <button id="noFlag" data-action="remove">Yes</button>
          <button id="flagIt" value="flagno" data-action="add">No</button></p>
          <p class="taxo-confirm">Thanks for your feedback.</p>
        </div>
      </li>
      <li>
              <a class="taxo-term" title="Search for articles about Type 2 diabetes risk"
                 href="/plosmedicine/search?filterSubjects=Type+2+diabetes+risk&filterJournals=PLoSMedicine&q=">Type 2 diabetes risk</a>
        <span class="taxo-flag">&nbsp;</span>
        <div class="taxo-tooltip" data-categoryname="Type 2 diabetes risk"><p class="taxo-explain">Is the Subject Area <strong>"Type 2 diabetes risk"</strong> applicable to this article?
          <button id="noFlag" data-action="remove">Yes</button>
          <button id="flagIt" value="flagno" data-action="add">No</button></p>
          <p class="taxo-confirm">Thanks for your feedback.</p>
        </div>
      </li>
      <li>
              <a class="taxo-term" title="Search for articles about Epidemiology"
                 href="/plosmedicine/search?filterSubjects=Epidemiology&filterJournals=PLoSMedicine&q=">Epidemiology</a>
        <span class="taxo-flag">&nbsp;</span>
        <div class="taxo-tooltip" data-categoryname="Epidemiology"><p class="taxo-explain">Is the Subject Area <strong>"Epidemiology"</strong> applicable to this article?
          <button id="noFlag" data-action="remove">Yes</button>
          <button id="flagIt" value="flagno" data-action="add">No</button></p>
          <p class="taxo-confirm">Thanks for your feedback.</p>
        </div>
      </li>
  </ul>
</div>
<div id="subjectErrors"></div>
  </aside>
</div>




</main>
<footer id="pageftr">
  <div class="row">
    <div class="block x-small">

<ul class="nav nav-secondary">
    <li class="ftr-header"><a href="https://plos.org/our-journals/">Publications</a></li>
    <li><a href="/plosbiology/" id="ftr-bio">PLOS Biology</a></li>
    <li><a href="/climate/" id="ftr-climate">PLOS Climate</a></li>
    <li><a href="/complexsystems/" id="ftr-complex-systems">PLOS Complex Systems</a></li>
    <li><a href="/ploscompbiol/" id="ftr-compbio">PLOS Computational Biology</a></li>
    <li><a href="/digitalhealth/" id="ftr-digitalhealth">PLOS Digital Health</a></li>
    <li><a href="/plosgenetics/" id="ftr-gen">PLOS Genetics</a></li>
    <li><a href="/globalpublichealth/" id="ftr-globalpublichealth">PLOS Global Public Health</a></li>
  </ul>
    </div>
    <div class="block x-small">

<ul class="nav nav-secondary">
    <li class="ftr-header">&nbsp;</li>
    <li><a href="/plosmedicine/" id="ftr-med">PLOS Medicine</a></li>
    <li><a href="/mentalhealth/" id="ftr-mental-health">PLOS Mental Health</a></li>
    <li><a href="/plosntds/" id="ftr-ntds">PLOS Neglected Tropical Diseases</a></li>
    <li><a href="/plosone/" id="ftr-one">PLOS One</a></li>
    <li><a href="/plospathogens/" id="ftr-path">PLOS Pathogens</a></li>
    <li><a href="/sustainabilitytransformation/" id="ftr-sustainabilitytransformation">PLOS Sustainability and Transformation</a></li>
    <li><a href="/water/" id="ftr-water">PLOS Water</a></li>
</ul>
    </div>
    <div class="block xx-small">	


<ul class="nav nav-tertiary">
  <li>
    <a href="https://plos.org" id="ftr-home">Home</a>
  </li>
  <li>
    <a href="https://blogs.plos.org" id="ftr-blog">Blogs</a>
  </li>
  <li>
    <a href="https://collections.plos.org/" id="ftr-collections">Collections</a>
  </li>
  <li>
    <a href="mailto:webmaster@plos.org" id="ftr-feedback">Give feedback</a>
  </li>
  <li>
    <a href="/plosmedicine/lockss-manifest" id="ftr-lockss">LOCKSS</a>
  </li>
</ul>
    </div>
    <div class="block xx-small">

<ul class="nav nav-primary">
  <li><a href="https://plos.org/privacy-policy" id="ftr-privacy">Privacy Policy</a></li>
  <li><a href="https://plos.org/terms-of-use" id="ftr-terms">Terms of Use</a></li>
  <li><a href="https://plos.org/advertise/" id="ftr-advertise">Advertise</a></li>
  <li><a href="https://plos.org/media-inquiries" id="ftr-media">Media Inquiries</a></li>
  <li><a href="https://plos.org/contact" id="ftr-contact">Contact</a></li>
</ul>
    </div>
  </div>
  <div class="row">
    <p>

<img src="/resource/img/logo-plos-footer.png" alt="PLOS" class="logo-footer"/>


<span class="footer-non-profit-statement">PLOS is a nonprofit 501(c)(3) corporation, #C2354500, based in California, US</span>    </p>
    <div class="block">
    </div>
  </div>
 
<script src="/resource/js/global.js" type="text/javascript"></script>
</footer>




<script type="text/javascript">
  var ArticleData = {
    doi: '10.1371/journal.pmed.1004591',
    title: '<article-title xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-α, IL-12/23, IL-17, and IL-23: A population-based retrospective cohort study<\/article-title>',
    date: 'Apr 17, 2025'
  };
</script>
<script src="/resource/js/components/show_onscroll.js" type="text/javascript"></script>
<script src="/resource/js/components/pagination.js" type="text/javascript"></script>
<script src="/resource/js/vendor/spin.js" type="text/javascript"></script>
<script src="/resource/js/pages/article.js" type="text/javascript"></script>
<script src="/resource/js/pages/article_references.js" type="text/javascript"></script>
<script src="/resource/js/pages/article_sidebar.js" type="text/javascript"></script>
<script src="/resource/js/vendor/foundation/foundation.dropdown.js" type="text/javascript"></script>
  <script src="/resource/js/components/table_open.js" type="text/javascript"></script>

        <script src="/resource/js/components/figshare.js" type="text/javascript"></script>
  <script src="/resource/js/vendor/jquery.panzoom.min.js" type="text/javascript"></script>
  <script src="/resource/js/vendor/jquery.mousewheel.js" type="text/javascript"></script>

  <script src="/resource/js/components/lightbox.js" type="text/javascript"></script>

  <script src="/resource/js/pages/article_body.js" type="text/javascript"></script>


<!-- This file should be loaded before the renderJs, to avoid conflicts with the FigShare, that implements the MathJax also. -->

<!--  mathjax configuration options  -->
<!-- more can be found at http://docs.mathjax.org/en/latest/ -->
<script type="text/x-mathjax-config">
MathJax.Hub.Config({
  "HTML-CSS": {
    scale: 100,
    availableFonts: ["STIX","TeX"],
    preferredFont: "STIX",
    webFont: "STIX-Web",
    linebreaks: { automatic: false }
  },
  jax: ["input/MathML", "output/HTML-CSS"]
});
</script>

<script type="text/javascript" src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=MML_HTMLorMML"></script>

<div class="reveal-modal-bg"></div>
</body>
</html>
